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Zusammenfassung 
 
Der Fas Ligand (FasL; CD95L; CD178; TNSF6) ist ein glykosyliertes Typ II 
Transmembranprotein, das zur Proteinfamilie der Tumornekrosefaktor (TNF)-
Liganden gehört. Das Mausprotein besteht aus 279 Aminosäuren, während der 
humane FasL 281 Aminosäuren umfasst. Im extrazellulären Teil des Liganden 
befinden sich eine TNF Homologie-Domäne, die Rezeptorbindestelle, ein 
Sequenzmotiv zur Selbstaggregation und Trimerisierung sowie mehrere Stellen, an 
denen der FasL N-glykosyliert oder von Metalloproteasen geschnitten werden kann. 
Die intrazelluläre Region des FasL ist die längste aller TNFL-Familienmitglieder und 
enthält verschiedene konservierte Signalmotive, z.B. ein Casein-Kinase I (CK-I) 
Substrat-Motiv, eine Prolin-reiche Domäne (PRD) und potentielle Tyrosin-
Phosphorylierungsstellen (Maus: Y7; Mensch: Y7, Y9, Y13). 
Die Bindung des FasL an den zugehörigen Rezeptor Fas löst in der 
rezeptortragenden Zelle apoptotischen Zelltod aus. Dies spielt eine besondere Rolle 
für verschiedenen Funktionen des Immunsystems, z.B. für die Lyse von Zielzellen 
durch natürliche Killerzellen (NK-Zellen) und zytotoxische T-Zellen, für die 
Selbsteliminierung von Effektorzellen nach der Expansionsphase einer 
Immunantwort (activation-induced cell death; AICD), für die Aufrechterhaltung eines 
immunprivilegierten Status bestimmter Gewebe und für die Induktion und Erhaltung 
der peripheren Toleranz. Im Gegensatz zu dem von vielen Zelltypen konstitutiv 
exprimiertem Fas-Rezeptor ist die Expression und Aktivität des FasL auf wenige 
Zelltypen beschränkt (Zellen des Immunsystems und immunprivilegierte Gewebe) 
und wird auf transkriptioneller und post-translationaler Ebene reguliert.  
Ebenso wichtig wie die pro-apoptotische Funktion ist die Vermittlung nicht-
apoptotischer Signale durch den Fas-Rezeptor. So wurde unter anderem gezeigt, 
dass Fas-Aktivierung ko-stimulatorisch wirken und das Überleben, die Aktivierung 
und die Proliferation von T-Zellen und Tumorzellen fördern kann. 
Zusätzlich zu der Vermittlung des klassischen „Vorwärtssignals“ in die 
rezeptortragende Zelle kann FasL selbst Signale empfangen und in die 
ligandexprimierende Zelle weiterleiten. Dieses Phänomen wird als „reverse“ oder 
„bidirektionale“ Signalübertragung bezeichnet und wurde ebenfalls für andere TNFL-
Familienmitglieder beschrieben. Erste Hinweise für die Existenz einer reversen 
Signalübertragung in die FasL-tragende Zelle stammen aus zwei Studien, in denen 
gezeigt wurde, dass die Vernetzung des FasL durch Fas-Fc oder anti-FasL-
Antikörper die T-Zell-Rezeptor (TZR)-vermittelte Proliferation muriner CD8
+ T-
Zelllinien ko-stimuliert bzw. die muriner CD4
+ T-Zellen inhibiert. In beiden Fällen Zusammenfassung 
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hingen die beobachteten Veränderungen des Proliferationsverhaltens von der 
Anwesenheit eines funktionellen Liganden ab.  
Es ist anzunehmen, dass das retrograde Signal durch die intrazelluläre Domäne 
(IZD) des FasL vermittelt wird: (i) Die IZD ist speziesübergreifend konserviert und 
beinhaltet mehrere Signalmotive, darunter eine innerhalb der TNFL-Familie 
einzigartige PRD. (ii) Eine Vielzahl von Proteinen bindet über eine SH3 oder WW 
Domäne an die PRD des FasL und reguliert so verschiedene Aspekte der FasL-
Biologie, wie z.B. die subzelluläre Lokalisation, die Expression an der Zelloberfläche 
und das Zusammenspiel mit intrazellulären Signalwegen. (iii) Post-translationale 
Modifikationen der IZD wurden mit der Sortierung des Liganden in Vesikel und der 
FasL-abhängigen Aktivierung von Nuclear factor of activated T cells (NFAT) in 
Verbindung gebracht. (iv) Die proteolytische Prozessierung des FasL führt zur 
Freisetzung der IZD in das Zytosol und ermöglicht die Translokation der IZD in den 
Zellkern, wo sie die Transkription von Genen regulieren kann. (v) Es konnte gezeigt 
werden, dass die Überexpression der FasL IZD ausreicht, um nach gleichzeitiger 
TZR-Stimulation und IZD-Vernetzung eine reverse Signalübertragung in murinen 
CD8
+ T-Zelllinien zu initiieren. 
Die möglichen Konsequenzen der FasL-vermittelten reversen Signalübertragung 
werden kontrovers diskutiert, und sowohl ko-stimulatorische wie auch inhibitorische 
Funktionen sind publiziert worden. Diese sich widersprechenden Beobachtungen 
basieren vermutlich darauf, dass die Experimente in artifiziellen Systemen 
durchgeführt wurden und weder der molekulare Mechanismus, noch die 
physiologische Bedeutung der reversen Signalübertragung auf der Ebene des 
endogenen Proteins in vivo untersucht wurden. 
Daher wurde in der Arbeitsgruppe von PD Dr. Martin Zörnig ein Mausmodell für eine 
defekte reverse FasL Signalübertragung (FasL  ∆Intra) etabliert. Diesen 
‚knockout/knockin’-Mäusen fehlt die intrazelluläre FasL Domäne, während die 
Transmembran- und die extrazelluläre Domäne weiterhin vorhanden sind. Im 
Verlauf der vorliegenden Arbeit wurden die FasL  ∆Intra Mäuse phänotypisch 
charakterisiert und als Modell genutzt, um die physiologische Funktion der reversen 
FasL Signalübertragung auf molekularer und zellulärer Ebene aufzuklären. 
 
Um sicherzustellen, dass die FasL ∆Intra Mäuse ein geeignetes Modellsystem zur 
Analyse der reversen FasL Signalübertragung darstellen, wurden die Expression 
und Funktionalität des trunkierten FasL untersucht. Die korrekte Ausführung 
FasL/Fas-vermittelter Apoptose ist ein wichtiger Punkt, da natürlich vorkommende 
Maus-Mutantenstämme, in denen die Fas-induzierte Apoptose durch Mutationen im Zusammenfassung 
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FasL ( FasL
gld/gld) bzw. im Fas ( Fas
lpr/lpr) Gen inaktiviert wird, eine schwere 
Autoimmunerkrankung entwickeln. Ein vergleichbarer Phänotyp in FasL  ∆Intra 
Mäusen könnte die Auswirkungen der defekten reversen Signalübertragung 
maskieren. Die Expression des FasL konnte durch RT-PCR und 
durchflußzytometrische Färbungen auf der Oberfläche aktivierter Lymphozyten in 
homozygoten  FasL  ∆Intra Mäusen verifiziert werden. Experimente, in denen 
aktivierte Lymphozyten mit Fas-sensitiven Zielzellen ko-kultiviert wurden, zeigten, 
dass der trunkierte FasL weiterhin Apoptose in Fas-tragenden Zellen auslösen 
kann. Außerdem weisen die FasL  ∆Intra Mäuse im gesunden Zustand keinerlei 
phänotypische Auffälligkeiten auf und entwickeln keine Symptome der mit FasL-
Defizienz (FasL
gld/gld,  FasL
-/-) verbundenen lymphoproliferativen 
Autoimmunerkrankung.  
Da die meisten Studien eine Beeinflussung der T-Zell Expansion durch die reverse 
FasL Signalübertragung nahe legen, wurde das Proliferationsverhalten von 
Lymphozyten aus homozygoten FasL ∆Intra oder Wildtyp Mäusen nach Stimulation 
des jeweiligen Antigenrezeptors analysiert. Experimente zur aktivierungsinduzierten 
Lymphozytenexpansion belegten eine deutlich höhere Proliferationskapazität von 
einzelpositiven CD4
+ und CD8
+ T-Zellen sowie B-Zellen ohne IZD. Dieser Effekt war 
in B-Zellen am stärksten ausgeprägt und konnte in CD4
+ T-Zellen nur dann 
beobachtet werden, wenn zuvor regulatorische CD4
+CD25
+ T-Zellen (Tregs) 
depletiert wurden. Nach unserem Kenntnisstand beschreibt die vorliegende Arbeit 
zum ersten Mal die Auswirkungen der reverse FasL Signalübertragung in B-Zellen. 
Um zu verstehen, wie reverses FasL-Signaling auf aktivierungsinduzierte 
Lymphozytenproliferation einwirkt, wurde das Anschalten verschiedener 
Signalwege, die bekanntermaßen für die vom Antigenrezeptor ausgehende 
Signalverarbeitung wichtig sind, untersucht. Als ein molekulares Korrelat für die 
beobachtete verstärkte Proliferation wurde eine deutlich erhöhte Phosphorylierung 
der  Extracellular signal regulated kinase (ERK1/2) nach Vernetzung des 
Antigerezeptors in homozygoten FasL  ∆Intra Mäusen gefunden. 
Überraschenderweise schienen die ERK1/2-vorgeschalteten Mitogen-aktivierten 
Proteinkinasen (MAPKs) Raf-1 und MEK1/2 nicht für die differentielle Regulation 
von ERK1/2 verantwortlich zu sein, da die Stimulation von Wildtyp und FasL-
mutanten B-Zellen zu einem vergleichbaren Ausmaß aktivierender 
Phosphorylierungen in c-Raf1 (S38) und MEK1/2 (S218/S222) führte. Ebenso 
wiesen Experimente, in denen die aktivierungsinduzierte Akt-Phosphorylierung 
(S473) untersucht wurde, nicht auf eine Beteiligung des Phosphoinositol-spezifische 
Kinase 3 (PI3K)/Akt Signalwegs an der reversen FasL Signalübertragung hin. Es Zusammenfassung 
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konnte jedoch gezeigt werden, dass durch Phospholipase C gamma (PLCγ) und 
Proteinkinase C (PKC) vermittelte Signale in die FasL-abhängige Regulation von 
ERK1/2 involviert sind.  
Unsere Gruppe konnte zeigen, dass FasL in einer ähnlichen Weise wie das 
Signalprotein Notch prozessiert wird. Dies führt nach proteolytischer Freisetzung der 
FasL IZD in das Zytoplasma zur transkriptionellen Regulation eines Reportergens. 
Des Weiteren wurde in der Arbeitsgruppe von PD Dr. M. Zörnig eine Interaktion der 
FasL IZD mit dem Transkriptionsfaktor Lymphoid-enhancer binding factor-1 (Lef-1) 
aufgezeigt, die die Lef-1-abhängige Transkription beeinflusste. Daher wurde im 
Rahmen dieser Doktorarbeit eine systematische Expressionsanalyse aktivierter 
Lymphozyten durchgeführt. Die dabei identifizierten Zielgene der reversen FasL 
Signalübertragung wurden durch quantitative real-time PCR (qRT-PCR) verifiziert. 
Es stellte sich heraus, dass vor allem Gene, die mit der Proliferation und Aktivierung 
von Lymphozyten assoziiert werden, in homozygoten FasL ∆Intra Mäusen stärker 
exprimiert werden. Interessanterweise wurde ebenfalls eine extensive Regulation 
von Genen, die mit Lef-1-abhängigen Wnt/β-Catenin-Signalen im Zusammenhang 
stehen, beobachtet. Obwohl andere Publikationen nahe legen, dass die Expression 
von Lef-1 während der B-Zell-Entwicklung stark herunterreguliert wird, konnten in 
der vorliegenden Arbeit Lef-1 mRNA (RT-PCR) und Protein (intrazelluläre, 
durchflußzytometrische Färbung) in naïven B-Zellen detektiert werden. Diese Daten 
weisen auf einen Zusammenhang von reverser FasL Signalübertragung und Lef-1 in 
reifen Lymphozyten hin. 
 
Zur Aufklärung der in vivo Funktion reverser FasL Signalübertragung wurden 
verschiedene Infektions- und Immunisierungsmodelle angewendet, mit denen eine 
mögliche Beteiligung der FasL IZD an der Regulation von Immunantworten 
untersucht werden kann. Experimente, in denen die Thymozytenproliferation oder 
die Expansion Antigen-spezifischer T-Zellen in Folge einer Infektion mit dem 
Superantigen  Staphylococcus enterotoxin B (SEB), mit dem Lymphozyten 
Choriomeningitis Virus (LCMV) oder dem intrazellulären Bakterium Listeria 
monocytogenes evaluiert wurden, ergaben vergleichbare Ergebnisse in Wildtyp und 
FasL  ∆Intra Mäusen. Auch die Rekrutierung von Neutrophilen in einem 
Thioglycollat-induzierten Peritonitismodell wurde nicht von der Deletion der FasL 
IZD beeinflußt. Möglicherweise spiegeln diese Befunde in vivo aktive, regulatorische 
Mechanismen wider, wie z.B. eine durch regulatorische T-Zellen ausgeübte 
Kontrolle. Ein Hinweis darauf ist die ex vivo Beobachtung, dass Unterschiede in der 
Proliferation von Wildtyp und mutanten CD4
+ T-Zellen nur beobachtet werden Zusammenfassung 
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konnten, wenn regulatorische T-Zellen vorher depletiert wurden. Außerdem zeigen 
verschiedene in vitro Studien, dass retrograde FasL-Signale nur bei sub-optimaler 
Lymphozyten-Stimulation beobachtet werden können, nicht aber bei optimaler 
Vernetzung des TZR. Daher könnten Stimuli wie SEB oder LCMV durch die starke 
Initiation von Antigenrezeptorsignalen die inhibitorische Funktion der reverse FasL 
Signaltransduktion maskieren. 
Im Einklang mit der ex vivo beobachteten Hyperaktivierung von Lymphozyten ohne 
FasL IZD wurden in FasL ∆Intra Mäusen nach Immunisierung mit dem Antigen 3-
hydroxy 4-nitrophenylacetyl (NP) signifikant mehr Keimzentrums-B-Zellen gebildet. 
Ein erhöhter prozentualer Anteil Plasmazellen in der Milz von FasL ∆Intra Mäuse 
korrelierte mit signifikant höheren Titern NP-bindender, d.h. Antigen-spezifischer 
IgM- und IgG1-Antikörper im Serum.  
Diese Befunde deuten darauf hin, dass die reverse Signalübertragung via FasL 
immunmodulatorische Funktionen ausübt. Damit übereinstimmend konnte in einem 
Model der Ovalbumin-induzierten allergischen Atemwegsentzündung gezeigt 
werden, dass retrograde FasL Signale den Krankheitsverlauf durch Verminderung 
der Immuneffektorzellrekrutierung und Verstärkung der T-Zell Aktivierung abmildern. 
 
Die hier beschriebenen, auf endogenem Proteinniveau erhaltenen, ex vivo und in 
vivo Befunde zeigen, dass die reverse Signalübertragung durch die FasL IZD unter 
bestimmten Bedingungen immunmodulatorische Funktionen übernimmt. Dabei 
könnte die reverse FasL Signalübertragung ein Mechanismus zur Termination und 
Feinabstimmung von Immunantworten sein, der zur Prävention von 
Autoimmunerkrankungen beiträgt. Zukünftige Studien an geeigneten Mausmodellen 
für Autoimmunerkrankungen werden diese Möglichkeit untersuchen. 
 Summary 
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Summary 
 
Fas Ligand (FasL; CD95L; CD178; TNSF6) is a 40 kDa glycosylated type II 
transmembrane protein with 279 aa in mice and 281 aa in humans that belongs to 
the tumor necrosis factor (TNF) family. The extracellular domain (ECD) harbors a 
TNF homology domain, the receptor binding site, a motif for self assembly and 
trimerization, and several putative N-glycosylation and a metalloprotease cleavage 
site/s. The cytoplasmic tail of FasL is the longest of all TNFL family members and 
contains several conserved signaling motifs, such as a putative tandem Casein 
kinase I phosphorylation site, a unique proline-rich domain (PRD) and 
phosphorylatable tyrosine residues (Y7 in mice; Y7, Y9, Y13 in human).  
The FasL/Fas system is renowned for the potent induction of apoptosis in the 
receptor-bearing cell and is especially important for immune system functions. It is 
involved in the killing of target cells by natural killer (NK) and cytotoxic T cells, in the 
(self) elimination of effector cells following the proliferative phase of an immune 
response (activation-induced cell death; AICD), in the maintenance of immune-
privileged sites and in the induction and maintenance of peripheral tolerance. Owing 
to its potent pro-apoptotic signaling capacity and important functions, FasL 
expression and activity are tightly regulated at transcriptional and post-
transcriptional levels and restricted to few cell types, such as immune effector cells 
and cells of immune-privileged sites. In contrast, Fas is expressed in a variety of 
tissues including lymphoid tissues, liver, heart, kidney, pancreas, brain and ovary. 
In addition to its pro-apoptotic function, the FasL/Fas system can also elicit non-
apoptotic signals in the receptor-expressing cell. Among others, Fas-signaling exerts 
co-stimulatory functions in the immune system, e.g. by promoting survival, activation 
and proliferation of T cells. 
Besides the capacity to deliver a signal into receptor-bearing cells (‘forward signal’), 
FasL can receive and transmit signals into the ligand-expressing cell. This 
phenomenon has been described for several TNF family ligands and is known as 
‘reverse signaling’. The first evidence for the existence of reverse signaling into 
FasL-bearing cells stems from two studies that demonstrated either co-stimulation of 
murine CD8
+ T cell lines by FasL cross-linking or inhibition of activation-induced 
proliferation of murine CD4
+ T cells. In both cases, the observed changes of 
proliferative behaviour critically depended on the presence of a signaling-competent 
FasL. Almost certainly, the FasL ICD is functionally involved in signal-transmission: 
(i) The ICD is highly conserved across species and harbors several signaling motifs, 
most notably a unique PRD. (ii) Numerous proteins have been identified which Summary 
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interact with the FasL PRD via their SH3 or WW domains and regulate various 
aspects of FasL biology, such as FasL sorting, storage, cell surface expression and 
the linkage of FasL to intracellular signaling pathways. (iii) Post-translational 
modifications of the ICD have been implicated in the sorting of FasL to vesicles and 
the FasL-dependent activation of Nuclear factor of activated T cells (NFAT). (iv) 
Proteolytic processing of FasL liberates the ICD and allows its translocation into the 
nucleus where it might influence gene transcription. (v) It could be shown that 
overexpression of the FasL ICD is sufficient to initiate reverse signaling upon 
concomitant T cell receptor (TCR) stimulation and ICD cross-linking. 
Conflicting data on the consequences of FasL reverse signaling exist, and co-
stimulatory as well as inhibitory functions have been reported. These discrepancies 
probably reflect the use of artificial experimental systems. Neither the precise 
molecular mechanism underlying FasL reverse signaling, nor its physiological 
relevance have been addressed at the endogenous protein level in vivo. 
Therefore, a ‘knockout/knockin’ mouse model in which wildtype FasL was replaced 
with a deletion mutant lacking the intracellular portion (FasL ∆Intra) was established 
in the group of PD Dr. Martin Zörnig. In the present study, FasL ∆Intra mice were 
phenotypically characterized and were employed to investigate the physiological 
consequences of FasL reverse signaling at the molecular and cellular level. 
 
To ensure that FasL  ∆Intra mice represent a suitable model to study the 
consequences of FasL reverse signaling, we demonstrated that activated 
lymphocytes from homozygous FasL ∆Intra or wildtype mice express comparable 
amounts of (truncated) FasL at the cell surface. The truncated protein retains the 
capacity to induce apoptosis in Fas receptor-positive target cells, as co-culture 
assays with FasL-expressing activated lymphocytes and Fas-sensitive target cells 
showed. Additionally, systematic screening of unchallenged mice did not reveal any 
phenotypic abnormalities. Notably, signs of a lymphoproliferative autoimmune 
disease associated with FasL-deficiency could not be detected. 
As several reports have implicated FasL reverse signaling in the regulation of T cell 
expansion and activation, proliferation of lymphocytes isolated from FasL ∆Intra and 
wildtype mice in response to antigen receptor stimulation was investigated. Using 
CFSE dilution assays it could be demonstrated that the proliferative response of 
CD4
+ T cells, CD8
+ T cells and of B cells was enhanced in the absence of the FasL 
ICD. Interestingly, this effect was most pronounced in B cells and could only be 
detected in CD4
+ T cells after depletion of CD4
+CD25
+ regulatory T cells. To our Summary 
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knowledge, this is the first time that FasL reverse signaling has been demonstrated 
in B cells. 
In a series of experiments, the activation of several pathways that are known to play 
important roles in signal-transmission initiated upon antigen receptor triggering was 
assessed. As a molecular correlate for the observed enhancement of activation-
induced proliferation, Extracellular signal regulated kinase (ERK1/2) phosphorylation 
was significantly increased in FasL ∆Intra mice following antigen receptor cross-
linking. Surprisingly, B cell stimulation lead to a comparable extent of activating 
phosphorylations on S38 in c-Raf and S218/S222 in MEK1/2 in cells isolated from 
wildtype and FasL  ∆Intra mice, indicating that Mitogen activated protein kinases 
(MAPKs) upstream of ERK1/2 (Raf-1 and MEK1/2) apparently do not contribute to 
the differential regulation of ERK1/2. Experiments in which activation-induced Akt 
phosphorylation (S473) was quantified also did not suggest a participation of 
Phosphoinositol specific kinase 3 (PI3K)/Akt signals in this process. Instead, further 
characterization of the upstream pathway revealed an involvement of Phospholipase 
C gamma (PLCγ) and Protein kinase C (PKC) signals in FasL-dependent ERK1/2-
regulation. 
Previous studies in our group revealed a Notch-like processing of FasL, resulting in 
the transcriptional regulation of a reporter gene. Furthermore, an interaction of the 
FasL ICD with the transcription factor Lymphoid-enhancer binding factor-1 (Lef-1) 
that affected Lef-1-dependent reporter gene transcription could be demonstrated. 
Therefore, a molecular analysis of activated lymphocytes was performed to identify 
FasL reverse signaling target genes. The differential expression of promising 
candidates was verified by quantitative real-time PCR (qRT-PCR), which showed 
that the transcription of genes associated with lymphocyte proliferation and 
activation was increased in FasL  ∆Intra mice compared to wildtype mice. 
Interestingly, an extensive regulation of Lef-1-dependent Wnt/β-Catenin signaling-
related genes was found. Lef-1 mRNA (RT-PCR) and protein (intracellular FACS 
staining) could be detected in mature B cells, suggesting the possibility of FasL ICD-
mediated inhibition of Lef-1-dependent gene expression in these cells, initiated by 
Notch-like processing of FasL. 
 
To investigate the consequences of FasL reverse signaling in vivo, a potential 
participation of the FasL ICD in the regulation of immune responses upon various 
challenges was analyzed. In experiments in which thymocyte proliferation or the 
expansion of antigen-specific T cells following a challenge with the superantigen 
Staphylococcus enterotoxin B (SEB), with Lymphocytic choriomeningitis virus Summary 
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(LCMV) or with Listeria monocytogenes were investigated, comparable results were 
obtained with wildtype and FasL  ∆Intra mice. Likewise, the recruitment of 
neutrophils in a thioglycollate-induced model of peritonitis was not affected by 
deletion of the FasL ICD. These findings might reflect regulatory mechanisms 
operating in vivo, such as control exerted by regulatory T cells. Along these lines, 
proliferative differences in CD4
+ T cells could only be detected ex vivo after 
depletion of CD4
+CD25
+ regulatory T cells. Furthermore, several in vitro studies 
indicate that retrograde FasL signals can be observed under conditions of sub-
optimal lymphocyte stimulation, but not when the TCR is optimally stimulated. 
Therefore, the potent initiation of antigen receptor signaling by stimuli like SEB or 
LCMV might have masked inhibitory FasL reverse signaling in these experiments. 
In agreement with the observed hyperactivation of lymphocytes in the absence of 
the ICD ex vivo, the increase in germinal center B cells (GCs) following 
immunization with the hapten 3-hydroxy 4-nitrophenylacetyl (NP) and the number of 
antibody-secreting PCs was significantly higher in FasL  ∆Intra mice. The larger 
quantity of PCs correlated with increased titers of NP-binding, i.e. antigen-specific, 
IgM and IgG1 antibodies in the serum of FasL  ∆Intra mice after immunization. 
These data suggest that FasL reverse signaling exerts immunmodulatory functions. 
Supporting this notion, a model of Ovalbumin-induced allergic airway inflammation 
revealed an involvement of retrograde FasL-signals in the recruitment of immune 
effector cells into the lung and in the activation of T cells following exposure of mice 
to Ovalbumin. 
 
Together, our ex vivo and in vivo findings based on endogenous FasL protein levels 
demonstrate that FasL ICD-mediated reverse signaling is a negative modulator of 
certain immune responses. It is tempting to speculate that FasL reverse signaling 
might be a fine-tuning mechanism to prevent autoimmune diseases, a theory which 
will be tested in adequate mouse models in the future. 
 
 Introduction 
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1 Introduction 
 
1.1 Apoptosis 
The term apoptosis, often used synonymously with ‘programmed cell death’, 
describes a physiological form of cell death that proceeds through a highly ordered 
sequence of events and results in the self destruction of cells. In multicellular 
organisms, apoptosis plays crucial roles during embryonic development, in adult 
tissue homeostasis, the weeding out of lymphocytes after an immune response and 
in the killing of virus-infected cells. Paying tribute to these essential functions, its 
course is tightly controlled and failure in its regulation are associated with the 
development of severe diseases such as cancer (defective apoptosis), 
neurodegeneration (excess apoptosis) or autoimmune pathologies (defective 
clearance of apoptotic cells and/or too little apoptosis). Apoptosis is characterized by 
different morphological and biochemical features, including cell shrinkage, 
membrane blebbing, chromatin condensation and DNA fragmentation (‘DNA 
laddering’). In a final step, so-called apoptotic bodies, loaded with cell contents, are 
phagocytosed by neighboring cells or macrophages to prevent an inflammatory 
response. This is in contrast to death by necrosis, during which leakage of cellular 
contents triggers a strong inflammatory reaction (Jin et al., 2005; Hotchkiss et al., 
2009). 
Apoptosis can proceed by two different mechanisms: the extrinsic and the intrinsic 
pathway (Fig. 1.1). The two pathways are triggered by different stimuli and involve a 
distinct apoptotic machinery. However, the cascade-like action of aspartate specific 
cystein proteases (caspases) is a key event in both cases, and considerable cross-
talk between the extrinsic and the intrinsic pathway occurs. Caspases are 
synthesized as inactive pro-enzymes that become activated by (auto-) catalytic 
cleavage. Triggering of the apoptotic machinery leads to the auto-catalytic cleavage 
of initiator caspases (Caspases-2, -8, -9, -10) which subsequently convert effector 
caspases (Caspases-3, -6, -7) into their active form. Effector caspases then mediate 
the final events of cell death by targeting proteins involved in DNA repair, cell cycle, 
the regulation of apoptosis (anti-apoptotic proteins) or in cell architecture (Green et 
al., 2003; Jin et al., 2005; Hotchkiss et al., 2009; Strasser et al., 2009).  
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Figure 1.1 Schematic overview of extrinsic and intrinsic apoptosis pathways. 
Right: The extrinsic apoptosis-pathway is triggered by death domain (DD)-containing 
members of the TNFR family (death-receptors; here, Fas is shown exemplary) and 
requires FADD-mediated activation of Caspase-8 within the DISC. Auto-proteolysis 
of Caspase-8 results in a heterotetrameric form that can escape the DISC and that 
is able to activate effector caspases (Caspase-3 and Caspase-7), eventually leading 
to cleavage of vital proteins within the cell. Left: The intrinsic Bcl-2-regulated 
pathway is triggered by the activation of BH3-only proteins and is balanced by the 
complex interplay between pro- and anti-apoptotic members of the Bcl-2 protein 
family. It involves mitochondrial outer membrane permeabilization (MOMP) which 
results in release of Cytochrome c from the intermembrane space of the 
mitochondria into the cytosol to initiate apoptosome formation. Within the 
apoptosome, Apaf-1 mediates activation of the initiator Caspase-9, further leading to 
proteolytic activation of the downstream effector caspases (Caspase-3 and 
Caspase-7). BH3-only: Bcl-2 homology domain 3-only protein; MOMP: mitochondrial 
outer membrane permeabilization; Cyt. C.: cytochrome c; ICAD: Inhibitor of caspase 
activated DNase (CAD); PARP: Poly (ADP-ribose) polymerase. Adapted from 
(Strasser et al., 2009).  
 
1.1.1 The extrinsic pathway of apoptosis 
The extrinsic pathway of apoptosis is initiated by the binding of death ligands to their 
corresponding death receptors at the cell surface. Death receptor/ligand pairs 
belong to the tumor necrosis factor (TNF) protein family (TNFR/TNF, Fas/FasL, 
TRAIL-DR4 or -DR5/TRAIL). TNF-family receptors (TNFR) are type I 
transmembrane proteins with a characteristic ~80 aa, death domain (DD)-containing 
cytoplasmic tail and with motifs important for self-assembly (preligand assembly Introduction 
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domain; PLAD) and ligand-binding (cystein-rich domains, CRDs) in the extracellular 
part. Notably, decoy receptors (DcR3, DcR6) with a non-functional DD have been 
identified and were reported to antagonize TNFR-mediated apoptosis in a dominant 
negative fashion.  
The cognate ligands are homotrimeric type II transmembrane proteins that bind their 
receptor via a TNF homology domain. Ligand binding induces the formation of the 
death-inducing signaling complex (DISC) by recruitment of DD-containing adaptor 
proteins like Fas-associated death domain (FADD) or TNF receptor-associated 
protein with a death domain (TRADD) and of pro-Caspase-8. Thereby, 
adaptor/receptor binding is mediated by the DD present in both proteins, and 
homophilic adaptor/pro-caspase interaction occurs via death effector domains 
(DED). FADD-dependent auto-catalytic processing of the pro-caspase within the 
DISC facilitates the Caspase-8-mediated activation of donwstream effector 
caspases. Caspase-8 activation at the DISC can be antagonized by cellular FLICE-
like inhibtory proteins (c-FLIPs). Although common players are involved in the 
extrinsic pathway, their assembly and utilization is unique for each death receptor 
(Wajant, 2003; Eissner et al., 2004; Guicciardi et al., 2009; Strasser et al., 2009). 
 
 
1.1.2 The intrinsic pathway of apoptosis 
The intrinsic pathway of apoptosis is triggered by different signals, for example DNA 
damage, UV radiation, growth factor withdrawl, chemicals or oxidative stress. In 
response to a specific death signal, distinct members of the Bcl-2-homology domain 
3 (BH3)-only protein family become activated and translocate to the outer 
mitochondrial membrane. Their association with pro-apoptotic members of the Bcl-2 
protein family results in the permeabilization of the membrane (mitochondrial outer 
membrane permeabilization; MOMP). Consequently, the mitochondrial membrane 
potential is lost, and pro-apoptotic proteins, such as Cytochrome c, inhibitor of 
apoptosis (IAP) antagonists and pro-caspases, are released into the cytoplasm. In 
the presence of dATP, the apoptosome, a ternary complex consisting of 
Cytochrome c, the Apoptosis protease-activating factor 1 (Apaf1) and pro-Caspase-
9, is formed. Within the apoptosome, the caspase cascade is initiated by 
autocatalytic processing of Caspase-9 that subsequently activates effector 
Caspase-3. Regulation of the intrinsic pathway occurs largely through the Bcl-2 
protein family: the balance between pro- and anti-apoptotic members determines the 
sensitivtiy of a cell to apoptosis (Shi, 2002; Jin et al., 2005; Peter et al., 2007; 
Guicciardi et al., 2009; Ramaswamy et al., 2009; Strasser et al., 2009). Introduction 
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1.2 The FasL/Fas system 
 
1.2.1 Molecular mechanism of FasL/Fas-induced apoptosis 
Fas (CD95; APO-1; TNFRSF6) is a prototypic member of the TNF receptor 
superfamily. When expressed at the cell surface, individual Fas proteins form 
homotrimers  via interaction of their PLA-domains. This pre-assembly is a pre-
requisite for ligand binding (Chan et al., 2000; Siegel et al., 2000). Signaling via Fas 
(Fig. 1.2) is initiated by binding of its cognate ligand, FasL, which induces an open 
conformation in the cytoplasmic tails of Fas and promotes the multimerization of 
receptor trimers. Subsequently, DISC components are recruited to the Fas DD 
(Algeciras-Schimnich et al., 2002; Ramaswamy et al., 2009; Scott et al., 2009). 
Cytoskeletal rearrangements and palmitoylation of Fas target the complex to 
glycosphingolipid-enriched membrane rafts (lipid rafts) (Chakrabandhu et al., 2007; 
Koncz et al., 2008). Upon coalescence of several lipid rafts, larger signaling 
platforms, so-called signaling protein oligomerization transduction structures 
(SPOTs), are formed to recruit pro-Caspase-8 (Siegel et al., 2004). Efficient 
apoptotic signaling then requires receptor clustering within SPOTs (‘capping’) and 
Clathrin-mediated receptor-complex endocytosis, as endosomes serve to locally 
concentrate components of the apoptotic machinery and to promote DISC formation 
(Lee et al., 2006; Chakrabandhu et al., 2008; Guicciardi et al., 2009).  
 
Figure 1.2 Initiation of Fas signaling.  
(I) Ligand-independent receptor pre-association via PLADs. (II) Ligand binding 
triggers a conformational change, receptor multimerization and low level of DISC 
formation. (III) Recruitment of FasL into lipid rafts to form SPOTs. (IV) Raft 
coalesence. This step depends on generation of active Caspase-8 by the DISC. In Introduction 
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the absence of internalization, signals from steps 2-4 rather activate non-apoptotic 
pathways. (V) Receptor internalization by Clathrin-mediated endocytosis. (VI) 
Further recruitment of DISC components into endosomes and high level DISC 
formation. Blue domains, DED; red domain, DD; the N-terminal PLAD in Fas is 
shown in a different green tone. Adapted from (Lee et al., 2006). 
 
Within the DISC, pro-Caspase-8 undergoes a FADD-mediated conformational 
change that facilitates its autocatalytic processing into the active, heterotetrameric 
enzyme. This process can be antagonized by the cellular FLICE-like inhibitory 
protein (c-FLIP), a caspase-like molecule without proteolytic activity that interferes 
with pro-Caspase-8 processing (Scaffidi et al., 1999). Mature Caspase-8 dissociates 
from the DISC to cleave effector Caspase-3 and/or the BH3-only protein Bid. 
Depending on the amount of active Caspase-8 and the actually targeted substrate, 
two cell types have been distinguished, type I and type II cells (Scaffidi et al., 1998; 
Scaffidi et al., 1999). In type I cells, Caspase-8 directly cleaves Caspase-3, and this 
is sufficient for effective apoptotic signaling. In contrast, type II cells require an 
amplification of the death receptor signal by Caspase-8-mediated cleavage of Bid. 
Truncated Bid (tBid) translocates to the mitochondria to trigger the caspase cascade 
via the intrinsic pathway (Andera, 2009; Ehrenschwender et al., 2009; Guicciardi et 
al., 2009; Ramaswamy et al., 2009; Strasser et al., 2009). 
 
 
1.2.2 Apoptotic Fas signaling in the immune system 
FasL/Fas-induced apoptosis is crucial for immune system homeostasis, effector 
functions and self tolerance and is involved in the killing of target cells by natural 
killer (NK) and cytotoxic T cells, in the (self) elimination of effector cells and in the 
maintenance of immune-privileged sites (Igney et al., 2005; Fas et al., 2006). Owing 
to the potent pro-apoptotic signaling capacity and the critical functions of the 
FasL/Fas system, FasL expression and activity are tightly regulated and restricted to 
few cell types, such as immune effector cells and cells of immune-privileged sites. In 
contrast, Fas is expressed in a variety of tissues including the lymphoid tissues, 
liver, heart, kidney, pancreas, brain and ovary (Kavurma et al., 2003; Guicciardi et 
al., 2009).  
The importance of proper execution of FasL/Fas-mediated apoptosis is pointed out 
by two naturally occuring mutant mouse strains, FasL
gld/gld and Fas
lpr/lpr, that harbor 
inactivating mutations in the FasL and Fas gene, respectively. A point mutation in 
the extracellular domain of FasL abolishes receptor binding in FasL
gld/gld mice. In 
Fas
lpr/lpr mice, the Fas gene either contains a transposon insertion in intron 2 leading 
to aberrant splicing, or a point mutation in the cytoplasmic DD that prohibits FADD Introduction 
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recruitment and DISC formation (Fas
lpr cg). All these mutations prevent apoptosis 
triggered by the FasL/Fas system and lead to the production of auto-antibodies and 
the development of a lymphoaccumulative disease (Adachi et al., 1993; Takahashi 
et al., 1994a). Dominant-interfering mutations in Fas or FasL cause a similar 
autoimmune disease in humans called autoimmune lymphoproliferative syndrome 
(ALPS) (Rieux-Laucat, 2006). In mice, lymphoaccumulation involves the emergence 
of an anormal, ‘double negative’ T cell population (CD3
+B220
+CD4
-CD8
-) that is 
derived from normal CD8
+ T cells and that is a critical mediator of the autoimmune 
pathology (Cohen et al., 1991). Despite FasL
gld/gld and Fas
lpr/lpr mice being commonly 
referred to as FasL- or Fas-deficient, it could be shown that cells of both mutants 
retain some residual FasL and Fas activity, respectively (Adachi et al., 1993; Chu et 
al., 1993; Karray et al., 2004), and that conventional homozygous FasL
-/- and Fas
-/- 
knockout-mice develop a much more pronounced phenotype than the naturally 
occurring mutants (Karray et al., 2004; Mabrouk et al., 2008).  
 
 
1.2.2.1 Lymphocyte death in the periphery: activation-induced cell death  
(AICD) and activated cell autonomous cell death (ACAD) 
Acute infection leads to the antigen-specific activation of immune effector cells and 
their massive clonal expansion. These armed effector cells help to clear the infection 
by direct or indirect lysis of infected target cells, mediated by FasL/Fas-, perforin- or 
granzyme-induced cell death (Brenner et al., 2008). Once pathogens have been 
cleared, the immune response needs to be terminated to eliminate the now excess 
and potentially dangerous effector cells. While a small percentage of antigen-
specific effectors becomes memory cells, retained as safeguards against future 
infections, most cells are deleted by suicide or fratricide.  
Once thought to be dependent on Fas, cell death following acute immune responses 
is attributed to activated cell autonomous death (ACAD) now. This death by neglect 
depends on the BH3-only protein BIM and occurs due to the relative cytokine 
deficiency after clonal expansion that leads to a shift in the balance of pro- and anti-
apoptotic proteins (Hildeman et al., 2002; Green et al., 2003; Fas et al., 2006; 
Krammer et al., 2007; Brenner et al., 2008). 
In contrast, activation-induced cell death (AICD), also sometimes referred to as re-
stimulation-induced cell death (RICD), is responsible for the elimination of cells in 
states of antigen persistance, for example in chronic infections. Persistent antigen 
re-stimulates already activated lymphocytes and thus, renders lymphocytes 
sensitive to apoptosis. AICD often, but not necessarily, is induced by death receptor Introduction 
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signaling, and the concomitant increases of FasL cell surface expression upon re-
stimulation and of sensitivity to Fas-mediated killing are crucial mediators (Stranges 
et al., 2007; Ramaswamy et al., 2009). AICD not only plays a role in chronic 
infections, but has also been implicated in the maintenance of peripheral tolerance. 
Self-reactive lymphocytes are repeatedly stimulated by the frequent encounter of 
(self) antigen, rendering them sensitive to AICD, especially in the absence of co-
stimulation (Brenner et al., 2008; Strasser et al., 2009). 
 
 
1.2.2.2 FasL/Fas-induced apoptosis in B cell function 
Besides its role in AICD, Fas-induced apoptosis of or by B cells is crucial for proper 
immune system functions and the prevention of autoimmunity. Antigen-activated B 
cells upregulate Fas, but are initially protected from apoptosis due to simultaneous 
cross-linking of their B cell receptor (BCR) and of the co-stimulatory receptor CD40. 
Upon immune response termination, T cells downregulate CD40 ligand (CD40L) 
expression and display increased levels of FasL. Consequently, B cells lose the co-
stimulatory signal, become Fas-sensitive and are deleted by FasL-expressing T 
cells (Rathmell et al., 1996; Mizuno et al., 2003; Ramaswamy et al., 2009). Likewise, 
B cell selection in germinal centers depends on apoptotic Fas signaling. Within 
germinal centers, B cells undergo somatic hypermutation, receptor editing and 
immunglobulin (Ig) isotype class switching, resulting in high affinity antibody-
producing plasma cells. Providing an important mechanism for maintenance and 
induction of peripheral tolerance, B cells that become auto-reactive during these 
mutational events or fail to produce high affinity antibodies are eliminated by FasL-
expressing intrafollicular CD4
+ T cells (Rathmell et al., 1996; Guzman-Rojas et al., 
2002; McHeyzer-Williams, 2003; Mizuno et al., 2003). 
In addition to receiving an apoptotic Fas signal, B cells themselves can deliver such 
a signal via FasL. Induction of FasL expression on B cells is observed upon 
bacterial, parasitic or viral infections, such as infection with Schistosoma mansoni, 
Trypanosoma cruzi, human immunodeficiency virus (HIV), murine leukemia virus 
(MuLV) or Epstein-Barr virus (EBV). Furthermore, FasL-expressing B cells control 
diseases caused by de-regulated T cells, and this is involved in peripheral tolerance 
and autoimmunity, for example during airway inflammation-, asthma- or transplant-
induced immune responses. In most instances, B cells were shown to eliminate 
activated, antigen-specific T cells via FasL-mediated AICD. This process might be 
aided by the capacity of B cells to serve as professional antigen presenting cells Introduction 
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(APCs) for T cells (Hahne et al., 1996; Lundy et al., 2002; Bonardelle et al., 2005; 
Lundy, 2009; Lundy et al., 2009). 
Interestingly, fully matured plasma cells, i.e. those having undergone class switching 
to IgA or IgG and secreting quantities of antibody, were shown to store high 
amounts of FasL in para-nuclear, probably Golgi-associated compartments. It was 
hypothesized (without direct experimental evidence) that plasma cells delivering 
antibodies to the site of infection concomitantly express FasL at their cell surface, or 
secrete exosome-associated FasL, to delete local effector T cells and to down-
modulate the immune response (Strater et al., 1999). 
 
 
1.2.3 Apoptotic Fas signaling outside the immune system 
FasL/Fas signaling contributes to tissue homeostasis and pathologic states in some 
non-immune tissues. Fas-induced apoptosis was shown to play a role in liver 
homeostasis, as Fas-deficient mice develop liver hyperplasia. In the neurological 
system, FasL/Fas-mediated apoptosis of neurons occurs as a consequence of 
growth factor withdrawl and spinal cord injury, is induced by the Alzheimer’s disease 
associate Aβ-peptide and plays a key role in neonatal brain disorders. Furthermore, 
pancreatic islet cell destruction in type I diabetes depends on Fas, and in the 
cardiovascular system apoptotic Fas signaling has been implicated in the regulation 
of cardiac hypertrophy, angiogenesis and the response to reperfusion injury in 
stroke and myocardial infarction (Green et al., 2003; Ehrenschwender et al., 2009; 
Hotchkiss et al., 2009). 
 
 
1.2.4 FasL/Fas signaling in the establishment of immune privilege and in  
         tumor biology 
Due to its very potent pro-apoptotic potential, FasL expression is restricted to 
immune effector cells and a few tissues outside the immune system, including the 
eye, brain, testis and uterus (French et al., 1996a; French et al., 1996b; Nagata, 
1997; Kavurma et al., 2003). The non-lymphoid FasL-expressing tissues are special 
as they do not reject allogenic transplants and, therefore, are said to be ‘immune-
privileged’. The immune-privileged status largely depends on the capacity to 
eliminate infiltrating lymphocytes by FasL/Fas-induced apoptosis to prevent tissue 
damage and a local inflammatory reaction (Griffith et al., 1995; Itoh et al., 1995; 
Streilein, 1995). However, the capacity to kill in a FasL-dependent manner is not the 
sole determinant of immune privilege, and production of immunsuppressive Introduction 
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cytokines, low levels of major histocompatibility (MHC) complex expression and a 
physical barrier are required concomitantly (Green et al., 2001). 
Besides the constitutive immune-privileged status of some tissues, induced immune 
privilege has been discussed for tissues like the small intestine, lung, liver and skin, 
as a mechanism to attenuate or terminate local immune responses and to prevent 
excess tissue damage (Schwarz et al., 1998; Green et al., 2001; Viard-Leveugle et 
al., 2003). Induced immune privilege involves the induction of FasL expression at 
the surface of non-lymphoid cells to eliminate infiltrating T cells by AICD. It is 
hypothesized, that FasL expression is mediated by the T cells themselves: activated 
T cells produce TNFα, which is known to induce FasL. In this scenario, an immune-
privileged status would only be obtained above a certain threshold of T cell signaling 
strength; below that threshold, peripheral T cells would not be deleted, and the 
immune response could proceed unhindered (Green et al., 2001; Krammer et al., 
2007).  
Using similar mechanisms as the ones used to establish natural immune-privileged 
sites, tumors can establish a quasi immune-privileged status for themselves. Many 
tumor cells express FasL and/or secrete FasL-containing microvesicles and were 
found to kill infiltrating, activated lymphocytes (Igney et al., 2005). This concept of a 
‘tumor counterattack’ is controversial and has been challenged by the observation of 
FasL
+ transplant rejection, the higher incidence of plasmacytoid lymphomas in Fas- 
and FasL-defective mice (Fas
lpr/lpr, FasL
gld/gld) and of enhanced inflammation upon 
Fas stimulation at the surface of tumor cells (Bellgrau et al., 1995; Davidson et al., 
1998; Brunner et al., 2001; Wasem et al., 2001; Allison et al., 2005; 
Ehrenschwender et al., 2009). However, inflammatory neutrophil recruitment has 
also been associated with tumor growth, possibly due to non-apoptotic Fas signaling 
(see below) mediated by FasL expressed on neutrophils (Restifo, 2000). Indeed, 
many tumors are resistant to Fas-mediated apoptosis, and non-apoptotic Fas 
signaling triggered by neighboring tumor cells or by infiltrating immune cells has 
been correlated with tumor motility and invasiveness in vitro (Barnhart et al., 2004; 
Ametller et al., 2010). A recent report demonstrates in various human cancer cell 
lines in vitro and in mouse models of ovarian and liver cancer in vivo that growth and 
survival of many cancer cells depend on constitutive, non-apoptotic Fas signaling 
(Chen et al., 2010). Intriguingly, these signals are delivered by tumor-produced 
FasL, not by FasL-expressing cells in the microenvironment or of the immune 
system, and require only very low levels of Fas and FasL protein expression.  
Thus, there might be a dual role for FasL/Fas in cancer: in some instances it might 
aid in tumor surveillance and regression, while in others, non-apoptotic Fas-Introduction 
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signaling into tumors and/or FasL-mediated killing of immune effectors by tumor 
cells (‘counterattack’) favour tumor growth and aggressiveness (Green et al., 2001; 
Igney et al., 2005; Peter et al., 2007).  
 
 
1.2.5 Non-apoptotic Fas signaling 
In addition to its potent pro-apoptotic function, the FasL/Fas system can elicit non-
apoptotic signals in the receptor-bearing cell as well. Fas signaling was shown to 
exert co-stimulatory functions, such as promotion of proliferation, cytokine 
production and survival of mature lymphocytes and thymocytes, of positive selection 
in the thymus and of dendritic cell maturation (Wajant et al., 2003; Guicciardi et al., 
2009). Additionally, proliferation of serum-starved fibroblasts depends on Fas, and 
liver regeneration after partial liver hepatectomy is blocked in Fas-deficient models. 
In the neural system, non-apoptotic Fas signaling induces neurite outgrowth and 
branching, mediates nerve regeneration and contributes to adult neuronal stem cell 
maintenance and function. Further known functions of non-apoptotic Fas signaling 
include contributions to the homeostasis of intestine, heart and pancreas and to 
oncogenic signaling leading to tumor progression (Janssen et al., 2003; Wajant et 
al., 2003; Barnhart et al., 2004; Ehrenschwender et al., 2009; Strasser et al., 2009; 
Chen et al., 2010).  
Which signals determine the consequences (pro- vs. anti-apoptotic) of Fas 
signaling? Although the precise mechanism of decision making has yet to be 
elucidated, it is clear that FasL/Fas signaling requires more than the mere 
ligand/receptor interaction and that the subcellular localization, post-translational 
modifications, strength of receptor triggering and the microenvironment, including 
the activity levels of intracellular signaling pathways, all play crucial roles. Along 
these lines, post-translational modifications of Y291 and/or C199 in the Fas 
intracellular domain control Fas multimerization, targeting to lipid rafts, receptor 
internalization and the route of receptor internalization (Clathrin-dependent vs. -
independent). Retention of Fas at the cell surface and Clathrin-independent 
internalization both favour non-apoptotic outcomes (Lee et al., 2006; Chakrabandhu 
et al., 2007; Chakrabandhu et al., 2008; Rossin et al., 2010).  
c-FLIP is discussed as another important player in the regulation of Fas signals. 
Well described for its blockade of apoptosis by inhibiting Caspase-8 processing, it 
has also been shown to exert pro-apoptotic functions by activating Caspase-8 and, 
on the other hand, to trigger pro-survival and pro-proliferative pathways like the 
Nuclear Factor-κb (NF-κb)-, the Mitogen-activated protein kinase (MAPK) and the Introduction 
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Phosphoinositide 3-kinase (PI3K)/Akt-pathway (Hu et al., 2000; Dohrman et al., 
2005; Yu et al., 2008a; Strasser et al., 2009): MAPK signaling is probably initiated 
by binding of c-FLIP to Raf-1; NF-κb activation requires pro-Caspase-8-mediated 
cleavage of FLIP into p43-FLIP and p22-FLIP, leading to direct or indirect 
degradation of the I-κb kinase (IKK) complex. Recently, a direct interaction between 
c-FLIP and Akt has been shown to promote anti-apoptotic Akt functions (Krammer et 
al., 2007; Brenner et al., 2008; Guicciardi et al., 2009; Quintavalle et al., 2010). 
In addition, the DISC components FADD and Caspase-8 link Fas to anti-apoptotic 
pathways, e.g. to the MAPK/Extracellular signal regulated kinase (ERK1/2)-, NFκB-, 
PI3K-, Jun N-terminal kinase (JNK) and p38 pathway. The exact roles of FADD and 
Caspase-8 are not clear, and it is debated whether enzymatic caspase activity is 
required. It seems likely that the strength of receptor triggering determines the level 
of Caspase-8 activation and localization. While mature Caspase-8 heterotetramers 
escape the DISC to initiate the caspase cascade, un- or not fully processed 
Caspase-8 has been shown to remain localized to the DISC and to be involved in 
non-apoptotic signaling. Additionally, FADD and Caspase-8 have been found in a 
complex with the kinase Receptor interacting protein 1 (RIP1). Post-translational 
modifications of RIP-1 are decisive for survial vs. death signaling (Bentele et al., 
2004; Krammer et al., 2007; Lavrik et al., 2007; Matsumoto et al., 2007; Peter et al., 
2007; Guicciardi et al., 2009; Strasser et al., 2009; Chen et al., 2010). 
Interestingly, the Fas DD contains a motif (YXXL) that resembles immunoreceptor 
tyrosine activation motifs (ITAMs) or immunoreceptor tyrosine inhibitory motifs 
(ITIMs) and that allows the binding of SH2 domain-containing proteins. Tyrosine 
phosphorylation within this motif correlates with activation of the Src-family kinases 
(SFK) Lyn and Fyn and with activation of the PI3K pathway. This tyrosine 
phosphorylation facilitates recruitment of the SFK-targeting Protein tyrosine 
phosphatase 1/2 (SHP1/2) and SH2-domain containing inositol polyphosphate   
5’-phosphatase (SHIP) in T cells and glioma cells. Apparently, the outcome of Fas 
signaling is also balanced by a kinase-phosphatase interplay (Corsini et al., 2009; 
Sancho-Martinez et al., 2009).  
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1.3 The Fas Ligand 
 
1.3.1 FasL structure  
Fas Ligand (FasL; CD95L; CD178; TNSF6) is a 40 kDa glycosylated type II 
transmembrane protein with 279 aa in mice and 281 aa in humans that belongs to 
the TNF family (Fig. 1.3). It is conserved across species with a sequence identity of 
76.9% in mice vs. humans (Suda et al., 1993; Takahashi et al., 1994b). The 
extracellular domain (ECD) harbors a TNF homology domain, the receptor binding 
site, a motif for self assembly and trimerization and several putative N-glycosylation 
and a metalloprotease cleavage site/s (Orlinick et al., 1997a; Orlinick et al., 1997b). 
FasL shedding by metalloproteases liberates soluble FasL (sFasL). Alternatively, 
sFasL is produced by splicing. The cytoplasmic tail of FasL is the longest of all 
TNFL family members and contains several conserved signaling motifs, such as a 
putative tandem Casein kinase I phosyphorylation site (CKI-S), a unique proline-rich 
domain (PRD) and, in mice, one potential tyrosine phosphorylation site at aa 7. 
Human FasL can be phosphorylated at three tyrosine residues: aa 7, 9, and 13 
(Hahne et al., 1995; Watts et al., 1999; Voss et al., 2008; Ehrenschwender et al., 
2009; Weinlich et al., 2010). 
 
 
Figure 1.3 Structure of the murine FasL. 
The C-terminal extracellular domain contains the receptor binding site (horizontal 
stripes), a region for self assembly (SA) and the TNF homology domain (THD) which 
contains potential N-glycosylation sites. Proteolysis at the metalloprotease cleavage 
site (MP-S) liberates soluble FasL (sFasL). The N-terminal intracellular domain 
harbors a unique proline-rich domain (PRD) and a tandem Casein kinase I 
phosphorylation site (CKI-S). Murine FasL has one tryosine residue that can be 
phosphorylated (Y7), while human FasL contains three phosphorylatable tyrosines 
(Y7, Y9, Y13). Modified from (Voss et al., 2008). 
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1.3.2 Regulation of FasL expression and activity 
Unlike Fas, FasL is only found in few cell types where its expression and activity is 
tightly regulated at the transcriptional level and by several post-translational 
modifications. While FasL is constitutively expressed in non-lymphoid, immune-
privileged tissues, it is present at very low levels or completely absent at the surface 
of resting lymphocytes. FasL only becomes upregulated upon antigen-receptor 
stimulation in T and B cells (French et al., 1996a). 
 
 
1.3.2.1 Transcriptional control 
Several  cis-acting promoter elements have been implicated in the positive or 
negative regulation of the FasL gene. Activation-induced transcription is mediated 
by classical transcription factors like Stimulating protein-1 (SP-1), Nuclear factor of 
activated T cells (NFAT), NF-κb, Activating protein 1 (AP-1), Early growth response-
3 (Egr-3), c-Myc, Interferon regulatory factor 1 (IRF-1) and the Cyclin B1/Cyclin-
dependent kinase 1 (Cdk 1) complex. Negative regulators of FasL expression that 
antagonize aforementioned transcriptional activators include MHC class II 
transactivator (CIITA), retinoic acid, Transforming growth factor-β (TGF-β) and nitric 
oxide (Lettau et al., 2009).  
 
 
1.3.2.2 FasL sorting and storage 
The localization of FasL is presumed to differ between hematopoietic and non-
hematopoietic cells. In hematopoietic cells FasL is stored intracellularly in 
multivesicular bodies and becomes externalized upon cell activation only, while non-
hematopoietic cells constitutively express FasL at the cell surface (French et al., 
1996a; Kavurma et al., 2003).  
According to a publication by Griffith and co-workers, FasL is sorted to so-called 
secretory lysosomes after its synthesis (Bossi et al., 1999). In the human system 
this was shown to require Src-family kinase-mediated lysine mono-ubiquitination 
and phosphorylation of tyrosine residues in the FasL intracellular domain (ICD) 
(Zuccato et al., 2007). It is further assumed that lysosomal sorting critically depends 
on the FasL PRD, since deletion of the cytoplasmic tail leads to the constitutive 
expression of FasL on the cell surface of hematopoietic cells (Blott et al., 2001). 
However, recent studies did not find a co-localization of FasL with classical markers 
(CD63, CD107a) or components (perforin, granzyme) of secretory lysosomes, Introduction 
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suggesting FasL storage in other compartments (He et al., 2007; Kassahn et al., 
2009; Schmidt et al., 2009).  
Lymphocyte stimulation via the antigen receptor triggers a biphasic expression of 
FasL at the cell surface. Shortly after activation, preformed FasL is released at the 
immunological synapse and aids in the locally restricted, highly specific killing of 
target cells (Lettau, 2004). Additionally, lysosomal degranulation releases 
microvesicular bodies in which FasL is embedded in the plasma membrane 
(Martinez-Lorenzo et al., 1999). The second wave of expression requires de novo 
synthesis and might involve direct transport of FasL to the cell surface, as it was 
shown to be independent of lysosomal degranulation. FasL de novo synthesis is 
controlled in at least two ways: Xiao and colleagues reported a negative regulation 
of FasL synthesis by aa 2-33 in the FasL cytoplasmic tail (Xiao et al., 2004). 
Recently, it was demonstrated that induction of de novo synthesis depends on 
strong antigen receptor-mediated signals and that release of newly synthesized 
FasL is associated with significant levels of bystander cell lysis. In contrast, weak 
receptor-signals trigger the delivery of stored FasL specifically to the immunological 
synapse and do not induce de novo synthesis (He et al., 2010). 
 
 
1.3.2.3 Regulation of FasL activity by dynamic localization in lipid rafts 
As described for the Fas receptor (Hueber et al., 2002), a fraction of FasL is 
constitutively localized in membrane lipid rafts (Gajate et al., 2005; Cahuzac et al., 
2006). In a collaboration with Dr. Anne-Odile Hueber’s laboratory (INSERM/CRNS, 
Nice, France), the group of PD Dr. Martin Zörnig could show that increased amounts 
of FasL are found in rafts after efficient FasL/Fas interaction (Cahuzac et al., 2006). 
Raft disorganization and deletions within the intracellular FasL domain, particularly 
removal of the PRD, diminish raft partitioning and lead to decreased FasL killing 
(Cahuzac et al., 2006; Nachbur et al., 2006). Thus, FasL raft partitioning seems to 
be essential for maximum contact with the Fas receptor and the ability of FasL to 
induce Fas-mediated apoptosis.  
It has been suggested that targeting of FasL to rafts depends on palmitoylation of a 
cystein residue in the very N-terminal region of the transmembrane domain (aa 82). 
In this study, a C82S mutation abolishes raft partitioning, FasL cleavage by 
ADAM10 and target cell killing (Guardiola et al., manuscript in preparation). 
However, further analysis of the physiological relevance is needed, as the 
palmitoylatable cystein residue is not conserved. While it is present in human and 
porcine FasL, murine and rat proteins harbor tryptophan at position 82 instead.  Introduction 
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1.3.2.4 FasL processing 
Upon expression at the cell surface, the extracellular domain of FasL can be shed 
by matrix metalloprotease activity to produce sFasL. The function of sFasL was 
discussed controversial, and sFasL was reported to either cause apoptosis at a 
distant site, to dampen the apoptotic response by blocking Fas receptors or to be 
inactive (Tanaka et al., 1995; Suda et al., 1997; Schneider et al., 1998; Tanaka et 
al., 1998; Knox et al., 2003). A recent study using knockout/knockin mouse models 
largely solved this issue by demonstrating that only membrane-bound FasL 
mediates target cell lysis and that sFasL rather provokes pro-inflammatory and 
tumorigenic effects (O' Reilly et al., 2009).  
Recently, we have described a Notch-like proteolytic processing of FasL (Fig. 1.4). 
In a first step, membrane FasL is cleaved by the metalloprotease ADAM10 to 
generate sFasL and a 17 kDa fragment which remains membrane-anchored (Kirkin 
et al., 2007; Schulte et al., 2007). As discussed above, this step might require FasL 
palmitoylation and raft partitioning (Guardiola et al., manuscript in preparation). A 
subsequent cleavage within the transmembrane region by the protease Signal 
peptide peptidase-like 2a (SPPL2a) releases the intracellular domain (ICD) into the 
cytoplasm. The FasL ICD then translocates to the nucleus and may influence gene 
transcription (Kirkin et al., 2007). 
 
 
Figure 1.4 Proteolytic FasL processing. 
The FasL ECD is shed by the protease ADAM10 to generate sFasL and a 
membrane-anchored fragment consisting of TM and ICD. A second cleavage by the 
intramembrane-protease SPPL2a liberates the ICD which is able to translocate to 
the nucleus to regulate target gene expression. Black: intracellular domain (ICD); 
light grey: transmembrane domain (TM); dark grey: extracellular domain (ECD) 
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1.3.2.5 Regulation of FasL by proteins that bind to its intracellular domain  
Several FasL binding partners have been identified by GST-pull downs, phage 
display technology or in Yeast-two-hybrid screens, and the interaction with FasL 
was verified for a number of these proteins by co-immunoprecipitation experiments. 
The majority of the FasL binding proteins interact with the FasL PRD domain via 
their SH3 or WW domains and regulate many aspects of FasL biology (Baum et al., 
2005; Qian et al., 2006; Thornhill et al., 2007; Thornhill et al., 2008; Voss et al., 
2009). Putative and verified interaction partners include Src-family kinases (Src, 
Fyn, Lyn, Lck, Hck, Fgr, Abl), adaptor proteins (Grb2, Gads, p85 subunit of PI3K, 
Nck) and pombe cdc15 homology (PCH) family members (e.g. CD2BP1/PSTPIP, 
PACSIN1-3, FBP17, CIP4), and they link FasL to various intracellular signaling 
pathways. Src-kinases and adaptors like Growth factor binding protein 2 (Grb2) and 
Grb2-related adaptor downstream of Shc (Gads) are important mediators of antigen 
receptor-stimulated lymphocyte activation and could fascilitate FasL reverse 
signaling by connecting FasL and antigen receptor signals. Additionally, Src-kinases 
mediate the phosphorylation of FasL required for proper lysosomal sorting (Zuccato 
et al., 2007). The adaptor protein Nck is involved in activation-induced 
reorganization of the actin cytoskeleton in lymphocytes, and binding of Nck to the 
PRD was shown to facilitate recruitment of FasL-containing vesicles to the 
immunological synapse for targeted delivery (Lettau et al., 2006). PCH-family 
members have been implicated in the regulation of FasL localization: The group of 
PD Dr. Martin Zörnig reported a ternary complex consisting of FasL, the SH3 
domain-containing adaptor protein Proline, serine, threonine phosphatase 
interacting protein (PSTPIP) and the Protein tyrosine phosphatase-PEST, non-
receptor type, 12 (PTP-PEST; PTPN12). According to the data, formation of this 
complex reduces FasL cell surface expression by promoting intracellular storage of 
the ligand which correlates with a decreased FasL-dependent killing capacity (Baum 
et al., 2005). Furthermore, this complex is an attractive candidate for the initiation of 
FasL reverse signaling, since PSTPIP and PTP-PEST have been shown to 
negatively affect lymphocyte activation (Badour et al., 2003; Yang et al., 2006).  
Adding another facette to this already complex picture, we could recently confirm an 
interaction of the FasL ICD with the transcription factor Lymphoid-enhancer binding 
factor-1 (Lef-1) that regulates Lef-1-dependent transcription in vitro (Lückerath et al., 
manuscript submitted). 
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1.4 Reverse ligand signaling 
 
1.4.1 Reverse signal-transduction by TNF family ligands 
Up to now, 19 TNF family ligands have been identified, most of which are 
synthesized as type II transmembrane proteins and play important roles in immune 
system functions (Bodmer et al., 2002). Binding to cognate TNF-receptors is 
mediated by their extracellular TNF homology domain. Although the existence of 
soluble forms has been demonstrated for most TNFLs, receptor binding and 
triggering predominantely depends on the membrane-anchored ligand (Aggarwal, 
2003; Matthies et al., 2006). In addition to the well-described capacity to deliver a 
signal into receptor-bearing cells, many TNF ligands can receive signals 
themselves, a phenomenon which is known as ‘reverse signal-transduction’. Among 
the ligands for which a reverse signaling has been reported are CD40L (CD154), 
mTNF, FasL, OX40L, CD70 (CD27L), 4-1BB-L (CD137L), TNF-related activation-
induced cytokine receptor (TRANCE; RANKL), TNF-related apoptosis-inducing 
ligand (TRAIL), CD30L (CD153) and LIGHT (Table 1.1). Most studies found a (co-) 
stimulatory potential during antigen receptor-induced lymphocyte activation, 
proliferation and cytokine production. However, inhibitory functions have been 
described as well, and the outcome of retrograde signal-transduction probably 
depends on the cellular context. Along these lines, the precise molecular 
mechanism involved is not clear. As the cytoplasmic tail of TNFLs is conserved 
across species, but not between different family members, and since it harbors 
signaling motifs, e.g. a CK-I substrate site in CD40L, mTNF, FasL, CD70, 4-1BB-L 
and CD30L, retrograde signal-transduction is likely mediated by the respective 
intracellular domain (Watts et al., 1999; Eissner et al., 2004; Sun et al., 2007a). 
Of note, bidirectional signaling is not restricted to TNF family members but has also 
been described for Notch (D'Souza et al., 2008), ephrins (Pasquale, 2008), EpCam 
(Maetzel et al., 2009), Interleukin-15 (Bulfone-Paus et al., 2006), CD47 (Matozaki et 
al., 2009), semaphorins (Zhou et al., 2008) and possibly others. Intriguingly, there is 
a striking similarity in the mechanisms underlying reverse signaling and its 
regulation. 
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Table 1.1 TNFL members for which reverse signaling has been described.  
BC : B cell ; DC : dendritic cell ; NK: NK cells; TC: T cell ; MΦ: macrophages; M: 
monocytes; PMN: polymorphonuclear granulocyte (neutrophils); modified after (Sun 
et al., 2007a). 
 
Name  Expression  Receptor  Implications of reverse signaling 
CD40L   activated TC  CD40  co-stimulation, direct stimulation 
mTNF  MΦ, M  TNFR2 co-stimulation,  desensitisation 
FasL  activated TC & NK, BC  Fas; DcR3  co-stimulation, co-inhibition 
OX40L  activated TC, BC, DC, M  OX40  direct stimulation 
CD70   activated TC, BC, DC, M  CD27  direct stimulation 
4-1BB-L   activated TC, BC, DC, 
activated M 
4-1BB  co-stimulation of B cells ; activation, 
migration and infiltration of 
monocytes; inhibition of 
osteoclastogenesis and T cell 
proliferation (Senthilkumar et al., 
2009) 
TRANCE   activated TC  RANK  co-stimulation; inhibition of 
osteoclastogenesis and T cell 
proliferation (Senthilkumar et al., 
2009) 
TRAIL  activated TC & NK  TRAILR1  co-stimulation 
CD30L   PMN, BC, MΦ, activated 
TC 
CD30  co-stimulation, direct stimulation, 
inhibition 
LIGHT  activated TC, immature 
DC, M 
HVEM, 
LTαβR, 
DcR3 
co-stimulation 
 
 
1.4.2 FasL reverse signaling 
The first evidence for the existence of reverse signaling into the FasL-bearing cell 
stems from two studies that demonstrated either co-stimulation of murine CD8
+ T 
cell lines by FasL cross-linking (Suzuki et al., 1998) or inhibition of activation-
induced proliferation of murine CD4
+ T cell lines (Desbarats et al., 1998). In both 
cases, T cell lines derived from FasL
gld/gld, Fas
lpr/lpr and wildtype mice were analyzed, 
and it could be shown that FasL-deficient FasL
gld/gld cells responded differentially to 
concomitant FasL and TCR engagement compared to wildtype and Fas
lpr/lpr cells. 
These findings revealed that co-stimulation or inhibition by FasL critically depended 
on the presence of signaling-competent ligand, and they support the existence of a 
true reverse signaling into the ligand-bearing cell (instead of FasL-mediated receptor 
signals (‘forward signals’)).  
Almost certainly, the FasL ICD is functionally involved in transmission of this signal: 
(i) The ICD is highly conserved across species and harbors several signaling motifs, 
such as a unique PRD, a potential Casein kinase I substrate site, and it contains 
phosphorylatable tyrosines (Y7 in mouse; Y7, Y9, Y13 in human). (ii) Numerous 
proteins that bind to the PRD have been identified. These interactions aid in the 
regulation of FasL sorting, storage and cell surface expression, and they link FasL to Introduction 
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intracellular signaling pathways (Lettau et al., 2009; Ramaswamy et al., 2009; 
Weinlich et al., 2010). (iii) Post-translational modifications of the ICD have been 
implicated in the sorting of FasL to vesicles (Zuccato et al., 2007), and targeted 
mutations of serines that can be phosphoylated by CK-I decreased the activity of a 
Luciferase reporter construct for NFAT activation (Sun et al., 2006). (iv) Proteolytic 
processing of FasL liberates the ICD and allows its translocation into the nucleus 
where it might influence gene transcription (Kirkin et al., 2007). (v) Sun and co-
workers (Sun et al., 2006) demonstrated that expression and cross-linking of a 
membrane-tethered FasL ICD construct sufficed to initiate reverse signaling. 
Interestingly, bi-directional FasL signaling has been observed in non-lymphoid cells 
as well. In a murine sertoli cell line, FasL engagement proved to be essential for 
MAPK/ERK1/2-dependent activation of cytosolic Phospholipase A2 (cPLA2) (Ulisse 
et al., 2000). 
 
 
1.4.3 Functional implications of FasL reverse signaling 
Conflicting data about the consequences of FasL reverse signaling exist, and co-
stimulatory as well as inhibitory functions have been reported. Employing CD8
+ T 
cell lines derived from FasL
gld/gld  mice, one group found an impaired proliferative 
capacity of these cells upon T cell receptor (TCR) cross-linking, compared to 
wildtype or Fas
lpr/lpr CD8
+ T cells (Suzuki et al., 1998). In contrast, TCR-stimulation-
induced proliferation of wildtype and Fas
lpr/lpr CD4
+ T cells, but not of FasL
gld/gld CD4
+ 
T cells, could be inhibited by immobilized Fas-Fc fusion proteins, and this was 
accompanied by inhibition of IL-2 production and cell cycle progression (Desbarats 
et al., 1998). 
Follow-up studies by the group of Pamela Fink collected data supporting FasL-
mediated co-stimulation, for example during positive selection of thymocytes 
(Boursalian et al., 2003) and the proliferative response of mature CD8
+ T cells 
(Suzuki et al., 2000b; Sun et al., 2006; Sun et al., 2007b). Contradicting the 
publication by Desbarats et al. (1998), they claimed that both, naïve CD4
+ T cells 
and CD8
+ T cells, receive co-stimulatory FasL signals. In their hands, AICD masks 
the co-stimulatory signal in CD4
+ T cells in later phases of the immune response, 
when CD4
+ T cells become Fas sensitive while still expressing FasL. This does not 
occur in CD8
+ T cells, as CD8
+ T cells downregulate FasL and are comparably 
resistant to Fas-mediated death (Suzuki et al., 2000a). 
According to their findings, reverse signaling requires concomitant engagement of 
FasL and the TCR. This recruits FasL into lipid rafts, where it associates with SH3 Introduction 
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domain-containing proteins, such as Fyn, Grb2 and the p85 subunit of PI3K. The Akt 
pathway is then triggered via p85-PI3K leading to ERK1/2 activation, proliferation 
and IFN-γ production. Similarly, the transcription factor AP-1 is activated via the JNK 
pathway (Sun et al., 2006). It could be shown, that co-stimulation necessarily 
depends on the PRD, precisely on the SH3 domain binding site (aa 45–54) within 
the PRD. Notably, activation and nuclear translocation of NFAT apparently do not 
rely on the presence of the PRD, but require serine phosphorylation by CK-I (Sun et 
al., 2007b). 
However, the notion of FasL-mediated co-stimulation has again been challenged by 
a recent publication, in which FasL cross-linking by plate-bound Fas-Fc inhibits 
TCR-triggered activation and proliferation of CD4
+ and CD8
+ T cells isolated from 
peripheral human blood (Paulsen et al., 2009). This report suggests that FasL 
reverse signaling regulates TCR-induced signal-transduction at the very early step 
of TCR internalization. Consequently, activation of downstream signaling molecules, 
such as ζ-chain-associated protein kinase of 70 kDa (ZAP-70), Linker for activation 
of T cells (LAT), Phospholipase C gamma 1 (PLCγ1) and ERK1/2, is blocked, thus 
attenuating T cell activation upon antigen-encounter. 
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1.5 Aims of the project 
The conflicting data about the consequences of FasL reverse signaling probably 
reflect the use of artificial experimental systems. Neither the precise molecular 
mechanism underlying FasL reverse signaling, nor its physiological relevance have 
been addressed at the endogenous protein level in vivo. Therefore, a 
‘knockout/knockin’ mouse model in which wildtype FasL was replaced with a 
deletion mutant lacking the intracellular portion (FasL ∆Intra) was established in the 
group of PD Dr. Martin Zörnig by Dr. Vladimir Kirkin. In the present study, FasL 
∆Intra mice are phenotypically characterized and are employed to investigate the 
physiological consequences of FasL reverse signaling on the molecular and cellular 
level. 
 
Issues addressed include: 
(i) Do FasL  ∆Intra mice indeed represent a suitable model to study the 
consequences of FasL reverse signaling?  
FasL expression and functionality will be compared in T and B cells derived from 
FasL ∆Intra and wildtype mice. Systematic phenotypic screening performed at the 
German Mouse Clinic (GMC, Munich) and in our laboratory should reveal any 
phenotypic abnormalities that might develop due to defective reverse signal-
transduction. 
 
(ii) Does FasL reverse signaling play a role in the regulation of lymphocyte 
proliferation ex vivo and in vivo?  
Proliferation of lymphocytes in response to antigen receptor stimulation will be 
analyzed. If retrograde FasL signals participate in the regulation of proliferation, the 
underlying molecular mechanism will be elucidated. 
 
(iii) Which target genes are influenced by FasL reverse signaling?  
Molecular phenotyping of activated lymphocytes will be performed by Affymetrix 
gene profiling. The differential expression of potential target genes will be verified by 
quantitative real time PCR (qRT-PCR). 
 
(iv) What are the consequences of FasL reverse signaling in vivo?  
A potential participation of FasL reverse signaling in the regulation of immune 
responses to various challenges will be investigated. 
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2 Materials and methods 
 
2.1 Materials 
 
2.1.1 Equipment 
Autoclave Tuttnauer Systec 2540 EL  Systec, Wettenberg 
BioRad Power PAC 300   BioRad, Munich 
Branson Sonifier 250  Heinemann, Schwäbisch Gmünd 
CASY
® Cell Counter  Schärfe System, Reutlingen 
Centrifuge Megafuge 1.0R  Heraeus, Hanau 
Centrifuge Micro 220R  Hettich Zentrifugen, Tuttlingen 
Centrifuge Minifuge GL  Heraeus, Hanau 
DNA sub cell
TM, for agarose gels  BioRad, München 
Electrophoresis power supply EPS 301  GE healthcare, Freiburg 
FACSCalibur  Becton Dickinson, Heidelberg 
FluoStar Optima ELISA reader  BMG Labtechnologies, Offenburg 
Freezer CFC free (-80°C)  Sanyo, Wiesloch 
Fridge (4°C) and freezer (-20°C)  Liebherr Int., Ochsenhausen 
SemiPhor, Semi dry blotting device  Pharmacia, Freiburg 
Hypercassette
TM   GE healthcare, Freiburg 
Incubator IR-sensor (37°C, 5% CO2) Sanyo,  Wiesbaden 
Laminar air flow cabinet   Clean Air, Woerden 
Light Cycler 480  Roche, Mannheim 
MACS magnet  Miltenyi, Bergisch Gladbach 
Magnetic stirrer IKA RCT basic  IKA Labortechnik, Staufen 
Micowave oven  Samsung, Berlin 
Microscope (cell culture)  Hund, Wetzlar 
Mini-Protean
® 3 Cell gel chamber  BioRad, München 
Nanodrop 1000 spectrophotometer  Thermo Scientific, Bonn 
Optimax Typ TR film developer  MS Laborgeräte, Wiesloch  
pH meter FE20 Five Easy  Mettler Toledo, Schwerzenbach, 
Switzerland 
Pipetus-accu Hirschmann,  Neckartenlingen 
Roller RM5 Assistant 348  Karl Hecht GmbH, Sondenheim 
Scale model 1219 MP and H10T  Satorius, Göttingen 
Shaker Rocky NG  Frögel Labortechnik, Lindau 
Table top centrifuge, Biofuge pico  Heraeus, Hanau 
Thermocylcer GeneAmp PCR System 
9700 
Applied Biosystems, Darmstadt  
Thermomixer compact, heating block  Eppendorf, Hamburg 
UV-table GelDoc 2000  BioRad, Munich 
Vortex Genie2  Bender&Hobein, Zurich, Switzerland 
Water bath  GFL, Burgwedel 
 
 
 
2.1.2 Consumables 
1.5 ml reaction tubes  Eppendorf, Hamburg 
Cell culture 6 well-plates  Cornig, Amsterdam, Netherlands 
Cell culture 96 well-plates  Cornig, Amsterdam, Netherlands 
Cell culture dishes 10 cm  Greiner, Frickenhausen 
Cell culture flasks   Sarstedt, Nümbrecht Materials and Methods 
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Cell strainer 100 µm  Becton Dickinson, Heidelberg 
Cryo tubes  Nunc, Denmark 
FACS-tubes Greiner,  Frickenhausen 
Fujifilm Medical XRAY Film Super RX  Fujifilm, Düsseldorf 
Gloves  Rösner-Mauby Meditrade, Kiefersfelden 
LS Columns  Miltenyi, Bergisch Gladbach 
Nitrocellulose membrane hybond
TM  GE healthcare, Freiburg 
Parafilm  Pechiney Plastic Packaging, USA 
Pipette tips   Sarstedt, Nümbrecht 
Pipette tips with filters  BioZym, Oldendorf 
Pipettes   Becton Dickinson, Heidelberg 
Polystyrene tubes   Becton Dickinson, Heidelberg 
QIAshredder columns  Qiagen, Hilden 
qRT-PCR 96 well plates  Roche, Mannheim 
Reagent reservoirs  Cornig, Amsterdam, Netherlands 
Sterile filter units (0.45 µm, 0.22 µm)  Millipore, Schwalbach 
Syringe, 0.5 ml  Becton Dickinson, Heidelberg 
Syringe, 10 ml  Servoprax, Wesel 
Whatman paper 3MM  Whatman, Malstone, UK 
 
 
 
2.1.3 Chemical reagents 
4-hydroxy-3nitrophenyl acetate chicken 
gamma globuline (NP-CGG) 
Biosearch Tech., Novato, USA 
agarose UltraPure™  Invitrogen, Karlsruhe,  
aluminium-potassium-dodecahydrate 
(KAL(SO4)2) 
Merck, Darmstadt 
ammoniumpersulfate (APS)  Carl Roth GmbH, Karlsruhe 
Bovine serum albumine (BSA)  PAA Laboratories, Pasching, Austria 
Bradford reagent RotiQuant®  Carl Roth GmbH, Karlsruhe 
bromphenol blue  Fluka Chemie AG; Buchs, Switzerland 
carboxyfluorescein diacetate 
succinimidyl ester (CFSE) 
Invitrogen, Karlsruhe 
citric acid  Sigma-Aldrich, Taufkirch 
Concavalin A  Sigma-Aldrich, Taufkirch 
deoxy nucleotide triphosphates (dNTPs)  GE healthcare, Uppsala, Sweden 
dimethyl sulfoxide (DMSO)  Merck, Darmstadt 
dithiothreitol (DTT)  Carl Roth GmbH, Karlsruhe 
Dulbecco´s modified eagles medium 
(DMEM) 
Invitrogen, Karlsruhe 
ECL Western Blotting Reagents  GE Healthcare, Uppsala, Sweden 
ethanol  Carl Roth GmbH, Karlsruhe 
ethidiumbromide  Carl Roth GmbH, Karlsruhe 
ethylendiamintetraacetate (EDTA)  Carl Roth GmbH, Karlsruhe 
FasL-Flag, recombinant  Alexis Biochemical, San Diego, USA 
fetal calf serum (FCS)   Sigma-Aldrich, Taufkirch 
fluorescein digalactoside  Invitrogen, Karlsruhe 
Forene
® Isofluran  Abbott GmbH, Wiesbaden 
formaldehyde [37%]  Carl Roth GmbH, Karlsruhe 
glycerol  Carl Roth GmbH, Karlsruhe 
Hank’s balanced salt solution (HBSS)  Invitrogen, Karlsruhe 
HEPES  Carl Roth GmbH, Karlsruhe 
Histopaque
®-1083 Ficoll  Sigma-Aldrich, Taufkirch Materials and Methods 
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hydrogen peroxide (H2O2) Sigma-Aldrich,  Taufkirch 
IL-2 Roche,  Mannheim 
ionomycine Merck,  Darmstadt 
L-glutamine   PAA Laboratories, Pasching, Austria 
lipopolysaccheride Sigma-Aldrich,  Taufkirch 
magnesium chloride (MgCl2)  Carl Roth GmbH, Karlsruhe 
milk powder, low fat  AppliChem, Darmstadt 
non-essential amino acids (100x)  Invitrogen, Karlsruhe 
NP(17)-BSA  Biosearch Tech., Novato, USA 
NP(3)-BSA  Biosearch Tech., Novato, USA 
NP-40; IGEPAL CA-630   Sigma-Aldrich, Taufkirch 
o-phenylenediamine tablets  Sigma-Aldrich, Taufkirch 
penicillin/streptomycin  PAA Laboratories, Pasching, Austria 
phenylmethylsulfonylfluoride (PMSF)  Sigma-Aldrich, Taufkirch  
phorbol 12-myristate 13-acetate (PMA)  Sigma-Aldrich, Taufkirch 
phosphate buffered saline (PBS; sterile)  PAA Laboratories, Pasching, Austria 
polyethylenimine (PEI)  Sigma-Aldrich, Taufkirch  
poly-L-lysine  R&D Systems, Wiesbaden 
ponceau solution  Fluka Chemie AG; Buchs, Switzerland 
potassium chloride (KCl)  Carl Roth GmbH, Karlsruhe 
propidium iodide  Sigma-Aldrich, Taufkirch 
Rosewell park memorial institute (RMPI)  Bio Whittacker, Belgium 
Rotiphorese-Gel 30 (30% 
acrylamide/0.8% bisacrylamide) 
Carl Roth GmbH, Karlsruhe  
sodium pyruvat solution (100x)  Invitrogen, Karlsruhe 
sodiumacetate (NaAc)  Carl Roth GmbH, Karlsruhe 
sodiumazide (NaN3)  Carl Roth GmbH, Karlsruhe 
sodiumcarbonate (Na2CO3)  Carl Roth GmbH, Karlsruhe 
sodiumchlorid (NaCl)  Carl Roth GmbH, Karlsruhe 
sodiumdodecylsulfate (SDS)  Carl Roth GmbH, Karlsruhe 
sodiumhydrogenecarbonate (Na2HCO3)  Carl Roth GmbH, Karlsruhe 
sodiumhydroxide (NaOH)  Carl Roth GmbH, Karlsruhe 
sodiummcitrate (NaCi)  Carl Roth GmbH, Karlsruhe 
Staphylococcus enterotoxin B  Sigma-Aldrich, Taufkirch 
SYBR Green PCR master mix  Thermo Scientific, Bonn 
tetramethylethylendiamine (TEMED)   Carl Roth GmbH, Karlsruhe 
thioglycollate broth  Fluka Chemie AG; Buchs, Switzerland 
tris(hydroxymethyl)-aminomethan (Tris)  Carl Roth GmbH, Karlsruhe 
triton-X 100   Fluka Chemie AG, Buchs, Switzerland 
Trypsin/EDTA   Invitrogen, Karlsruhe 
tween-20  Carl Roth GmbH, Karlsruhe 
β-mercaptoethanol  Carl Roth GmbH, Karlsruhe 
 
 
 
2.1.4 Inhibitors 
Complete Protease Inhibitor Cocktail  Roche, Mannheim 
FasFc fusion protein, recombinant  Apogenix, Heidelberg 
GF 109203x hydrochloride  Sigma-Aldrich, Taufkirch 
Ly294002 hydrochloride  Sigma-Aldrich, Taufkirch 
Phosphatase Inhibitor Cocktail 2  Sigma-Aldrich, Taufkirch 
Raf1 Kinase Inhibitor I  Merck, Darmstadt 
U-0126 Merck,  Darmstadt 
U-73122 Merck,  Darmstadt Materials and Methods 
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2.1.5 Enzymes 
Platinum
® Pfx DNA Polymerase  Invitrogen, Karlsruhe 
REDTaq
® Genomic DNA Polymerase  Sigma-Aldrich, Taufkirch 
RNase A   Roche Diagnostics, Mannheim  
 
 
 
2.1.6 Size standards 
Benchmark™ Prestained Protein Ladder  Invitrogen, Karlsruhe 
GeneRuler™ 1 kb PLUS DNA ladder   Fermentas GmbH, St. Leon Rot  
 
 
 
2.1.7 Commercial kits 
B cell isolation kit  Miltenyi, Bergisch Gladbach 
BrdU Flow kit, FITC  Becton Dickinson, Heidelberg  
CD4
+CD25
+ Regulatory T cell isolation kit Miltenyi, Bergisch Gladbach 
CD4
+ T cell isolation kit  Miltenyi, Bergisch Gladbach 
CD8
+ isolation kit  Miltenyi, Bergisch Gladbach 
Cell-Based ELISA base kit 3  R&D Systems, Wiesbaden 
Cell-Based ELISA base kit 4  R&D Systems, Weisbaden 
DNeasy Tissue kit  Qiagen, Hilden 
ECL detection kit  GE healthcare, Freiburg  
FASER kit, PE  Miltenyi, Bergisch Gladbach 
FoxP3 staining kit  Miltenyi, Bergisch Gladbach 
Inside stain kit  Miltenyi, Bergisch Gladbach 
Omniscript
® Reverse transcriptase kit   Qiagen, Hilden 
OptEIA™ Mouse TNF ELISA Kit II  BD Bioscience, Heidelberg 
Pan T cell isolation kit  Miltenyi, Bergisch Gladbach  
pAkt (S473) Pan Specific Cell-Based 
ELISA 
R&D Systems, Wiesbaden 
pERK1 (T202/Y204)/ERK2 (T185/Y187) 
Cell-Based ELISA 
R&D Systems, Wiesbaden 
RNase-free DNase set  Qiagen, Hilden 
RNeasy
® Mini kit  Qiagen, Hilden 
RT
2 First strand kit  SABiosciences, Frederick, USA 
RT
2 Profiler
TM PCR Array Mouse Wnt 
Signaling Pathway 
SABiosciences, Frederick, USA 
RT
2 SYBR Green qPCR Master Mix  SABiosciences, Frederick, USA 
 
 
 
2.1.8 Buffer and solutions 
Cell biology 
Annexin V binding buffer  10mM HEPES pH 7.4 
150mM NaCl 
5mM KCl 
1mM MgCl2 
1.8mM CaCl2 
FACS buffer  3% FCS/PBS 
MACS buffer  0.5% BSA/2mM EDTA/PBS 
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ELISA 
[0.2M] carbonate buffer pH 9.5 (for 1 l)  16.8 g NaHCO3  
10.6 g Na2CO3 
adjust to pH 9.5 
ELISA-blocking buffer  1% milkpowder (low fat)/PBS 
Fixation solution  8% formaldehyde/PBS 
Quenching buffer  0.6% H2O2/PBS 
Substrate buffer pH 5.0 (for 1 l)  10.5 g [0.1M] citric acid  
12.1 g [0.1M] Tris 
adjust to pH 5.0 
 
 
 
Molecular biology 
Tris borate EDTA (TBE, 10x)  108.0 g Tris 
55.0 g boric acid 
40 ml [0.5M] EDTA pH 8.0 
fill up to 1 l with H2O 
Phosphate buffered saline (PBS, 10x)  80.0 g NaCl 
2.0 g KCl 
14.4 g Na2HPO4 
2.4 g KH2HPO4 
fill up to 1 l with H2O 
Tris buffered saline (TBS, 10 x)  250mM Tris-HCl pH7.8 
1.5M NaCl 
adjust pH to 8.1 
fill up to 1 l with H2O 
DNA loading dye (6x)  50% (w/v) glycerol 
1mM EDTA 
0.04% bromphenolblue 
0.4% (w/v) xylenecyanol 
[0.5M] Tris-HCl, pH 6.8  30.1g Tris in 500 ml H2O 
adjust pH to pH 6.8 
[1.5M] Tris-HCl, pH 8.8  91.1 g Tris in 500 ml H2O 
adjust pH to pH 8.8 
 
 
 
Protein biochemistry 
Blocking buffer  5% milkpowder (low fat) 
1x PBS 
0.05% Tween 
Cell lysis buffer   10mM KCl 
1.5mM MgCl2 
10mM Tris-HCl pH 7.4 
0.5% SDS 
2% NP-40 
1 tablet (in 50 ml) protease inhibitor 
cocktail 
SDS-PAGE 2.5% stacking gel  2.5 ml Rotiphorese-Gel 30 
3.7 ml [0.5M] Tris pH 6.8 
8.5 ml H2O Materials and Methods 
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150 µl [10%] SDS 
10 µl TEMED 
100 µl [10%] APS 
SDS-PAGE 12.5% running gel   4.2 ml Rotiphorese-Gel 30 
2.5 ml [1.5 M] Tris, pH 8.8 
3.2 ml H2O 
0.1 ml [10%] SDS 
7 µl TEMED 
70 µl [10%] APS 
SDS-PAGE running buffer  1.5% [20% SDS] 
300.0 g Tris 
750.0 g glycerol 
H2O up to 5 l 
SDS-PAGE sample buffer (5x)  62.5mM Tris HCl pH 7.8 
50mM DTT 
20% glyerine 
2% SDS 
0.01% bromphenol blue 
Semi-dry blotting buffer (10x)  291.0 g Tris 
145.0 g glycerol 
H2O up to 5 l 
Semi-dry blotting buffer  
(working solution) 
10% 10x stock solution 
70% H2O 
20% methanol 
Washing buffer  PBS/0.05% Tween 
 
 
 
2.1.9 Antibodies 
All antibodies used recognize murine proteins. 
 
Cell stimulation 
name isotype  supplier 
CD3ε (clone 145-2C11)  hamster  Becton Dickinson, Heidelberg 
CD40 (clone FGK 45.5)  rat  Miltenyi, Bergisch Gladbach 
IgM, µ chain-specific   rabbit  antibodies-online, Aachen 
 
 
ELISA 
name isotype  supplier 
IgG1, purified  mouse  Becton Dickinson, Heidelberg 
IgG1-biotin  rat  Becton Dickinson, Heidelberg 
IgM, purified  mouse  Becton Dickinson, Heidelberg 
IgM-biotin  rat  Becton Dickinson, Heidelberg 
MEK1 (H-8)  mouse  Santa Cruz, Heidelberg 
pMEK1/2 (Ser218/Ser222)  goat  Santa Cruz, Heidelberg 
pRaf-1 (Ser338)  goat  Santa Cruz, Heidelberg 
Raf-1 (C20)  rabbit  Santa Cruz, Heidelberg 
Streptavidin-AP  -  Vector Labs, Burlingame, USA 
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FACS 
name isotype  supplier 
Alexa Fluor 546-anti goat  donkey  Molecular probes, Karlsruhe 
Annexin V-APC  rat  Becton Dickinson, Heidelberg 
B220-PE  rat  Becton Dickinson, Heidelberg 
B220-PerCp  rat  Becton Dickinson, Heidelberg 
CD138 (Syndecan)-biotin  rat  Becton Dickinson, Heidelberg 
CD19-APC  rat  Becton Dickinson, Heidelberg 
CD25-Pe  mouse  Miltenyi, Bergisch Gladbach 
CD3ε-PE  rat  Becton Dickinson, Heidelberg 
CD4-FITC  rat  Miltenyi, Bergisch Gladbach 
CD4-PE  rat  Becton Dickinson, Heidelberg 
CD4-TriColour rat  Invitrogen,  Karlsruhe 
CD69-PeCy7  hamster  Becton Dickinson, Heidelberg 
CD80-APC  hamster  Becton Dickinson, Heidelberg 
CD86-FITC  rat  Becton Dickinson, Heidelberg 
CD8α-FITC  rat  Becton Dickinson, Heidelberg 
CD8α-TriColour rat  Invitrogen,  Karlsruhe 
Fas (JO2)-PE  hamster  Becton Dickinson, Heidelberg 
Fas (JO2)-PeCy7  hamster  Becton Dickinson, Heidelberg 
FasL (MFL3)-PE  hamster  Becton Dickinson, Heidelberg 
Fc blocking reagent, mouse  -  Miltenyi, Bergisch Gladbach 
FoxP3-APC  mouse  Miltenyi, Bergisch Gladbach 
IgD-FITC  rat  Becton Dickinson, Heidelberg 
IgG1 (H+L)-PE (isotype control)  hamster  Becton Dickinson, Heidelberg 
IgG1-FITC  rat  Becton Dickinson, Heidelberg 
IgM-APC  rat  Becton Dickinson, Heidelberg 
IgM-FITC  rat  Becton Dickinson, Heidelberg 
IgM-PE  rat  Becton Dickinson, Heidelberg 
Lef-1 (C19)  goat  Becton Dickinson, Heidelberg 
Ly6G-FITC  rat  Becton Dickinson, Heidelberg 
NP7-PE  -  Biosearch Tech., Novato, USA 
PNA-FITC  -  Vector Labs, Burlingame, USA 
pPKCα (pT497)-PE  mouse  Becton Dickinson, Heidelberg 
pPLCγ2 (pY759)-Alexa Fluor 488  mouse  Becton Dickinson, Heidelberg 
Straptavidin-PE  -  Becton Dickinson, Heidelberg 
Vβ6-FITC  mouse  Becton Dickinson, Heidelberg 
Vβ8-FITC  rat  Becton Dickinson, Heidelberg 
 
 
 
Western blot 
name isotype  supplier 
β-Actin   goat  Santa Cruz, Heidelberg 
HRP-rabbit IgG  donkey  GE Healthcare, Freiburg 
HRP-goat IgG  rabbit  Zymed, Vienna, Austria 
pErk1/2 (Thr202/Tyr204)  rabbit  New England Biolabs, Frankfurt  
 
 
 
2.1.10 Vectors 
pEVR-FL9B Lef-1  Wiebke Baum 
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2.1.11 Oligonucleotides 
Oligonucleotides were purchased from BioSpring (Frankfurt) and resolved in HPLC-
H2O at a concentration of 100µM. Sequences are shown in 5’ Æ 3’ orientation. 
 
 
PCR primer for genotyping of mice using genomic DNA 
gene primer  sequence  product  size 
fasl  loxP-ctrl-for  CCATGAAATCATTTTATGGTTGGGG  wt: 219 bp 
  loxP-ctrl-rev GAACAAGACACAAAATTGATTTTCATC  ∆Intra: 280 bp 
fas
lpr  lpr-common  GTA AAT AAT TGT GCT TCG TCA G     
  lpr-wildtype  CAA ATC TAG GCA TTA ACA GTG    wt: 179 bp 
  lpr-mutant  TAG AAA GGT GCA CGG GTG TG    Fas
lpr: 217 bp 
lacZ  lacZ-for CGGTGATGGTGCTGCGTTGGA  370  bp 
 lacZ-rev  ACCACCGCACGATAGAGATTC   
 
 
 
PCR primer for detection of mRNA transcripts (semi-quantitative) 
gene primer  sequence  product  size 
fasl  screen-for  GCGGAAACTTTATAAAGAAAACTTAG  wt: 460 bp 
  screen-rev CGGAGTTCTGCCAGTTCCTTCTG  ∆Intra: 220 bp 
lef-1  Lef1-for TGCAGCTATCAACCAGATCC  311  bp 
 Lef1-rev  GGGTTTCAACAAGCTTCCAT   
 
 
 
qRT-PCR primer 
gene   forward primer  reverse primer 
survivin  AGGCAAAGGAGACCAACAAC ATGTGGCATGTCACTCAGGT 
ccl 3  TCTCCTACAGCCGGAAGATT CTCTCAGGCATTCAGTTCCA 
cyclin D2  ATTTCAAGTGCGTGCAGAAG AGGTAATTCATGGCCAGAGG 
c-myc  GTGTCTGTGGAGAAGAGGCA GCGTAGTTGTGCTGGTGAGT 
cxcl 10  CTGAGTGGGACTCAAGGGAT TTTCATCGTGGCAATGATCT 
cyclin D1  GCCGAGAAGTTGATGCATCTA TGGTCTGCTTGTTCTCATCC 
eda  GGGCCTCAGATAGTGGTTGT  CAAAGAAACCCAGGAAGAGC 
egr 1  GTTATCCCAGCCAAACGACT ATGAAGAGGTCGGAGGATTG 
fgf 4  ACGAGGGACAGTCTTCTGGA AAGAAAGGCACACCGAAGAG 
gaddα  AGAGCAGAAGACCGAAAGGA  GCACAGTACCACGTTATCGG 
gapdh  TGGCAAAGTGGAGATTGTTG CATTATCGGCCTTGACTGTG 
histone1, h4a CGTGGTAAGGGTGGTAAAGG GATCACGTTCTCCAGGAACA 
hprt 1  TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 
il-10  CCCAGAAATCAAGGAGCATT TCACTCTTCACCTGCTCCAC 
il-4  ACGGCACAGAGCTATTGATG  TGCCGATGATCTCTCTCAAG 
il-5  TGAAAGAGACCTTGGCACTG CTCCAGTGTGCCTATTCCCT 
irf 4  GAGCTGTAGGTTGCCCAGAT AGAAGAGGGAGCAAACAGGA 
jak 1  TGAACCACCTCAAGAAGCAG GGGCTTTCTTAGTGGCTACG 
lef-1  TGCAGCTATCAACCAGATCC GGGTTTCAACAAGCTTCCAT 
nfatc 1  CCAGTATACCAGCTCTGCCA GTGGGAAGTCAGAAGTGGGT 
nfκb  GAAGGCTGGAGAAGATGAGG CCAGCAGTTTGCAGAGTTGT 
nr4a1  CCTGGACGTTATCCGAAAGT AAGAGTTCCAGGAAGGCAGA 
numb  TGGCAGACAGATGAAGAAGG CCTTCACTGCTTTCTTTCCC 
phlda1  GAAGGAAGGAGTGCTGGAAA CCACTAGGTTGGGACGGTT Materials and Methods 
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s100a6  GGAGCTGAAGGAGTTGATCC AGGCGACATACTCCTGGAAG 
sprouty2  CATCAGAGGCAGCAATGAAT  TGCTATTCACATTGGCTGGT 
tagap  CCATTGTCCAACAAGACAGG ATCTTCAGCTTCATCGCCTT 
tnfα  GAGCACAGAAAGCATGATCC CCACAAGCAGGAATGAGAAG 
 
 
 
2.1.12 Mouse lines 
All mice were bred to a pure black-six background. 
name description  reference/origin 
FasL ∆Intra  ‘knockout/knockin’ of wildtype FasL 
with a truncated FasL lacking aa 2-
74  
Group of PD Dr. M. 
Zörnig 
B6Smn.C3-FasL
gld/J 
(gld) 
A-to-C point mutation near the 3’ 
end of the coding sequence 
resulting in an aa exchange 
(F273L) 
Jackson laboratory 
FasB6.MRL-Fas
lpr/J (lpr)  transposon insertion in Fas intron 2  Jackson laboratory 
FasL knockout (FasL
-/-)  knockout of the complete FasL 
locus 
(Karray et al., 2004) 
FasL ∆Intra/Fas
lpr   cross of heterozygous FasL ∆Intra 
mice with Fas
lpr mice  
- 
FasL ∆Intra/TopGaL   cross of heterozygous FasL ∆Intra 
mice with TopGal mice (Stock 
Tg(Fos-lacZ)34Efu/J) 
TopGal mice 
(DasGupta et al., 
1999) obtained 
from Dr. S. Liebner, 
University Frankfurt
B6;129S4-
Gt(ROSA)26Sor
tm1Sor/J 
(Rosa) 
targeted mutation of the ROSA26 
locus to introduce a LacZ reporter 
gene resulting in constitutive LacZ 
gene expression 
Jackson Laboratory
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2.2 Methods 
 
2.2.1 Animal models 
Mice were bred and maintained under specific pathogen-free conditions in filter top- or 
isolated, ventilated cages (IVC) according to the German animal welfare law. For 
experimental use,  mice were anaesthetized with isofluran and sacrificed by cervical 
dislocation. All mice were bred to a pure C57Bl/6N background. 
 
2.2.2 Genotyping 
The genotype of mice was determined by amplifiying a fragment of the respective 
targeted locus via PCR. For this purpose, genomic DNA was isolated from tail biopsies 
using the DNeasy Tissue Kit according to the manufacturer’s instructions (Qiagen). The 
tissue was digested in the presence of 20 µl Proteinase K and 180 µl lysis buffer at 
55°C overnight. Using spin column purification, DNA was bound to the column, 
repeatedly washed and eluted with 200 µl elution buffer. Purified genomic DNA was 
stored at 4°C until further use. PCR was performed on 2 µl genomic DNA using RedTaq 
genomic DNA Polymerase (Sigma) as follows:  
 
PCR reaction mix    Thermo cycler program 
tail DNA  2.0 µl    temperature [°C] time [min]  cycles 
dNTP mix [2.5nM each]  3.0 µl    94  3  1 
5’ primer [3µM]  5.0 µl    94  1   
3’ primer [3µM]  5.0 µl    57  1  30 
10x Taq buffer   2.5 µl    72  3   
RedTaq gDNA 
Polymerase 
1.5 µl    72  10  1 
H2O 6.0  µl    4  ∞ 1 
 
PCR products were analyzed on a 2% agarose-gel. 
 
For genotyping of the Fas
lpr locus, a three primer strategy was employed using primers 
at 20µM each and annealing at 59°C according to the protocol provided by the Jackson 
Laboratory.  
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2.2.3 Cell culture methods 
 
2.2.3.1 Isolation of naïve murine lymphocytes 
Primary lymphocytes were isolated by negative selection using magnetic bead 
purification and MACS technology according to the manufacturer's instructions 
(Miltenyi). Negative selection allows the purification of untouched cells of interest. The 
appropriate isolation kits contain mixtures of biotinylated antibodies recognizing lineage 
markers of unwanted cell populations. Antibody-cell complexes are coupled to magnetic 
micro beads which are retained on the purification column when placed in a magnetic 
field, while the cells of interest are in the flow through. 
Mice were sacrificed and the spleen was removed, transferred into 10 ml cold PBS and 
grinded through a screen cup sieve using a syringe plunger. Erythrocytes in the 
homogenate were lyzed by hypotonic cell lysis. To allow antibody-cell complex 
formation, cell suspensions were incubated with 40 µl MACS buffer and 10 µl 
biotinylated antibody mix per 10
7 cells for ten minutes at 4°C. Biotinylated antibodies 
were coupled to magnetic micro beads in the presence of additional 30 µl MACS buffer 
and 20 µl anti-biotin magnetic microbeads per 10
7 cells for 15 minutes at 4°C. After 
washing with ten times of the volume of the labeling reaction, the pellet was 
resuspended in 500 µl MACS buffer/10
8 cells and applied onto an equilibrated MACS 
LS-column placed in a MACS magnetic field. Columns were allowed to empty by gravity 
flow and were subsequently washed three times by the addition of 3 ml MACS buffer 
each. Cell number and viability were analyzed with a Casy counter. Purity of the cell 
population was determined by flow cytometry using appropriate lineage surface 
markers (B cells: CD19 or B220; T cells: CD4 and CD8). 
 
2.2.3.2 Generation of T cell blasts 
For the generation of T cell blasts, spleen homogenates were incubated at a 
concentration of 3x10
6 cells/ml for two days in the presence of 2 µg/ml Concavalin A. 
After repeated washing, cells (3x10
6 cells/ml) were cultivated for further five days in the 
presence of 100 U/ml human-recombinant IL-2. Fresh medium was added when 
required. For the final isolation of viable T cells, samples were subjected to density 
gradient centrifugation. The cell suspension was underlayed with a Ficoll solution 
(density 1.083) 1:1 and centrifuged at 800 xg for 20 minutes without brake. The Materials and Methods 
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interphase cells were collected, washed twice with PBS and used for co-culture 
experiments. 
 
2.2.3.3 Lymphocyte maintenance and stimulation 
Primary lymphocytes were maintained in Rosewell Park Memorial institute medium 
(RMPI 1640) medium supplemented with 10% FCS, 2% L-glutamine,   
1% penicillin/streptomycin, 1% sodium pyruvat solution (100x), 1% non-essential amino 
acids (100x) and 0.1% β-mercaptoethanol (1000x) at 37°C and 5% CO2. 
Stimuli used to activate B cells include various concentrations of solubly added anti-IgM 
antibody, anti-CD40 antibody, lipopolysaccharide (LPS) or 100 ng/ml phorbol myristate 
acetate (PMA)/0.2 µg/ml ionomycine. T cells were activated using various 
concentrations of plate-bound anti-CD3ε  antibody or 100 ng/ml PMA/0.2 µg/ml 
ionomycine. 
 
2.2.3.4 Erythrocyte lysis 
Prior to lymphocyte isolation from lymphoid organs and to FACS analysis of organ 
homogenates, erythrocytes were lyzed by hyptonic cell lysis. Cell suspensions were 
pelleted by centrifugation at 500 xg for five minutes, resuspended in 500 µl 1x PBS and 
lyzed by the addition of 5 ml H2O for ten seconds. The reaction was stopped with 500 µl 
10x PBS and then 5 ml 1x PBS. Removal of cell debris was achieved by passing the 
cell suspension through a 100 µm cell strainer. 
 
2.2.3.5 Determination of cell number and viability 
The total cell number and the number of viable cells in a sample were determined with 
a Casy cell counter. The Casy technology exploits the property of intact cell membranes 
to function as an insulator for electric currents. An appropriate programm for 
measurement was established using Casyblue, following the manufacturer’s 
instructions.  
 
Casy counter settings  
dilution of cell suspension  1:400 
measured sample volume  400 µl 
measurement cycles  3 
auto aggregation  on 
normalization cursor  3.2 µm 
evaluation cursor  5.3 µm Materials and Methods 
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2.2.3.6 Cultivation of cell lines 
All cells were maintained at 37°C and 5% CO2 in humid atmosphere in an incubator. 
The murine B cell lymphoma cell line A20 (ATCC number TIB-208) was maintained in 
RMPI medium containing 10% FCS, 2% L-gluatmine, 1% penicillin/streptomycin and 
0.1%  β-mercaptoethanol. Cells were split 1:10 approximately every third day. The 
adherent human epithelial kidney cell line HEK293T, which was derived from the 
HEK293 cell line (ATCC number CRL11268) by transformation with the SV40 large T-
antigen, was cultivated in DMEM supplemented with 10% FCS, 2% L-glutamine and 
10% penicillin/streptomycin. For cell passaging, growth medium was removed and cells 
were washed with PBS. Addition of 1 ml Trypsin-EDTA facilitated cell dispersal. The 
Trypsin reaction was stopped with growth medium, and cells were resuspended by 
pipetting and split 1:10. 
 
2.2.3.7 Freezing and thawing of cells 
Cells were pelleted and resuspended in freezing medium (10% DMSO/20% 
FCS/growth medium without antibiotics). The suspension was slowly cooled to -80°C by 
placing the vials into an isopropanol filled box (cooling rate 1°C/min) and subsequently 
transferred to liquid nitrogen for long term storage. Frozen cells were swiftly thawed at 
37°C and mixed with 5 ml complete growth medium. Cells were then pelleted to remove 
DMSO, resuspended in growth medium and cultivated as desired. 
 
2.2.3.8 Transfection of cells 
HEK293T cells were transiently transfected using polyethylenimine (PEI). One to two 
million cells were seeded onto a 10 cm cell culture dish to achieve a confluencey of 
~60% at the day of transfection. Next day, the transfection reaction was assembled by 
mixing 5 µg plasmid DNA, 13.5 µl 100mM PEI and 300 µl PBS and incubating this 
mixture for 15 minutes at room temperature to allow DNA-PEI complex formation. The 
culture medium of cells was exchanged for growth medium without antibiotics. 
Subsequently, the transfection mix was added dropwise and distributed evenly by 
gently swaying the culture dish. Four hours later, medium was supplemented with FCS 
to a concentration of 10%. Cells usually were harvested 48 hours post-transfection. 
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2.2.4 Flow cytometry 
 
2.2.4.1 Analysis of cell surface marker expression 
Single cell suspensions of purified lymphocytes or lymphoid organ homogenates were 
prepared, pelleted, resuspended in 100 µl FACS buffer and stained for cell surface 
molecules for 20-30 minutes at 4°C. Fluorochrome-conjugated antibodies recognizing 
FasL (MFL3), Fas (JO2), CD3ε, CD4, CD8α, CD19, B220, CD69, CD80, CD86, IgM, 
IgD, IgG1, CD138 (Syndecan), Peanut agglutinin (PNA), Vβ6 TCR chain, Vβ8 TCR 
chain, CD11b, Ly6G (Gr-1), F4/80, Annexin V and isotype control antibodies were 
purchased from BD Bioscience. For all stainings, cells were pre-incubated with FcBlock 
(1:10;  Miltenyi) for ten minutes at room temperature to block unspecific binding of 
antibodies to Fc receptors present on lymphocyte cell surfaces. Propidium iodide   
(2.5 µg per sample) was used for live/dead cell discrimination wherever required. At 
least 10,000 cells per sample were analyzed using a FACSCalibur with the professional 
CellQuest software for evaluation. 
 
2.2.4.2 Intracellular stainings 
Intracellular stainings were performed using the Inside Stain Kit from Miltenyi, including 
the reagents InsidePerm and InsideFix for cell permeabilization and fixation, according 
to the manufacturer's instructions. All incubations were performed at room temperature. 
Cells were resupended in 250 µl FACS buffer per 10
6 cells and fixed with 250 µl/10
6 
cells InsideFix (containing 3.7% formaldehyde) for 20 minutes, prior to staining with 
 100 µl of the desired antibody diluted in InsidePerm for 20 minutes. After washing with 
1 ml InsidePerm, cells were resuspended in 300 µl FACS buffer, and at least   
10,000 cells per sample were analyzed using a FACSCalibur (BD Bioscience). Lef-1 
protein was detected with a goat anti-mouse Lef1 antibody (C19) in a dilution of 1:50 
and an Alexa Fluor546-coupled anti-goat antibody (1:250) as secondary antibody. For 
the analysis of phosphorylated proteins in primary lymphocytes cells were rested for 
one hour after isolation before they were activated as desired. Labeled antibodies to 
phosphorylated PLCγ2 and phosphorylated PKCα were purchased from BD Bioscience 
and used according to the manufacturer’s instructions (15 µl per test). 
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2.2.4.3 Staining of unfixed cells with Annexin V and propidium iodide  
Spontaneous and activation-induced cell death was assessed by staining with   
Annexin V and propidium iodide. Annexin V binds to phosphatidylserine exposed on the 
surface of apoptotic cells. Propidium iodide discriminates live and dead cells, as it is 
excluded from intact cells while diffusing into dead cells with a porous membrane.  
Cells were washed with Annexin V binding buffer and stained with 3 µl Annexin V-APC 
diluted in 200 µl Annexin V binding buffer for 15 minutes at room temperature. Before 
flow cytometric measurement, 2.5 µg propidium iodide were added. Late apoptotic and 
necrotic cells stain positive for Annexin V and propidium iodide, while early apoptotic 
cells become Annexin V positive and PI negative. 
 
2.2.4.4 Propidium iodide staining of ethanol fixed cells – Nicoletti test 
Nicoletti et al. (Nicoletti et al., 1991; Riccardi et al., 2006) described a method how to 
simultaneously quantify the number of living and dead cells in one sample and to 
analyze their cell cycle status. After fixation and permeabilization, propidium iodide is 
used to stain cellular DNA. In apoptotic cells DNA is hydrolyzed and diffuses out of the 
cell. As propidium iodide intercalates into double-stranded DNA, the resulting 
fluoerescent staining is proportional to the ploidy of the cell. 
Cells were fixed by dropwise addition of 1 ml ice-cold 70% ethanol and subsequent 
storage at 4°C overnight. After ethanol removal by washing with 38mM sodium citrate 
(pH 7.4), cells were stained with 50 µg/ml propidium iodide and 5 µg/ml RNase A in 
38mM sodium citrate (pH 7.4) for 20 minutes at room temperature. The fluorescence 
light intensity in the FL-2 channel was quanitfied using the doublet discrimination 
module (DDM). A gate was set on the cell population present in a FL2-A/FL2-W dot 
plot, so that the cell cycle profile could be visualized in a FL2-A histrogram. The extent 
of cell death is represented by the percentage of cells in the sub-G1 peak of the cell 
cycle profile (hypoploid cells). 
 
2.2.4.5 Carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assay for  
lymphocyte proliferation 
Proliferation of lymphocytes can be tracked by staining of cells with the cell permeable 
dye CFSE. Taken up by living cells, it is cleaved by endogenous esterases to become 
cell impermeable and fluorescent. Each cell division diminishes the fluorescence by 
half, so that the decrease in staining intensity is proportional to cell proliferation.  Materials and Methods 
 
 
- 46 - 
Lymphocytes were incubated with 1µM CFSE in 3% FCS/PBS for three minutes at 
room temperature, washed twice and seeded at a density of 5x10
5 cells/100 µl growth 
medium in a 96well-plate. Cells were left untreated or were stimulated using various 
concentrations of plate-bound anti-CD3ε antibody (T cells), or soluble anti-CD40 
antibody or rabbit anti-IgM antibody (B cells). 48 or 72 hours later cells were harvested 
and resuspended in 300 µl FACS buffer containing 2.5 µg propidium iodide. 
Proliferation of living cells was measured by FACS in the FL-1 channel as the decrease 
in CFSE fluorescence intensity. 
 
2.2.4.6 Co-culture of primary lymphocytes with Fas-sensitive A20 target cells 
To assess the capability of primary murine lymphocytes to kill target cells in a 
FasL/Fas-dependent manner, T cell blasts were co-cultured with Fas-expressing A20 
target cells. T cell blasts were re-stimulated with 10 µg/ml plate-bound anti-CD3ε 
antibody for 24 hours. Afterwards, half of each cell population was pre-incubated with 
100 µg/ml FasFc for 30 minutes at 37°C to specifically block FasL-dependent killing. 
A20 target cells were labeled with CFSE. Activated T cells, pre-incubated with FasFc or 
left untreated, and labeled A20 cells were co-cultured in an effector:target ratio of 2.5:1 
for six hours in the presence of 10 µg/ml anti-CD3ε antibody. Cells were then fixed with 
ice-cold 70% ethanol and stained with propidium iodide. FasL-dependent killing was 
quantified by substracting the percentage of cells with hypoploid DNA content (sub-G1 
cells) of FasFc-treated samples from that of sub-G1 cells in the corresponding 
untreated sample. Experimental controls included A20 cells not subjected to co-culture 
but incubated in the presence of recombinant FasL protein (67 ng/ml FasL-Flag/1 µg/ml 
anti-Flag antibody (M2)), recombinant FasL protein plus 100 µg/ml FasFc or FasFc 
only. 
 
2.2.4.7 β-Galactosidase activity assay for the analysis of Wnt signaling in vivo 
A TopGal based mouse line was used to analyze a potential influence of FasL reverse 
signaling on Wnt/Lef-1 signaling in vivo (DasGupta et al., 1999; Barolo, 2006). TopGal 
mice express a β-Galactosidase reporter gene under the control of a Lef-1-dependent 
regulatory sequence, consisting of three consensus Lef-1 binding sites upstream of a 
minimal  c-Fos promoter. Breeding with heterozygous mice of the FasL  ∆Intra line 
resulted in offspring homozygous for either the wildtype or the mutant FasL locus and 
heterozygous for the LacZ locus. FACS analysis of β-Galactosidase-mediated Materials and Methods 
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sequential hydrolysis of Fluorescein Digalactoside (FDG) to Fluorescein 
Monogalactoside (FMG) and then to highly fluorescence Fluorescein was performed in 
B cells derived form FasL ∆Intra/TopGal mice. Cells (1x10
6 cells/100 µl medium) were 
stimulated for 4-48 hours with 5 µg/ml anti-IgM antibody, 10 µg/ml anti-CD40 antibody, 
10mM LiCl or were left untreated. Cells were harvested, and 50 µl cell suspension were 
transferred to a FACS tube. A 20mM FDG stock solution in DMSO was prepared and 
diluted tenfold in H2O for use. Equal amounts of diluted FDG solution and cell 
suspension were mixed and incubated for one minute at 37°C for hypotonic cell lysis. 
The reaction was stopped with a tenfold volume ice-cold growth medium. During a 
subsequent incubation for 30-45 minutes on ice, any β-Galactosidase present in the 
sample converts FDG into its fluorescence form. For FACS analysis, 2.5 µg PI were 
added and β-Galactosidase activity was quantified in the FL-1 channel. B cells derived 
from Rosa mice were included as a positive control for the assay. 
 
 
2.2.5 Enzyme-linked immunoabsorbant assay (ELISA) 
 
2.2.5.1 Cell-based ELISA 
Cell-based ELISAs are modified solid phase sandwich ELISAs. For analysis, cells are 
grown directly on the ELISA plate. Following treatment, cells are fixed, permeabilized 
and simultaneously incubated with primary antibodies recognizing two different epitopes 
(phosphorylated protein or total protein). The primary antibodies are derived from 
different species so that two appropriate enzyme-linked secondary antibodies can be 
used for the simultaneous detection of fluorgenic substrate conversion. Relative levels 
of phosphorylated protein are calculated by normalization to levels of the total protein. 
In this study, commerically available cell-based ELISAs for the detection of 
phosphorylated ERK1/2 (T202/Y204) and Akt (S473) were used according to the 
manufacturer’s instructions (R&D Systems).  
Phosphorylation of c-Raf and MEK1/2 was analyzed using the cell-based ELISA kits 
number 3 (MEK1/2) and number 4 (c-Raf) (R&D Systems). These ELISA kits follow the 
same protocol, but only contain two different enzyme-linked secondary antibodies. 
Primary antibodies against the proteins of interest can be chosen by the investigator. 
For the detection of c-Raf activation, goat anti-pRaf1 (S338) and rabbit anti-Raf1 (C20) 
antibodies were used (Santa Cruz). Total MEK1/2 protein and the phosphorylated Materials and Methods 
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isoforms were detected with mouse anti-MEK1 (H-8) and goat anti-pMEK1/2 
(S218/S222) antibodies (Santa Cruz). Antibodies against c-Raf and MEK1/2 were used 
at a 1:50 dilution. 
All incubation and washing steps were performed at room temperature with gentle 
shaking. Inbetween each consecutive assay step, samples were washed three times 
with 200 µl/well 1x wash buffer for five minutes each time unless stated otherwise. The 
substrates F1 and F2 were included in the kits (R&D Systems). 
ELISA plates were coated with 100 µl/well poly-L-lysine (10 µg/ml) to promote 
lymphocyte adhesion. After incubation for 1.5 hours at 37°C, the poly-L-lysine solution 
was removed and plates were washed twice with PBS. Splenic B cells were isolated 
and 10
6 cells/100 µl medium were seeded onto the coated plate. Cells were allowed to 
recover from stress caused by the isolation procedure, that might lead to overall higher 
protein phosphorylation levels, by resting them for two hours. B cells were then 
stimulated by the addition of 1 µg/ml anti-IgM antibody for the indicated times, after 
which the reaction was stopped with 100 µl/well formaldehyde (8%). To properly fix the 
cells, plates were incubated for 20 minutes. Following incubation with 100 µl/well 
quenching buffer for 20 minutes, unspecific binding sites were blocked with 100 µl/well 
blocking buffer for one hour. Primary antibodies (100 µl/well) were allowed to bind 
overnight at 4°C. No primary antibody was added to negative control wells. The 
following day, the two secondary antibodies were applied for two hours (100 µl/well). 
For fluorgenic detection, cells were washed twice with 200 µl/well 1x wash buffer and a 
third time with 200 µl/well PBS. Thereafter, 75 µl/well substrate F1 were added for one 
hour. Finally, 75 µl/well substrate F2 were applied for 30-40 minutes, before measuring 
the fluorescence light intensity with an ELISA reader. Phosphorylated protein was 
detected by setting the excitation wavelength to 540 nm and that of the emission to  
600 nm; total protein was detected by setting the excitation wavelength to 360 nm and 
that of the emission to 450 nm. For evaluation, background fluorescence was 
substracted from all samples. The relative amount of phosphorylated protein in each 
sample was calculated by dividing the fluorescence reading representing the 
phosphorylated isoform by that of the total protein. 
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2.2.5.2 Standard solid phase sandwich ELISA  
Standard solid phase sandwich ELISAs detect proteins in cell culture supernatants, 
serum or plasma. Usually, assay plates are pre-coated with a specific antibody, so that 
the protein of interest in the sample binds to the immobilized antibody. The addition of a 
secondary enzyme-linked antibody produces an ‘antibody sandwich’. Substrate 
conversion by the linked enzyme is directly proportional to the amount of protein of 
interest present in the sample and can be measured as the light absorbance by or the 
fluorescence intensity of the colored product in an ELISA reader. Here, the activation-
induced TNFα secretion was quantified with a commerically available assay following 
the manufacturer’s guidelines (BD Bioscience). Assay reagents were brought to room 
temperature before use. All incubations were done at room temperature with gentle 
shaking. Plates were washed inbetween consecutive assay steps by twenty times filling 
and decanting of wells with 300 µl/well 1x wash buffer. 
B cells were isolated, seeded at a concentration of 10
6 cells/100 µl medium onto a  
96 well-plate and were rested for two hours before stimulation with 1 µg/ml anti-IgM 
antibody for four, six or 24 hours. After the indicated times, cells were harvested from 
the plate, transferred to 1.5 ml reaction tubes and pelleted by centrifugation at   
15,000 xg for five minutes at 4°C. Supernatant was collected and stored at -80°C until 
analysis. A standard containing a defined amount of recombinant mouse TNFα protein 
was serially diluted in Standard/Sample diluent to cover a concentration range between 
zero and 2000 pg/ml. After pipetting 50 µl ELISA diluent to wells pre-coated with an 
anti-TNFα antibody, 50 µl of each standard and sample were added in duplicate for two 
hours. After incubation with 100 µl/well biotinylated anti-TNFα detection antibody for 
one hour, 100 µl/well enzyme working reagent were applied for 30 minutes. In a final 
wash step, washing buffer was left in the wells for 30 seconds before decanting. 
Thereafter, 100 µl/well TMB one-step substrate reagent were added for 30 minutes. 
Plates were covered to protect from direct light. Substrate conversion was stopped by 
50 µl/well Stop solution, and the absorbance was measured at 450 nm in an ELISA 
reader. For evaluation, the mean absorbance of each duplicate was calculated and the 
mean zero standard absorbance (background) was substracted. A standard curve was 
plotted with the TNFα concentration represented by the x-axis and the absorbance by 
the y-axis. The TNFα concentration in the samples was determined based on the linear 
regression of the standard curve. 
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2.2.6 Molecular biological methods 
 
2.2.6.1 Isolation of total RNA  
Total RNA was isolated with the RNeasy Mini Kit following the manufacturer's 
guidelines (Qiagen). For cell lysis, pelleted cells were resuspended in 600 µl lysis buffer 
RLT (containing β-mercaptoethanol), pipetted onto a QIAshredder column and 
centrifuged for two minutes at 15,000 xg. Lysates were mixed with one volume   
70% ethanol, and the RNA was bound to RNeasy mini columns by centrifugation for  
15 seconds at 15,000 xg. To eliminate contaminating genomic DNA, on-column 
digestion of genomic DNA with the RNase-free DNase set (Qiagen) was performed by 
adding 10 µl DNase I and 70 µl RL-buffer to the spin column membrane and incubating 
samples for 15 minutes at room temperature. After washing the column twice with   
500 µl buffer RPE each, RNA was eluted with 42 µl HPLC-H2O. RNA concentration was 
determined spectrophotometrically using a Nanodrop device.  
 
2.2.6.2 Quantification of nucleic acid concentration and purity 
Nucleic acids were diluted in water and the concentration was determined using a 
Nanodrop device based on the optical density readings at 260 nm and 280 nm. The 
quotient OD260 nm/OD280 nm was used to determine the purity of nucleic acids. Purified 
RNA should display a ratio of 1.8 and DNA of 2.0 (Maniatis et al., 1982). 
 
2.2.6.3 Complementary DNA (cDNA) synthesis  
cDNA synthesis using the Omniscript Reverse Transcriptase kit for First-Strand cDNA 
synthesis (Qiagen) was performed as described in the manual using 0.5-2 µg RNA. The 
RT-PCR reaction was set up to contain 1x RT buffer, 0.5mM of each dNTP, 1µM 
oligo(dT) primer, 10 units RNase inhibitor, 4 units Omniscript Reverse Transcriptase 
and H2O up to a final volume of 20 µl. Reverse transcription proceeded at 37°C for  
60 minutes in a thermo cycler. cDNA was stored at -20°C for further use. 
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2.2.6.4 Polymerase chain reaction (PCR) 
PCR reactions were performed using 10 ng template cDNA derived from primary 
lymphocytes or transiently transfected HEK293T cells as follows:  
 
PCR reaction mix    Thermo cycler program 
template cDNA  10 ng    temperature [°C] time [min]  cycles 
10x PCR buffer  5.0 µl    94  3  1 
MgSo4  2.0 µl    94  1   
dNTPs [2.5mM each]  6.0 µl    57  1  30 
primer 5’ [10µM]   1.5 µl    68  3   
primer 3’ [10µM]   1.5 µl    68  10  1 
Platinum Pfx Polymerase  0.8 µl    4  ∞ 1 
H2O up to 25 µl           
 
 
2.2.6.5 Electrophoresis of PCR products 
PCR products were separated at 90V on a 2% agarose-gel (in 0.5x TBE) containing  
0.1 µg/ml ethidiumbromide. Either the 100 bp DNA ladder or the 1 kb DNA ladder from 
Invitrogen was used as size standard.  
 
2.2.6.6 Quantitative real time polymerase chain reaction (qRT-PCR) 
qRT-PCR is an amplification method for nucleic acids based on standard PCR analysis 
but allowing the relative or absolute quantification of mRNA transcripts by fluorescence 
labeling of newly synthesized products. Here, relative quantification of mRNA 
transcripts was performed using cDNA derived from activated B cells (1 µg/ml anti-IgM 
antibody for four hours) and SYBR Green PCR Master Mix (Thermo scientific) with a 
Light Cycler 480 (Roche). One to two microgramms of RNA were transcribed into cDNA 
and for each pair of primers the reaction was set up in triplicates as follows: 
 
PCR reaction mix  
component  one reaction [µl]  one sample (triplicate) [µl] 
cDNA   0.67  2.00 
5’ primer [10µM]  1.25  3.75 
3’ primer [10µM]  1.25  3.75 
SYBR Green PCR mix  12.50  37.50 
H2O 10.00  30.00 
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Light cycler program 
temperature [°C]  time [min] ramp rate [°C/sec] Cycles 
95 15:00  4.4  1 
95 00:20  4.4 
57 00:30  2.2 
72 00:30  4.4 
 
40 
50 00:10  2.2  1 
95  continuous 0.06  10 acquisitions per °C 
37  ∞   1 
 
Each sample was assessed in triplicate and normalized to the expression levels of the 
housekeeping genes Hypoxanthin-guanin-phosphoribosyltransferase ( Hprt) or 
Gylerinaledhyde 3-phosphate dehydrogenase (Gapdh). Primers were designed using 
the Genescript online resource (https://www.genscript.com/ssl-bin/app/primer), and 
specificity of their annealing was ensured by agarose-gel electrophoresis. To exclude a 
contamination in the PCR reaction, a triplicate sample containing water instead of cDNA 
was included for each set of primers used. Relative quantification of target gene 
expression was determined with the comparative threshold cycle method. For this 
purpose, the threshold cycle (Ct) value of the reference housekeeping gene was 
substracted from the Ct of the target gene to obtain the ∆Ct value. To relate the 
expression of a target gene in the study group (here: FasL ∆Intra) to that in the control 
group (here: wildtype) the ∆∆Ct value is calculated by substracting the respective ∆Cts. 
Subsequent logarithmization yields the fold difference of mRNA levels. As the gene 
expression level for each target gene in the control group is set to one, values below 
one indicate reduced and those larger than one higher mRNA levels in the study group 
compared to the control group.  
 
Exemplary calculation 
Calculate the ∆Ct of each target gene in wildtype (Wt) and FasL ∆Intra (∆Intra) samples 
∆Ct = Ct target gene/Wt – Ct reference gene/Wt  
∆Ct = Ct target gene/∆Intra – Ct reference gene/∆Intra 
 
Relate the expression of a target gene in FasL ∆Intra mice to that in wildtype mice by 
calculating the ∆∆Ct 
Wildtype: ∆∆Ct = ∆Ct Wt - ∆Ct Wt = 0 
FasL ∆Intra: ∆∆Ct = ∆Ct ∆Intra - ∆Ct Wt = relative difference in target gene expression 
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Logarithmize the ∆∆Ct to the basis of two to determine the fold change in target gene 
expression level. Using a logarithmic basis of two assumes an optimal PCR efficient, 
where each product present is doubled in every cycle. 
Wildtype: 2
(-∆∆Ct) = 2
(0) = 1 
FasL ∆Intra: 2
(-∆∆Ct) = fold difference in target gene mRNA levels in FasL ∆Intra cells 
compared to wildtype cells 
 
2.2.6.7 mRNA expression profiling of Wnt signaling-related genes 
For the detailed analysis of Wnt signaling in activated B cells the RT² Profiler™ PCR 
Array Mouse Wnt Signaling Pathway (SABioscience) was used according to the 
manufacturer’s instructions. The array contains primers for 86 Wnt singaling pathway-
related genes, housekeeping genes, probes to detect contaminating genomic DNA and 
a positive PCR control. RNA isolated from primary B cells that had been activated for 
four hours in the presence of 1 µg/ml anti-IgM antibody was transcribed into cDNA 
using the RT
2 First strand kit (SABioscience): Genomic DNA was eliminated by 
incubating 0.5 µg RNA (8 µl) and 2 µl GE (5x genomic DNA elimination buffer) at 42°C 
for five minutes, followed by chilling on ice for some minutes. For reverse transcription, 
a cocktail containing 4 µl BC3 (5x RT buffer 3), 1 µl P2 (primer and external control 
mix), 2 µl RE3 (Reverse Transcriptase enzyme mix 3) and 3 µl H2O was prepared. 
Equal amounts of RNA solution and Reverse Transcriptase cocktail were mixed, 
incubated for exactly 15 minutes at 42°C, and the reaction was stopped by heating at 
95°C for five minutes. After diluting the synthesized cDNA with 91 µl H2O it was used 
together with the RT
2 SYBR Green qPCR Master Mix (SABioscience) for qRT-PCR. 
The reaction was assembeled to contain 102 µl cDNA, 1350 µl 2x RT
2 qPCR Master 
Mix and 1248 µl H2O. Twentyfive microliters of this mixture were distributed into each 
well on the PCR array 96 well-plate. The qRT-PCR reaction proceeded according to a 
two-step cycling program on a Light Cycler 480 (Roche). 
 
Light cycler program 
temperature [°C]  time [min] cycles ramp rate [°C/sec]
95 10:00  1  1.0 
95 00:15  45  1.0 
60 01:00  1  1.0 
 
For evaluation, the Ct values were exported into an Excel sheet and subjected to 
SABioscience’s web-based PCR array data analysis tool Materials and Methods 
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(http://www.sabiosciences.com/pcr/arrayanalysis.php). Using this tool, fold changes in 
mRNA levels in B cells from FasL  ∆Intra mice compared to wildtype ones were 
calculated based on the threshold cycle method. 
 
 
2.2.7 Protein-biochemical methods 
 
2.2.7.1 Protein-extraction from mammalian cells  
For protein extraction, cells were harvested, washed with PBS and resuspended in lysis 
buffer containing SDS and protease inhibitors. Before use, 495 µl 10% SDS, 132 µl 
PMSF (100mM) and one tablet Complete Mini protease inhibitor cocktail were added to 
9.5 ml lysis buffer (10x stock solution). The cells were disrupted by sonification (two 
times 15 seconds; 30% amplitude) and cellular debris was removed by centrifugation 
for ten minutes at 15,000 xg and 4°C. 
 
2.2.7.2 Determination of protein concentration using the Bradford method 
Protein concentration in the lysates was determined with a commerically available 
Bradford assay system (BioRad) that exploits the unspecific interaction of Coomasie 
blue dye with aromatic amino acids. A mixture containing 5 µl lysate, 200 µl Bradford 
reagent and 800 µl H2O was incubated for five minutes at room temperature before 
being transferred into a plastic cuvette for spectrophotometric determination of the 
extinction at 595 nm. Calculation of protein concentration was based on a BSA 
standard curve. 
 
2.2.7.3 SDS polyacrylamide gel electrophoresis (PAGE)  
For the size-dependent electrophoretic separation of proteins, a defined amount of cell 
lysate was mixed with an equal volume of 2x sample buffer and boiled for five minutes 
at 95°C to denature the proteins. Samples were stored on ice until use. Stacking- and 
running-SDS-polyacrylamide gels were casted and allowed to polymerize for two hours, 
before 30-50 µl denatured sample were loaded and the gel was run at 80V until 
samples were concentrated at the end of the stacking gel (approximately 10-20 
minutes) and then at 120V for sample separation. The Benchmark pre-stained protein 
ladder (Invitrogen) was used as a size standard. 
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2.2.7.4 Immunoblotting 
Proteins separated by electrophoresis were transferred onto 0.45 µm nitrocellulose 
membranes using a semi-dry transfer system. The immunoblot was assembled 
between the electrodes of the transfer system by creating a stack of three buffer-
soaked sheets of Whatmann paper, a piece of nitrocellulose membrane, the SDS-
polyacrylamide gel and three final, buffer soaked sheets of Whatman paper. Proteins 
were transferred onto the membrane at 0.8 mA/cm
2 for two hours. Transfer efficiency 
and homologous loading of proteins were assessed by staining with Ponceau S. 
For the immunoblot, membranes were incubated in blocking buffer for one hour at room 
temperature or overnight at 4°C to block unspecific binding. Antibodies against the 
proteins of interest were diluted in blocking buffer and incubated with the membrane 
overnight at 4°C. Following three washing steps, the membrane was incubated with an 
appropriate HRP-coupled antibody diluted in blocking buffer for one to two hours at 
room temperature. After three final washing steps, HRP-mediated chemiluminescence 
was detected with an ECL detection kit (Amersham).  
 
 
2.2.8 In vivo studies 
 
2.2.8.1 Analysis of thymocyte proliferation - Bromodesoxyuridine (BrdU)  
incorporation 
To investigate the proliferation of thymocytes in vivo, incorporation of the thymidine 
analogue BrdU into newly synthesized DNA was analyzed. Three mice per group were 
intraperitoneally injected with 1 mg BrdU/100 µl PBS, followed by a second injection of 
1 mg BrdU/100 µl PBS 30 minutes later. Control groups received twice 100 µl PBS 
instead of BrdU. The thymus was removed six hours after the second injection and was 
homogenized by grinding through gauze. After blocking Fc-receptors with FasFc (BD 
Bioscience) to prevent unspecific binding of antibodies, 10
6 total thymocytes were co-
stained for CD4 and CD8 cell surface expression. BrdU incoporation into newly 
synthesized DNA was determined with the FITC BrdU Flow Kit according to the 
manufacturer's instructions (BD Bioscience). Cells stained for cell surface antigens 
were fixed and permeabilized with 100 µl Cytofix/Cytoperm buffer (20 minutes, room 
temperature). After washing with 1 ml Perm/Wash buffer, cells were incubated with   
100 µl Cytoperm Plus buffer for ten minutes on ice. Following the treatment of cells with Materials and Methods 
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Cytoperm Plus buffer, cells need to be re-fixed. For this purpose, cells were washed, 
resuspended in 100 µl Cytofix/Cytoperm buffer, incubated for five minutes on ice and 
were washed again. To allow binding of the anti-BrdU antibody, the cellular DNA was 
digested with DNase I to expose the incorporated BrdU. This was accomplished by the 
addition of 30 µg DNase I (300 µg/ml) for one hour at 37°C. Samples were washed and 
stained with an anti-BrdU-FITC antibody (BD Bioscience) diluted 1:50 in 50 µl 
Perm/Wash buffer for 20 minutes at room temperature. Finally, cells were washed, 
resuspended in FACS buffer and analyzed on a FACSCalibur.  
 
2.2.8.2 Expansion of Vβ8 T cell receptor chain-expressing T cells 
Challenge with the bacterial superantigen Staphylococcus enterotoxin B (SEB) causes 
the specific expansion of Vβ8 T cell receptor chain-expressing T cells and can be used 
to assess the proliferative capacity of T cells in vivo. Three mice per group were 
intravenously injected with 100 µg SEB/200 µl PBS. Control groups received PBS only. 
Mice were sacrificed 48 hours post-injection and spleen and lymph nodes were 
removed. Single cell suspensions were prepared and stained for FACS analysis with 
fluorochrom-conjugated antibodies recognizing CD4, CD8 and Vβ8 or Vβ6. Staining for 
the Vβ6 TCR chain served as a control as Vβ6 TCR chain-expressing T cells do not 
respond to SEB challenge. For analysis of results, the increase in Vβ8 or Vβ6 TCR 
chain-expressing T cells in challenged versus unchallenged mice was calculated. 
 
2.2.8.3 Germinal center formation 
To compare the capacity of wildtype and FasL ∆Intra B cells to participate in thymus-
dependent (TD) immune responses, mice were immunized and levels of responding B 
cell populations were determined by flow cytometry. For the immunization, 100 µg   
4-hydroxy-3-nitrophenyl acetyl chicken
  gamma globulin (NP-CGG) per mouse were 
coupled to the adjuvant aluminium-potassium-dodecahydrate (KAL(SO4)2) by mixing 
equal volumes of NP-CGG (2 mg/ml) and 10% KAL(SO4)2 (in H2O). After careful 
titration to pH 6.5 with 1N NaOH, the mixture was kept on ice for 30 minutes and was 
then centrifuged for ten minutes at 1,700 xg and 4°C. The pellet was washed three 
times with 1 ml PBS and resuspended in PBS to yield a concentration of 100 µg NP-
CGG/200 µl PBS. Sterile filtrated, alum-precipitated NP-CGG was injected 
intrapertitoneally into five mice per group. Fourteen days post-immunization, mice were 
sacrificed, and 10
6 cells from spleen homogenates were stained for FACS analysis with Materials and Methods 
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50 µl of the respective staining solution for 20 minutes at 4°C. Cell surface markers 
used to distinugish cell populations and set up of the specific staining reactions are 
described below. The dye TopRo-3 iodide was included in some stainings as a 
live/dead cell discriminator. All antibodies were purchased from BD Bioscience and had 
a concentration of 0.2 mg/ml. 
 
Staining 1: B cells (B220
+), T cells (CD3
+) and B cell activation status (CD80
+, CD86
+) 
Gating: for the discrimination of B and T cells: lymphocyte population (FSC/SSC dot 
plot); for B cell activation status: B220
+ lymphocytes 
  dilution factor
CD86-FITC 1:300 
CD3-PE 1:50 
B220-PerCp 1:100 
CD80-APC 1:1200 
 
 
Staining 2: Germinal center B cells (PNA
+ CD95
+)  
Gating: TopRo
- B220
+ lymphocytes 
  dilution factor
PNA-FITC 1:500 
CD95-PE 1:75 
B220-PerCp 1:100 
TopRo-3 iodide  1:200 
 
 
Staining 3: Plasma cells (Syndecan (CD138)
+, B220
low) 
Gating: TopRo
- cells (TopRo/FSC dot plot) 
  dilution factor
Syndecan (CD138)-Bio  1:250 
SA-PE 1:400 
B220-PerCp 1:100 
TopRo-3 iodide  1:200 
 
 
Staining 4: Follicular zone B cells (IgM
+ IgD
+) and marginal zone B cells (IgM
high IgD
low)  
Gating: Lymphocyte population  
  dilution factor
IgD-FITC 1:800 
IgM-PE   1:30 
B220-PerCp 1:100 
TopRo-3 iodide  1:200 
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Staining 5: Isotype class switch to IgG and antigen-specific B cells (NP7
+) 
Gating: B220
+ lymphocytes 
  dilution factor
IgG1-FITC   1:200 
NP7-PE 1:400 
B220-PerCp 1:100 
IgM-APC 1:200 
 
 
Additionally, antibody titers in serum of the immunized animals were determined. To 
obtain serum, heart blood was collected. Therefore, the heart was incised, blood was 
drawn with a Pasteur capillary and transferred into 1.5 ml reaction tubes. Blood was 
incubated on ice for at least 2-3 hours until the cruor had settled, and centrifuged for ten 
minutes at 15,000 xg (4°C). Supernatant was transferred into fresh 1.5 ml reaction 
tubes, cleared again and stored at -80°C until analysis. 
To determine immunglobulin isotype concentrations and NP-specific antibodies solid 
phase sandwich ELISAs were performed. Incubations were done at room temperature 
and plates were washed between each assay step by addition of 200 µl PBS/well and 
subsequent decanting unless stated otherwise. Microtiter plates were coated with   
Ig-specific anti-mouse antibodies (anti-IgG1 or anti-IgM antibodies; cfinal = 5 µg/ml) to 
determine antibody specificity, or, to determine antibody affinity, with NP3-BSA and 
NP17-BSA (cfinal = 5 µg/ml) in carbonate buffer at 4°C overnight. Unspecific binding was 
blocked by incubation with 200 µl/well blocking buffer (one hour). Serum samples and 
standards (purified mouse IgM or IgG1; for the detection of NP-specific antibodies: 
standard serum) were pre-diluted in blocking buffer as follows: 
 
  standard serum sample
total IgG1 titer  1:100  1:50 
total IgM titer  1:100  1:50 
NP-specific IgG1 titer  1:1000  1:200 
NP-specific IgM titer  1:200  1:50 
 
One hundred microliters pre-diluted sample and standard were added to the top row on 
the microtiter plate and was serially diluted (1:2) in blocking buffer down to the bottom 
row using a 12-channel pipette, so that each well contained a total volume of 50 µl. 
Samples were allowed to bind for 1 hour at room temperature before the ELISA 
sandwich was formed by addition of 50 µl biotinylated secondary antibodies (anti-IgM-
biotin or anti-IgG1-biotin, 1:500 in blocking buffer) for 30 minutes at room temperature. Materials and Methods 
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Following a 30 minutes incubation with 50 µl/well AP-coupled streptavidin (1:2000),   
100 µl substrate solution (35 ml substrate-buffer/1 o-phenylendiamine tablet/21 µl H2O2) 
were added. AP-mediated substrate conversion was detected in an ELISA reader set to 
405 nm. For evaluation, the OD readings were corrected for background signals. A 
standard curve was plotted with the OD readings represented on the y-axis and the 
concentration on the x-axis. Antibody concentration in the samples was calculated 
based on the linear regression of the standard curve.  
 
2.2.8.4 Thioglycollate-induced peritonitis  
Thioglycollate broth injection into the peritoneal cavity followed by peritoneal lavage 
represents a well-described model for the mimicry of a systemic bacterial infection. 
Innate host immune responses become activated and lead to an increase of local 
neutrophils within the first hours after infection.  
Mice were injected intraperitoneally with 1 ml 3% thioglycollate broth in the evening of 
day one and treated a second time in the morning of the following day. Control groups 
were left untreated. Three hours after the second injection, mice were sacrificed. The 
animals were carefully skinned to keep the peritoneum intact. Incissions were made at 
both flanks of the mouse and across the abdomen, so that the skin could be detached 
from the peritoneum and be peeled off towards the head. For peritoneal lavage, 10 ml 
sterile Hank’s balanced salt solution (HBSS)/0.25% BSA were injected into the 
peritoneal cavity. Therefore, the syringe was pierced through the abdominal fat, since 
the fat serves as a natural plug preventing leakage of administered fluid. Cells were 
washed out by massaging the peritoneum for two minutes. Finally, the cell-containing 
fluid was recollected from the peritoneal cavity using a syringe. The number of 
infiltrating neutrophils was determined as the percentage of Ly6G (Gr-1)-expressing 
cells by FACS analysis of 10
6 cells. 
 
 
2.2.8.5 Statistics 
Statistical analysis was performed using two-tailed Student’s t-test. 
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3 Results 
 
3.1 Mouse model for FasL reverse signaling deficiency 
To study the physiological consequences of FasL reverse signaling in vivo, a mouse 
model for FasL reverse signaling deficiency was established in the group of PD Dr. 
Martin Zörnig (Georg-Speyer-Haus, Frankfurt). In these mice, the FasL gene was 
replaced by a truncated version that completely lacks the ICD (∆ aa 1-74) while it still 
expresses the wildtype transmembrane and extracellular domain (Fig. 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Mouse model for FasL reverse signaling deficiency.  
The  FasL ∆Intra mouse line was established by replacing the wildtype FasL with a 
truncated version lacking the FasL ICD (∆ aa 1-74). Homologous recombination of the 
targeting construct with the endogenous FasL locus deleted the first 74 N-terminal 
amino acids in exon 1 and introduced a floxed tk-neo cassette for positive selection into 
intron 1. Chimeric mice carrying the truncated FasL ∆Intra allele were crossed with the 
early deleter transgenic mouse strain CMV-Cre to remove the tk-neo cassette and 
subsequently were bred into the C57Bl/6N genetic background (at least eight 
generations). Intra = intracellular domain; TM = transmembrane domain; extra = 
extracellular domain; Ex = exon; tk-neo = Thymidine kinase-neomycine resistance 
cassette (positive selection); dth = Diphteria toxin A gene cassette (negative selection); 
solid black arrowheads = loxP sequences Results 
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Heterozygous mice (FasL
Wt/∆) were crossed, and resulting offspring were genotyped to 
identify wildtype and homozygous FasL  ∆Intra chimeras. PCR with genomic DNA 
isolated from tail biopsies revealed that all offspring were viable. Inheritance followed a 
clear Mendelian pattern, i.e. an inheritance ratio of wildtype to heterozygous to 
homozygous mutant mice of 1:2:1. Of 1200 animals, 278 mice carried two wildtype 
alleles (FasL
Wt/Wt) and 293 possessed two FasL ∆Intra alleles (FasL
∆/∆), while 625 mice 
were heterozygous (FasL
Wt/∆). This corresponds to a ratio of the different genotypes of 
1:2.3 :1.1 (wildtype:heterozygous:homozygous; Fig. 3.2).  
 
 
 
 
 
 
 
 
Figure 3.2 Genotyping and Mendelian inheritance pattern of FasL  ∆Intra mice. 
Homozygous mice (FasL
Wt/∆) were crossed, and offspring were routinely genotyped by 
PCR using genomic DNA as template and primers which amplify the region around the 
remaining loxP sequence in intron 1 of the mutated allele. As only the targeted FasL 
locus harbours the loxP site, the resulting PCR product is elongated (FasL
∆/∆: 280 bp 
vs. FasL
Wt/Wt: 219 bp). A representative picture of an agarose-gel electrophoresis of 
PCR products is shown. Of 19 animals analyzed, five mice carry two wildtype alleles 
(FasL
Wt/Wt) and five possess two FasL  ∆Intra alleles (FasL
∆/∆), while nine mice are 
heterozygous (FasL
Wt/∆).  
 
 
3.2 FasL ∆Intra mice represent a suitable model to study FasL reverse signaling 
 
3.2.1 FasL ∆Intra mice express functional FasL that is capabale of inducing  
apoptosis 
To verify that the FasL ∆Intra mouse line represents a suitable model to study FasL 
reverse signaling, FasL expression was investigated. This is an important point, as 
FasL
-/- mice and Fas or FasL-defective mice (the natural mouse mutants Fas
lpr, FasL
gld 
and the genetic Fas and FasL knockout models) develop a severe lymphoproliferative 
disease with the occurence of an aberrant T cell population, auto-antibodies and 
splenomegaly (Nagata et al., 1995). The lethal pathology is mostly attributed to the lack 
of Fas-mediated apoptosis. By RT-PCR analysis using primers that bind sequences in 
the 5’-UTR (screen-for) and near the 3’-end of exon 1 (screen-rev), the presence of Results 
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wildtype and truncated FasL transcript in activated B and T cells could be proven (Fig. 
3.3 A). Comparable expression of FasL protein at the cell surface of activated splenic 
lymphocytes became evident by flow cytometric staining using the anti-mFasL antibody 
clone MFL3 (Fig. 3.3 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 FasL expression in FasL ∆Intra mice.  
(A) FasL mRNA expression from the wildtype or targeted FasL locus was analyzed by 
RT-PCR. Using total RNA isolated from activated T and B cells (1 µg/ml anti-CD3 or 
anti-IgM antibody, for four hours) as template and primers that bind sequences in the  
5’-UTR and near the 3’-end of exon 1 resulted in a 460 bp fragment for the wildtype and 
a 220 bp fragment for the FasL ∆Intra transcript. (B) Expression of FasL at the cell 
surface of activated lymphocytes. Lymphocytes were activated by stimulation with   
5 µg/ml anti-CD3 antibody (T cells) or 10 µg/ml LPS (B cells) for 24 hours before 
staining with PE-conjugated anti-FasL (MFL-3) or isotype control antibody. One 
representative experiment out of four is shown. Wildtype cells are depicted by the solid, 
those of FasL ∆Intra mice by the dotted, and the isotype control by the wide dashed 
line. Results 
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Co-culture assays employing re-stimulated T cell blasts as effectors and Fas-sensitive 
target cells (B cell lymphoma cell line A20) indicated that the expressed FasL ∆Intra 
protein is functional in terms of its apoptosis-inducing function (Fig. 3.4). Notably, the 
killing capacity of FasL ∆Intra-effectors is reduced by approximately 40% compared to 
that of wildtype cells, but still is significantly higher than that of homoyzgous and 
heterozygous FasL
gld mice. The latter (FasL
Wt/gld) are rescued from development of the 
lymphoproliferative disease observed in homozygous animals by the presence of the 
single wildtype allele. Thus, the expression of a functional FasL (in terms of its 
apoptosis-inducing function) at the cell surface of activated lymphocytes makes the 
newly established FasL ∆Intra mouse line a suitable model to study the physiological 
consequences of FasL reverse signaling in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 FasL  ∆Intra mice express a functional FasL protein capable of 
inducing apoptosis. The capacity of FasL-dependent killing was evaluated in co-
culture experiments using re-stimulated (10 µg/ml anti-CD3 antibody for 24 hours) T cell 
blasts of wildtype, FasL ∆Intra and FasL
gld mice as effectors and Fas-sensitive, CFSE-
labeled target cells (A20) in an effector : target ratio of 2.5 : 1. After 6 hours, the extent 
of target cell death was assessed by PI staining of ethanol-fixed cells. Killing capacity is 
expressed as the percentage of cells with hypoploid DNA content (sub-G1 cells) minus 
the percentage of sub-G1 cells when FasL-dependent killing was blocked by addition of 
100 µg/ml FasFc. Columns represent the mean values and error bars the standard error 
of the mean (SEM) of four individual experiments.  
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3.2.2 FasL ∆Intra mice do not display obvious phenotypic anomalies 
In a broad, standardized phenotypic screen performed at the German Mouse Clinic 
(GMC, Munich) with five to 21 week old, unchallenged mice, no relevant differences 
between FasL ∆Intra and wildtype mice could be detected (data not shown). Likewise, 
an extensive analysis of main T and B cell compartments in spleen, lymph nodes, 
peritoneal cavity, blood and bone marrow of 8-12 week old mice revealed comparable 
levels of each population inspected (Table 3.1).  
 
 
Table 3.1 Unchallenged FasL ∆Intra mice do not show any phenotypic anomalies.  
B and T cell populations in spleen, lymph nodes, bone marrow and peritoneal cavity 
were analyzed by flow cytometry by staining for characteristic cell surface markers as 
indicated. Mice were used at an age of 8-12 weeks. Numbers represent the mean 
values and SEM of at least four mice per group. 
 
Spleen 
   Marker profile  wildtype  FasL ∆Intra 
T cells  CD3
+  29.54 ± 3.31  32.12 ± 0.88 
CD4
+ T cells  CD3
+ CD4
+  63.04 ± 4.60  61.64 ± 1.67 
CD8
+ T cells  CD3
+ CD8
+  30.87 ± 4.10  31.02 ± 1.59 
Lymphocyte 
populations 
B cells  B220
+  53.82 ± 5.02  59.19 ± 1.23 
T cells  CD4
+ or CD8
+, 
CD69
+ 
  7.50 ± 1.50    7.52 ± 1.29  Activation 
status 
B cells  B220
+CD86
+  10.36 ± 0.13  11.02 ± 0.26 
T cells  CD4
+ or CD8
+, 
CD95
+ 
26.00 ± 3.00  27.00 ± 2.00  Fas 
expression 
B cells  B220
+CD95
+  22.99 ± 2.69  23.87 ± 2.21 
CD4
+ T cells, naïve   CD4
+CD62L
+CD44
-  70.59 ± 2.69  67.30 ± 4.08 
CD4
+ T cells,  
central memory 
CD4
+CD62L
+CD44
+    3.03 ± 1.63    4.74 ± 0.69 
CD4
+ T cells,  
effector memory 
CD4
+CD62L
-CD44
+  16.12 ± 5.65  22.40 ± 2.99 
CD8
+ T cells, naïve   CD8
+CD62L
+CD44
-  59.04 ± 5.04  51.23 ± 4.74 
CD8
+ T cells,  
central memory 
CD8
+CD62L
+CD44
+  10.97 ± 5.91  15.90 ± 2.51 
CD8
+ T cells,  
effector memory* 
CD8
+CD62L
-CD44
+    3.61 ± 1.07    8.71 ± 1.58 
Transitional B cells T1   AA1.4
+CD23
-IgM
high  22.74 ± 1.59  22.05 ± 1.78 
Transitional B cells T2 AA1.4
+CD23
+IgM
high  21.78 ± 0.86  24.13 ± 1.24 
Transitional B cells T3 AA1.4
+CD23
+IgM
low  17.69 ± 1.52  19.19 ± 1.57 
Marginal zone B cells  B220
+IgM
highIgD
low    7.31 ± 0.90    8.92 ± 1.15 
Lymphocyte 
subsets 
Follicular B cells  B220
+IgM
+IgD
+  80.65 ± 0.18  80.27 ± 0.88 
* The difference in effector memory CD8
+ T cells between FasL ∆Intra and wildtype 
mice is significant (p = 0.5). 
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Other lymphoid organs 
   Marker  profile  wildtype  FasL ∆Intra 
T cells  CD3
+  66.19 ± 2.55  70.52 ± 2.57 
total CD4
+ T cells  CD3
+CD4
+  58.08 ± 3.09  57.43 ± 2.95 
total CD8
+ T cells  CD3
+CD8
+  38.84 ± 2.75  39.07 ± 3.35 
B cells  B220
+  28.52 ± 0.30  26.36 ± 1.82 
Follicular B cells  B220
+IgM
+IgD
+  27.31 ± 0.70  25.06 ± 1.27 
Activated B cells  B220
+CD86
+    9.77 ± 0.31  10.17 ± 0.26 
Lymph node 
Fas expression  B220
+CD95
+  20.67 ± 1.33  19.49 ± 0.44 
Pro B cells  B220
lowCD43
low    3.83 ± 0.05    4.77 ± 0.78 
Pre Bcells  B220
lowCD43
-  32.83 ± 3.55  25.90 ± 3.52 
Immature B cells  B220
+IgM
+IgD
-  16.19 ± 0.27  11.46 ± 3.44 
Bone marrow 
Recirculating B cells  B220
+IgM
+IgD
+  32.64 ± 2.96  35.49 ± 3.37 
T cells  CD3
+    6.11 ± 0.45    6.23 ± 0.20 
B1a B cells  CD5
+B220
low  32.07 ± 4.47  33.42 ± 4.13 
B1b B cells  CD5
-B220
low    7.96 ± 0.66    6.38 ± 1.05 
Peritoneal 
cavity 
B2 B cells  CD5
-B220
+  40.12 ± 4.37  40.13 ± 5.38 
 
 
The life expectancy of mutant mice could not be determined, as mice were sacrificed 
before death of natural causes. However, even in old animals (12-18 month) no 
relevant difference regarding phenotype and viability was found between FasL ∆Intra 
and wildtype mice. Importantly, the old FasL ∆Intra mice did not develop any signs of 
the lymphoproliferative disease associated with the FasL
gld/gld- and Fas
lpr/lpr-mutation, as 
indicated by the absence of anti-dsDNA auto-antibodies, rheumatoid factor, 
CD3
+B220
+CD4
-CD8
- T cells or splenomegaly (Table 3.2). The absence of any obvious 
phenytopic anomalies supports the notion that the FasL ∆Intra mouse line is suitable to 
decipher the physiological function of the FasL ICD. 
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Table 3.2 FasL ∆Intra mice do not develop signs of the FasL
gld/gld-phenotype.  
Enlargement of the spleen was assessed by visual inspection. Of note, FasL
gld/gld mice 
exhibited splenomegaly, while three FasL  ∆Intra mice had only slightly enlarged 
spleens. Cell viability and organ cell counts were measured with a Casy cell counter. 
Aberrant T cells were detected by flow cytometric staining of splenocytes and 
thymocytes for cell surface markers as indicated. All mice were used at an age of 12-18 
month. Mean values and SEM of at least three mice per group are shown. S=spleen; 
T=thymus; sn=statistically significant difference in wildtype or FasL  ∆Intra mice vs. 
FasL
gld/gld mice; sn*=statistically significant in wt vs. FasL
gld/gld; n.d.=not determined 
 
  organ Marker  profile  wildtype  FasL ∆Intra  FasL
gld/gld   
Spleen enlarged   0/4  3/16  4/4   
Viability   S    93.53 ± 0.83 93.16 ± 3.84  88.36 ± 1.28  sn 
S    20.82 ± 2.47 25.80 ± 8.38  53.50 ± 16,27  sn*  Cell counts 
[*10
7]  T      3.48 ± 0.76   5.87 ± 1.10  19.33 ± 09.53  sn 
S  CD3
+B220
+    2.00 ± 0.41   2.50 ± 0.34  23.25 ± 06.02  sn 
CD3
+B220
+    0.43 ± 0.07 n.d.  41.00 ± 02.45  sn 
Thy1
+CD4
-CD8
-  n.d.    4.00 ± 0.32  22.67 ± 10.20  sn 
Aberrant T cell 
population  T 
Thy1
+CD4
+CD8
+  n.d.  83.40 ± 1.03    3.67 ± 02.67  sn 
 
 
3.3 Analysis of FasL reverse signaling ex vivo 
 
3.3.1 The FasL ICD impairs lymphocyte proliferation 
Several reports have implicated FasL reverse signaling in the regulation of T cell 
proliferation and activation (Lettau et al., 2009). Based on these findings, the 
proliferation of different lymphocyte populations was investigated in FasL ∆Intra mice. 
Primary lymphocytes were isolated from the spleens of wildtype and mutant mice using 
magnetic bead purification and lineage specific kits for the negative selection of the 
desired cell subset. A purity of lymphocyte preparations of over 90% was usually 
achieved (data not shown). CFSE-labeling experiments revealed that the proliferation of 
B cells, CD4
+ T cells and CD8
+ T cells in response to mitogenic stimulation for 72 hours 
was strongly enhanced in the absence of the FasL ICD (Fig. 3.5 A). This effect was 
most pronounced in B cells. Interestingly, differences in the proliferative capacity of 
CD4
+ T cells could only be detected after the depletion of CD25
+CD4
+ regulatory T 
cells. Thus, the presence of the FasL ICD appears to negatively impact lymphocyte 
proliferation. In accordance with these results, cells completely lacking FasL (FasL
-/-) 
(Karray et al., 2004; Mabrouk et al., 2008) responded even stronger to mitogenic 
stimulation than those lacking only the FasL ICD (Fig. 3.5 B).  
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Figure 3.5 Increased proliferation in the absence of the FasL ICD.  
CFSE-labeled lymphocytes were left untreated or were stimulated with 5 µg/ml anti-
CD3 antibody (T cells) or 10 µg/ml anti-CD40 antibody (B cells) for 72 hours. 
Proliferation of living cells was measured by FACS analysis as the decrease in 
fluorescence intensity of the CFSE-staining. The grey peak represents non-stimulated 
lymphocytes that did not proliferate. (A) In the absence of the FasL ICD (dotted line), 
lymphocyte proliferation is enhanced compared to wildtype cells (solid line). One 
representative experiment out of five is shown. (B) B cells completely lacking FasL 
(FasL
-/-) responded even stronger to mitogenic stimulation than those lacking only the 
FasL ICD. One experiment out of two is shown. 
 
 
3.3.2 Defective FasL reverse signaling accounts for the observed enhanced  
         proliferation of FasL ∆Intra lymphocytes  
 
3.3.2.1 Comparable extent of cell death in FasL ∆Intra and wildtype lymphocytes 
In the immune system, activation-induced cell death (AICD), i.e. deletion of re-
stimulated lymphocytes, plays a crucial role in the regulation of clonal 
expansion/deletion of effector cells and the termination of immune responses. AICD 
proceeds through death receptor-mediated apoptosis, and the FasL/Fas system plays a Results 
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pivotal role in its course (Green et al., 2003; Krammer et al., 2007). Therefore, what 
appears as an enhanced proliferation might alternatively reflect a survival advantage 
instead. 
To eliminate this possibility, cell death in response to TCR or BCR cross-linking was 
analyzed by Annexin V/PI staining. The extent of cell death in T and B cells in response 
to stimulation for zero, 48 or 72 hours was not affected by the absence or presence of 
the FasL ICD (Fig. 3.6 A). Likewise, the number of viable T cell blasts upon re-
stimulation (1 µg/ml anti-CD3 antibody for 24 hours) was decreased by approximately 
30% in both, mutant and control cells (Fig. 3.6 B). Therefore, the enhanced proliferation 
in FasL ∆Intra lymphocytes does not reflect decreased cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Comparable extent of cell death in lymphocytes of FasL ∆Intra and 
wildtype mice. Cell death was quantified by staining with Annexin-V/PI and FACS 
analysis. Diagrams display the percentage of positively stained dead cells as the 
percentage of dead cells. (A) Naïve lymphocytes were stimulated with 1 µg/ml of either 
anti-IgM antibody (B cells) or anti-CD3 antibody (T cells) for the indicated times. 
Columns represent mean values and bars represent the SEM of five individual 
experiments. (B) AICD in T cell blasts re-stimulated with 1 µg/ml anti-CD3 antibody for 
24 hours. One single experiment was performed. 
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3.3.2.2 Non-apoptotic signaling through Fas does not account for the proliferative  
differences in FasL ∆Intra and wildtype lymphocytes 
To exclude signaling through the Fas receptor (instead of FasL reverse signaling) as a 
cause for the differential response, activation-induced proliferation was investigated in a 
Fas signaling-defective setting. Crossing FasL  ∆Intra with Fas
lpr mice resulted in 
offspring homozygously harboring the mutant Fas
lpr and either the wildtype or the 
truncated  FasL locus (Fas
lpr/lpr/FasL
Wt/Wt  and
  Fas
lpr/lpr/FasL
∆/∆). Using the same 
experimental set up as in previous experiments, it was demonstrated that the 
proliferative differences between mutant and wildtype lymphocytes could be reproduced 
in the absence of a functional Fas receptor (Fig. 3.7 A), pointing to a causative role for 
FasL reverse signaling. In support of this notion, levels of Fas at the cell surface of 
resting and activated lymphocytes are comparable between FasL ∆Intra (Fas
Wt/Wt) and 
wildtype (Fas
Wt/Wt) mice (Fig. 3.7 B). 
 
Figure 3.7 Signaling through Fas does not account for proliferative differences in 
FasL ∆Intra and wildtype lymphocytes. (A) B cell proliferation in a Fas signaling-
deficient model. FasL  ∆Intra mice were mated with Fas
lpr/lpr animals to obtain 
homozygous  Fas
lpr/lpr  offspring that express either wildtype or truncated FasL 
(Fas
lpr/lpr/FasL
Wt/Wt, Fas
lpr/lpr/FasL
∆/∆). Activation-induced proliferation of B cells (10 µg/ml 
anti-CD40 antibody, 72 hours) was investigated in CFSE-labeling experiments. Resting 
lymphocytes are represented by the filled grey curve. The solid black line represents B 
cells with wildtype FasL, the dotted line those prepared from FasL ∆Intra mice. One 
representative experiment out of three is shown. (B) Comparable levels of Fas at the 
cell surface of T cells. Splenic T cells were isolated and stimulated for the indicated 
times with 1 µg/ml anti-CD3 antibody. The percentage of Fas-expressing T cells was 
analyzed by flow cytometry using an anti-Fas (JO2) antibody. Columns represent mean 
values and bars represent the SEM of three independent experiments. Results 
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3.3.3 The FasL ICD regulates ERK1/2 activation and proliferation by influencing  
         phosphorylation of PLCγ2 and PKC 
Upon antigen encounter, lymphocytes acquire an activated phenotype, characterized by 
a blastic morphology and the expression of activation markers at the cell surface, and 
they expand clonally. At the molecular level, these changes correlate with the activation 
of various signaling pathways, such as the Mitogen-activated protein kinase (MAPK)-, 
the Phosphoinositide-specific phospholipase C (PLC)/Protein kinase C (PKC)- and the 
Phosphoinositide 3-kinase (PI3K)/Akt-pathway. 
 
3.3.3.1 The presence of the FasL ICD reduces ERK1/2 activation 
To identify a molecular correlate for the differential proliferative capacity of FasL ∆Intra 
and wildtype lymphocytes, activation-induced ERK1/2 phosphorylation was analyzed as 
a prototypic marker for cell proliferation (Krishna et al., 2008). In cell-based ELISAs, 
phosphorylation of ERK1/2 (T202/Y204) in B cells upon BCR cross-linking with anti-IgM 
antibody for various time points was quantified. As expected, mitogenic stimulation 
resulted in a strong increase of phosphorylated ERK1/2. While initial levels of 
phosphorylated protein were comparable, mitogenic stimulation led to significantly 
higher levels of activated ERK1/2 in FasL ∆Intra B cells compared to wildtype cells (Fig. 
3.8 A). This finding was confirmed by Western blot experiments in which ERK1/2 
phosphorylation in lysates from activated B cells was detected with an anti-pERK1/2 
antibody (Fig. 3.8 B). Both experiments revealed that in the absence of the FasL ICD, 
ERK1/2 activation was already elevated five minutes after stimulation and remained 
elevated at all time points analyzed, as compared to the presence of the full length 
protein in wildtype cells. 
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Figure 3.8 The presence of the FasL ICD reduces ERK1/2 activation.  
(A) B cells were stimulated with 1 µg/ml anti-IgM antibody for the indicated time points, 
and ERK1/2 phosphorylation was analyzed by ELISA. The diagram displays the relative 
induction of ERK1/2 activation, measured as the increase in relative fluorescence 
intensity of phosphorylated ERK1/2 compared to total ERK1/2 protein. Data are 
presented as the mean values and SEM of four independent experiments. (B) Western 
blot analysis of ERK1/2 phosphorylation in lysates of B cells stimulated with 1 µg/ml 
anti-IgM antibody for the indicated times. Phosphorylated ERK1/2 was detected with an 
anti-pERK1/2 antibody. β-Actin served as loading control. One representative 
experiment out of two is shown. 
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3.3.3.2 MAP-kinases upstream of ERK1/2 do not appear to be regulated by FasL  
reverse signaling 
Further characterizing the MAPK-pathway upstream of ERK1/2, the protein kinases c-
Raf and MEK1/2 were analyzed in analogous experimental set ups. Although mitogenic 
stimulation again induced phosphorylation (c-Raf: S38; MEK1/2: S218/S222), neither c-
Raf nor MEK1/2 were differentially regulated in B cells isolated from FasL ∆Intra mice 
compared to those from wildtype mice (Fig. 3.9 A). When activation-induced 
proliferation was investigated in the presence of the MEK1/2 inhibitor U0126, it could be 
shown that B cell proliferation was markedly impaired, but not completely abolished 
(Fig. 3.9 B). These findings suggested, that B cell proliferation is partially MAPK-
dependent, but that the MAPK-cascade upstream of ERK is not subject to FasL reverse 
signaling-mediated regulation.  
 
Figure 3.9 Neither c-Raf nor MEK1/2 are regulated by FasL reverse signaling.  
(A) Splenic B cells were stimulated with 1 µg/ml anti-IgM antibody for the indicated time 
points and analyzed for c-Raf (left) or MEK1/2 (right) phosphorylation by ELISA. The 
diagrams display the relative induction of specific protein activation, measured as the 
ratio of the relative fluorescence intensities of phospho-protein vs. total protein. Mean 
values and SEM of eight (c-Raf) or four (MEK1/2) experiments are shown. (B) B cell Results 
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proliferation is partially MAPK-dependent. Activation-induced (10 µg/ml anti-CD40 
antibody, 72 hours) B cell proliferation in the absence (solid line) or presence (dashed 
line) of the MEK inhibitor U0126 (10µM) was asessed in CFSE-labeling experiments. 
One experiment out of two is shown. 
 
 
3.3.3.3 FasL reverse signaling via PLCγ2 and PKC regulates ERK1/2 activation   
            and proliferation 
In agreement with a partial dependence on the MAPK pathway, PMA/ionomycine-
mediated proliferation of B cells was not affected by the MEK1/2 inhibitor U0126 (Fig. 
3.10). As stimulation with PMA/ionomycine specifically triggers the activation of PKC 
(Kurosaki et al., 2000; Paulsen et al., 2009), this finding indicates an involvement of the 
PLC/PKC pathway in the regulation of BCR-induced proliferation of wildtype and   
FasL ∆Intra B cells.  
 
 
Figure 3.10 PMA/ionomycine-mediated proliferation is not affected by MEK 
inhibition.  Splenic B cells were stimulated with 100 ng/ml PMA and 0.2 µg/ml 
ionomycine for 72 hours in the absence (solid line) or presence (dashed line) of the 
MEK1/2 inhibitor U0126 (10µM). Proliferation was quantified in CFSE-dilution assays by 
FACS analysis. One experiment of two is shown. 
 
 
Indeed, intracellular stainings for phosphorylated PLCγ2 (Y759) and PKC (T497) after 
BCR cross-linking revealed an enhanced phosphorylation of both molecules in FasL 
∆Intra B cells compared to wildtype cells (Fig. 3.11 A). To link PKC activity to ERK 
phosphorylation and proliferation, the effects of the general PKC inhibitor GF 109203x 
hydrochloride were determined (Fig. 3.11 B). PKC inhibition severely impaired ERK Results 
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activation as well as proliferation of B cells derived from FasL ∆Intra and from wildtype 
mice. These results suggest an important role for PKC activity in FasL reverse 
signaling. 
 
 
Figure 3.11 PLCγ2/PKC signaling regulates ERK1/2 activation and proliferation in 
B cells. (A) The activation of PLCγ2 and PKC is repressed by FasL reverse signaling. 
B cells were stimulated with 1 µg/ml anti-IgM antibody for the indicated times. Activation 
of PLCγ2 (left) and PKC (right) was evaluated by intracellular staining with anti-
phospho- PLCγ2 and anti-phospho-PKC antibodies and subsequent FACS analysis. 
The geometric mean fluorescence intensity (MFI) was related to the MFI of untreated 
cells. Data are expressed as the mean values and SEM of four independent 
experiments. (B) left: PKC inhibition impairs ERK1/2 activation. ERK1/2 activation in Results 
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response to B cell stimulation with 1 µg/ml anti-IgM antibody in the presence (dashed 
bars) or absence (filled bars) of the PKC inhibitor GF109203x hydrochloride (1µM) was 
determined by ELISA. The diagram shows the relative induction of ERK1/2 activation, 
measured as the ratio of relative fluorescence intensities of phosphorylated ERK1/2 to 
total ERK1/2 protein. One experiment out of four is shown. right: PKC inhibition impairs 
B cell proliferation. PKC-dependent B cell proliferation (100 ng/ml PMA and 0.2 µg/ml 
ionomycine, 72 hours) in the presence (dotted line) or absence (solid line) of 1µM 
GF109203x hydrochloride was measured in CFSE-dilution assays. Unstimulated cells 
are represented by the grey curve. One representative experiment out of four is shown.  
 
 
3.3.3.4 The PI3K/Akt pathway is apparently not involved in FasL reverse signaling 
To explore a potential involvement of a third pathway important for lymphocyte 
activation in FasL ICD-mediated signaling, signal transduction via the PI3K/Akt pathway 
was analyzed. Using phosphorylation of the protein kinase Akt (S473) as readout in 
cell-based ELISA experiments, it could be demonstrated that kinetics and extent of Akt 
activation in B cells in response to mitogenic stimulation were not affected by the 
presence or absence of the FasL ICD (Fig. 3.12). 
 
 
Figure 3.12 The PI3K/Akt pathway is not involved in FasL reverse signaling.  
B cells were stimulated with 1 µg/ml anti-IgM antibody for the indicated time points, and 
Akt phosphorylation was analyzed by ELISA. The diagram shows the relative induction 
of Akt activation measured as the ratio of relative fluorescence intensities of 
phosphorylated Akt vs. total Akt protein. Data are expressed as the mean values and 
SEM of eight independent experiments.  
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3.3.4 Identification of FasL reverse signaling target genes 
Previous studies in our group revealed a Notch-like proteolytic processing of FasL 
(Kirkin et al., 2007) and identified the transcription factor Lef-1 as an interaction partner 
of the FasL ICD (Lückerath et al., manuscript submitted). Additionally, data presented in 
this study show a FasL ICD-dependent differential activation of the transcriptional 
regulator ERK1/2. These findings promted the search for genes that are targeted by 
FasL reverse signaling. 
 
 
3.3.4.1 Global gene expression profiling 
Molecular phenotyping was performed to screen for potential target genes on a close to 
genome-wide basis. Co-operating with the German Mouse Clinic, cDNA derived from 
activated or resting T cells of either FasL ∆Intra or wildtype mice was hybridized to 
Affymetrix 21K cDNA chips (21,000 genes covered). In resting cells, the expression of 
only 22 genes deviated slightly, with 0.4-0.7 fold changes in relative transcript levels 
(appendix Table A.1). In contrast, 181 genes were found to be significantly regulated 
(up to eight fold) in activated lymphocytes (appendix Table A.2). None of the genes 
present on the array was regulated in both, unstimulated and stimulated, samples, 
indicating specific signals. Despite the large number of genes identified, cluster analysis 
did not reveal the regulation of any particular functional gene group.  
 
 
3.3.4.2 FasL reverse signaling regulates genes associated with lymphocyte  
proliferation and activation 
To identify bona fide target genes of FasL ICD-mediated singaling, the differential 
expression of candidate genes was verified by quantitative real-time PCR (qRT-PCR). 
Candidates were chosen among the genes which differed mostly between wildtype and 
FasL  ∆Intra mice in microarray screens. By default, relative expression levels were 
normalized to the housekeeping gene Hypoxanthine phosphoribosyltransferase 1 
(Hprt1) and calculated using the threshold cycle method. Interestingly, when comparing 
activated B cells from FasL ∆Intra mice with those form wildtype mice, various genes 
associated with lymphocyte proliferation and activation were significantly (≥ two-fold) 
up-regulated in FasL ∆Intra B cells (Fig 3.13 A), for example Nuclear factor kappa-light-
chain-enhancer of activated  B cells ( NF-κb1),  Nuclear factor of activated T cells 1 Results 
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(NFAT1) and Interferon regulatory factor 4 ( Irf4), providing an explanation for the 
enhanced proliferative response in the absence of the FasL ICD. Importantly, results 
could be reproduced when gene expression was normlized to an alternate 
housekeeping gene (Glycerinaldehyde-3-phosphate-dehydrogenase; Gapdh) (Fig. 3.13 
B). 
 
 
Figure 3.13 FasL reverse signaling target genes.  
Splenic B cells were stimulated with 1 µg/ml anti-IgM antibody for four hours before 
isolation of total RNA and cDNA synthesis. Relative abundance of transcripts was 
quantified by qRT-PCR. Each sample was assessed in triplicate and normalized to Hprt 
(A) and Gapdh (B) as housekeeping genes. Transcript levels in FasL ∆Intra cells were 
related to expression levels in wildtype cells using the 2
-∆∆Ct method. (A) Columns 
represent mean values, bars represent the SEM of four independent experiments. (B) 
One experiment out of two is shown. 
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3.3.4.3 Significant regulation of Wnt signaling pathway-associated genes by the  
FasL ICD 
In addition to proliferation- and activation-associated genes, transcript levels of several 
Lef-1 target genes, such as Survivin,  Cyclin D1,  Ectodysplasin A ( EDA),  Fibroblast 
growth factor 4 (FGF4) and Interleukin-4 (IL-4), were found to be affected in FasL ∆Intra 
B cells (Fig. 3.13). Based on this observation and on the previously demonstrated FasL 
ICD : Lef-1 interaction, expression of Wnt signaling pathway-related genes was 
investigated in more detail. A commercially available PCR array (mouse Wnt signaling 
pathway PCR array; SABiosciences) was used to compare the regulation of 86 Wnt 
pathway-related genes in activated B cells from FasL  ∆Intra and wildtype mice. 
Surprisingly, a noticable regulation was observed, with a significantly (≥ two-fold) 
reduced expression of 40 genes and a significantly elevated expression of one gene 
(Cyclin D2) (Fig. 3.14). Altogether, these data support a role for the FasL ICD in the 
Lef-1-dependent regulation of gene transcription.  
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Figure 3.14 Extensive regulation of Wnt signaling pathway-associated genes.  
The expression of 86 Wnt pathway-related genes in activated B cells (1 µg/ml anti-IgM 
antibody, four hours) was analyzed with the Mouse Wnt Signaling Pathway PCR Array 
from SABiosciences. Samples were normalized to six housekeeping genes. Relative 
mRNA levels were calculated using an appropriate web-based analysis tool 
(http://www.sabiosciences.com/pcr/arrayanalysis.php). The top panel shows a heat 
map of the fold change in FasL ∆Intra cells compared to wildtype cells. The bottom 
panel displays the genes analyzed and the respective fold change in FasL ∆Intra cells. 
Array analysis was performed once. 
 
 
3.3.5 B cells isolated fom spleen express Lef-1 
The expression of Lef-1 in B cells is controversially discussed. While Lef-1 expression 
in B cell progenitors (pre- and pro-B cells) is widely accepted, Lef-1 expression in 
mature B cells is debated (Reya et al., 2000). As the findings presented in this study 
strongly suggest an interplay of FasL ICD and Lef-1 in mature B cells, Lef-1 mRNA and 
protein expression were investigated in B cells isolated from the spleen of FasL ∆Intra 
or wildtype mice. Using conventional RT-PCR, the presence of Lef-1 transcript in B 
cells from mutant and control mice could be demonstrated (Fig. 3.15 A). The proper 
identity of the PCR products obtained was supported by an identical signal derived from 
cDNA of HEK293T cells transfected with a Lef-1 expression plasmid. Likewise, 
intracellular staining with an anti-Lef-1 antibody for flow cytometric analysis revealed 
comparable amounts of Lef-1 protein in FasL ∆Intra and wildtype B cells (Fig. 3.15 B). 
These data indicate, that indeed Lef-1 mRNA and protein are expressed in mature B 
cells.  
 
Figure 3.15 Lef-1 is expressed in splenic B cells.  
(A) Lef-1 mRNA expression in B cells of wildtype and FasL ∆Intra mice. B cells were 
isolated from spleen and stimulated with 1 µg/ml anti-IgM for four hours before RNA Results 
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isolation and RT-PCR analysis using Lef-1 specific primers. HEK293T cells transfected 
with a Lef-1 expression construct served as positive control. (B) Lef-1 protein 
expression in B cells of wildtype and FasL ∆Intra mice. Freshly isolated splenic B cells 
were intracellularly stained for flow cytometric analysis using an anti-Lef-1 antibody and 
an Alexa Fluor546-coupled secondary antibody. One representative experiment out of 
six is shown. Wildtype cells are represented by the solid, FasL ∆Intra cells by the dotted 
line. The grey curve shows staining with an isotype control antibody. 
 
 
To support this finding, Wnt signaling was investigated in vivo. Homozygous mice of the 
FasL ∆Intra mouse line were crossed to TopGal mice that express β-Galactosidase 
under the control of a Lef-1-dependent promoter (DasGupta et al., 1999). Therefore, 
induction of Lef-1-dependent transcription correlates with β-Galactosidase activity, 
which can be quantified by flow cytometry as the extent of β-Galactosidase-mediated 
substrate conversion. For experiments, offspring bearing the LacZ transgene and either 
the wildtype or the truncated FasL locus was selected. B cells isolated from spleen 
were stimulated by BCR cross-linking for various time points before measurement of 
substrate conversion. Unfortunately, β-Galactosidase activity could never be detected 
(data not shown). This was not due to a general failure of the assay, as enzymatic 
activity could be detected reliably in B cells from Rosa mice that constitutively express a 
LacZ transgene. 
 
 
3.4 In vivo studies to investigate the consequences of FasL reverse signaling 
Hallmarks of an immune repsponse include the activation, recruitment and clonal 
expansion of innate and adaptive immune effector cells. Thus, changes in the 
proliferative capacity of lymphocytes, as observed in the absence of the FasL ICD ex 
vivo, should have an impact on the course of immune responses in vivo. Here, a 
potential participation of FasL reverse signaling in the regulation of immune responses 
to various challenges was investigated. 
 
3.4.1 Analysis of thymocyte proliferation 
Within the thymus, T cells develop from a double negative (CD3
+CD4
-CD8
-) to a double 
positive (CD3
+CD4
+CD8
+) and finally to a single positive (either CD3
+CD4
+ or 
CD3
+CD8
+) state. In order to reach the next maturational stage, thymocytes have to 
pass several selection steps to ensure that only T cells that function properly and do not 
recognize self-molecules are released into the periphery  (Boursalian et al., 2003; Results 
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Mueller, 2010). In a study from the group of Pamela Fink (Boursalian et al., 2003) FasL 
was reported to function as a co-stimulatory factor during positive selection. To 
investigate if T cell proliferation in the thymus is affeced by the absence or presence of 
the FasL ICD, mice were intraperitoneally injected with the thymidine analogue 
bromodesoxyuridine (BrdU). Co-staining of CD4, CD8 and BrdU revealed that BrdU 
was incorporated into the DNA of thymocytes of each developmental stage to the same 
extent in FasL ∆Intra and wildtype mice (Fig. 3.16). Together with the observation of 
normal mature T cell populations in the periphery of FasL ∆Intra mice (Table 3.1), this 
suggests, that the FasL ICD does not affect T cell development in the thymus.  
 
 
Figure 3.16 FasL ICD deletion does not affect thymocyte proliferation.  
Three mice per group were injected i.p. twice with 1 mg BrdU/100 µl PBS (30 minutes 
delay). Control groups received PBS only. Six hours later, total thymocytes were 
stained for CD4 and CD8 cell surface expression and BrdU incoporation. The diagram 
shows the percentage of BrdU
+ cells in the depicted thymocyte populations normalized 
to untreated mice. Mean values and SEM of three experiments are shown. SP = single 
positive thymocytes; DP = double positive thymocytes 
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3.4.2 Expansion of Vβ8 T cell receptor (TCR) chain-expressing T cells 
The proliferative capacity of T cells was analyzed in a simple in vivo model in which 
mice were intravenously injected with the bacterial superantigen Staphylococcus 
enterotoxin B (SEB). Mimicking a bacterial infection, SEB causes specifically the 
expansion of Vβ8 TCR chain-bearing T cells, whereas for example expansion of T cells 
with the Vβ6 TCR chain is not triggered (Desbarats et al., 1998). In a three-color FACS 
analysis, the relative increase of helper (CD4
+) and cytotoxic (CD8
+) Vβ8- or Vβ6-
expressing T cells was determined in spleen and lymph nodes of challenged versus 
untreated animals. As expected, a significant expansion of Vβ8
+ T cells, but not of Vβ6
+ 
T cells could be observed upon SEB administration (Fig. 3.17). However, the response 
of  FasL  ∆Intra mice matched that of wildtype mice. This indicates regulatory 
mechanisms operating in vivo that mask FasL reverse signaling, e.g. control exerted by 
regulatory T cells. Alternatively, the potent T cell stimulation by SEB might have 
overridden FasL reverse signaling which is only detectable under conditions of sub-
optimal stimulation (Desbarats et al., 1998; Suzuki et al., 1998; Suzuki et al., 2000b; 
Paulsen et al., 2009). 
 
 
Figure 3.17 SEB-triggered expansion of Vβ8 TCR chain-expressing T cells.  
Three mice per group were injected i.v. with 100 µg SEB. Total splenocytes and 
thymocytes were stained for cell surface expression of CD4, CD8 and Vβ8 or Vβ6  
48 hours post-injection. Diagrams show the relative increase in Vβ8- or Vβ6-expressing 
T cells in challenged vs. unchallenged mice as fold induction. Columns represent the 
mean values and bars the SEM of three independent experiments.  
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3.4.3 Anti-viral response of CD8
+ T cells following Lymphocytic choriomeningitis  
         virus (LCMV) infection 
LCMV belongs to the arenaviridae and is a widely used infection model to study various 
aspects of anti-viral immune reponses. LCMV-infection induces a protective response 
of virus-specific CD8
+ cytotoxic T cells (CTLs), peaking after six to eight days, to clear 
the acute infection. In co-operation with Prof. Dr. Thomas Brunner (Bern, Switzerland), 
FasL ∆Intra and wildtype mice were intravenously infected with 10
3 PFU LCMV (strain 
WE) as previously described (Corazza et al., 2000). The amount of virus-specific CD8
+ 
T cells present in spleen was quantified by tetramer staining (epitope H-2D
b/gp33–41) 
eight days post-infection. At the peak of the anti-viral response, eight to nine percent of 
all CD8
+ CTLs were virus-reactive (tetramer
+) in both, FasL ∆Intra and wildtype animals 
(Fig. 3.18). Apparently, acute anti-viral CD8
+ CTL responses to LCMV-infection are not 
regulated by the FasL ICD, or the strong immune stimulation by LCMV overrides 
reverse FasL signals . 
 
Figure 3.18 Antigen-specific expansion of CD8
+ T cells after LCMV infection.  
10
3 PFU LCMV-WE were injected i.v. into three mice per group. One control mouse 
was not infected. The amount of virus-specific CD8+ T cells present in spleen was 
quantified by tetramer staining (epitope H-2D
b/gp33-41) eight days post-infection.  
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3.4.4 Acute and long-term immunity in an infection model of listeriosis 
Besides LCMV, infection with the intracellular bacterium Listeria monocytogenes is 
another well-described model to study antigen-specific T cell responses which clear the 
acute infection and constitute long-term immunological memory. Upon antigen 
encounter, antigen-specific naïve T cells expand clonally and acquire effector functions 
and the capacity to home to peripheral lymphoid tissues. Once the acute infection has 
been cleared, only a small subset of cells survive as antigen-specific memory cells with 
the capacity to rapidly respond to subsequent challenges.  
With the help of the German Mouse Clinic (Dr. Thure Adler), acute and memory T cell 
responses towards infection with Ovalbumin (OVA)-expressing L. monocytogenes 
(L.m.-ova; strain 10403s) were analyzed in this study according to standard protocols 
(Busch et al., 2001). 
In a first experiment, the general capacity of FasL ∆Intra mice to cope with the bacterial 
burden was investigated. Therefore, mice were intravenously infected with a high dose 
(25,000) wildtype L. monocytogenes, provoking a non-specific inflammatory immune 
response within the first 72 hours. Livers and spleens from infected mice were prepared 
at day three, and the number of Listeria colony forming units (CFU) was calculated by 
plating dilutions of tissue homogenates on brain heart infusion (BHI) agar plates. As 
Fig. 3.19 shows, high bacterial loads were present in spleen and liver of FasL ∆Intra 
and wildtype mice, indicating a comparable sensitivity to infection with Listeria.  
 
Figure 3.19 Sensitivity to infection with Listeria.  
Four mice per group were injected i.v. with 25,000 wt Listeria monocytogenes (strain 
10403s). Livers and spleens were prepared at day three post-infection. To assess the 
bacterial burden, Listeria CFU were calculated by plating dilutions of tissue 
homogenates on BHI agar plates.  
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To study acute antigen-specific immunity, mice were infected with a low dose (5,000) 
L.m.-ova, and the responses of epitope-reactive CD8
+ or CD4
+ T cells were 
characterized at day seven, i.e. at the peak of the primary T cell response. Tetramer 
stainings with the epitope H2-K
b
/SIINFEKL revealed approximately four percent 
epitope-specific CD8
+ T cells in all animals (Fig. 3.20 A, left), the majority being 
effector T cells (~ 90% tetramer
+CD8
+ T cells were CD62L
-CD127
-) (Fig. 3.20 A, right). 
Clonal expansion correlated with the acquisition of effector functions in three to four 
percent of all CD4
+ or CD8
+ T cells, as indicated by the induction of cytokine production 
(Fig. 3.20 B). Levels of Interferon gamma (IFN-γ) and TNF-α-producing cells were 
quantified by intracellular stainings of cells in vitro stimulated for 5 hours with either the 
Listeria epitope (CD4
+ T cells: H2-K
b/LLO188-201; CD8
+ T cells: H2-K
b/SIINFEKL), 
DMSO (negative control) or PMA/ionomycine (positive control). Again, no difference in 
the number of cytokine-producing antigen-reactive CD4
+ or CD8
+ T cells was observed. 
Thus, the FasL ICD does not affect the sensitivity to acute infection with Listeria and 
apparently does not regulate the clonal expansion of bacteria-specific T cells or the 
acquisition of T cell effector functions. 
 
The development of long-term immunity was investigated by sensitizing mice with a low 
dose of L.m.-ova (5,000) as before and subsequent challenge by a recall infection with 
a high dose L.m.-ova (250,000) ten weeks later, i.e. a long time period after clearance 
of the initial infection. Analogous to the primary infection, the sensitivity towards 
infection was assessed as the number of Listeria CFUs in spleen and liver 
homogenates two days after the challenge. While in naïve mice (not sensitized), the 
recall infection resulted in a high number of CFUs, the number of CFUs in spleen and 
liver of sensitized mice was almost below the detection limit in both, FasL ∆Intra and 
wildtype mice (Fig. 3.21 A). In agreement with the capacity of sensitized animals to 
rapidly cope with the bacterial burden, elevated numbers of Listeria-specific, cytokine-
producing CD4
+ or CD8
+ T cells were found (Fig. 3.21 B, compare Fig. 3.20). These 
data suggest a normal development of immunologic memory in FasL  ∆Intra mice 
following Listeria-infection. 
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Figure 3.20 Analysis of the acute antigen-specific immunity following infection 
with Listeria. Five FasL ∆Intra mice and three wildtype littermates were injected i.v. 
with 5,000 L.m.-ova. Spleenocytes were prepared at day seven. (A) The epitope-
specific CD8
+ T cell response was quantified by FACS analysis. left: Total amount of 
CD3
+CD8
+ tetramer
+  (H2-K
b
/SIINFEKL) cells in the spleen of infected animals. right: 
Percentage of CD3
+CD8
+ tetramer
+ (H2-K
b
/SIINFEKL) cells that express CD62L and/or 
CD127. (B) Intracellular cytokine staining for IFN-γ and TNF-α production. Cells were 
stimulated  in vitro with either the Listeria epitope (CD4
+  T cells: H2-K
b/LLO188-201; 
CD8
+
 T cells: H2-K
b
/SIINFEKL), DMSO (negative control) or PMA/ionomycine (positive 
control). Subsequent flow cytometric analysis revealed the percentage of CD45
+ CD3
+, 
CD4
+ or CD8
+ lymphocytes producing IFN-γ and/or TNF-α.  Results 
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Figure 3.21 Long-term immunity following infection with Listeria.  
Three mice per group were infected i.v. with 5,000 L.m.-ova and challenged with 
250,000 L.m.-ova ten weeks later. One wildtype and one FasL ∆Intra mouse were not 
sensitized and received the second infection only (naïve). Livers and spleens were 
prepared two days after the recall infection. (A) Protection assay. Listeria CFU were 
calculated by plating dilutions of tissue homogenates on BHI agar plates. The diagram 
shows the bacterial burden in sensitized and naïve animals after the challege. (B) 
Intracellular cytokine staining for IFN-γ and TNF-α production after Listeria challenge of 
sensitized mice. Splenocytes were stimulated in vitro with either the Listeria epitope 
(CD4
+
 T cells: H2-K
b
/LLO188-201; CD8
+
 T cells: H2-K
b
/SIINFEKL), DMSO (negative 
control) or PMA/ionomycine (positive control). Subsequent flow cytometric analysis 
revealed the percentage of CD45
+CD3
+, CD4
+ or CD8
+ lymphocytes producing IFN-γ 
and/or TNF-α. Results 
 
 
- 88 - 
3.4.5 Participation of the FasL ICD in Ovalbumin-induced allergic airway disease  
In the initial phenotypic screen by the GMC, slightly elevated IgE levels were found in 
the serum of unchallenged FasL ∆Intra mice. This promted the use of an Ovalbumin 
(OVA)-induced model of allergic airway disease (AAD) in co-operation with the GMC. In 
this model, mice are sensitized to OVA peptide and later challenged by exposure to an 
OVA peptide-aerosol that leads to leukocyte recruitment to and their proliferation in the 
lung. Here, mice were sensitized with a low dose of alum-precipitated OVA peptide 
(OVA/alum; 10 µg on days zero and eight), hyposensitized with 200 µg OVA/alum on 
days 29 and 32 and finally challenged by exposure to OVA-aerosols (1% OVA peptide) 
on days 39, 42 and 45. The OVA peptide-induced overall number of branchoalveolar 
lavage (BAL)-infiltrating cells is very low, making analysis of sufficient cell numbers to 
obtain significant results difficult. Therefore, the hyposenzitation step was included into 
the protocol as it leads to enhanced cell recruitment into the BAL upon OVA-aerosol 
exposure (Aguilar-Pimentel et al., 2010). After the final challenge, cell recruitment into 
the the BAL was determined by flow cytometry. Surprisingly, the total number of cells 
present in the BAL was significantly lower in FasL ∆Intra mice (Fig. 3.22 A, left). When 
analyzing the composition of cell populations within the BAL, it was revealed that 
significantly less B, T and NK cells had been recruited in the absence of the FasL ICD, 
while numbers of eosinophils, neutrophils and macrophages were similar (Fig. 3.22 A, 
right). At the same time, the overall percentage of activated CD8
+ T cells was 
significantly increased in the absence of the FasL ICD, as indicated by reduced levels 
of CD62L or Ly-6c-expressing CD8
+ T cells (Fig. 3.22 B). However, the activation 
status of antigen-specific (tetramer
+) CD8
+ T cells did not differ (data not shown). 
Together, these data suggest, that the enhanced activation of CD8
+ T cells in FasL 
∆Intra mice attenuates the inflammatory reaction in this model of AAD by impairing 
leukocyte recruitment into the lung. 
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Figure 3.22 Participation of the FasL ICD in OVA peptide-induced allergic airway 
disease. Ten mice per group mice were sensitized with 10 µg OVA/alum each on days 
zero and eight, hyposensitized with 200 µg OVA/alum on days 29 and 32 and finally 
challenged by exposure to OVA-aerosols (1% OVA) on days 39, 42 and 45. Twentyfour 
hours after the final challenge, cell recruitment into the the branchoalveolar lavage 
(BAL) was determined by flow cytometry. (A) left: Significantly reduced cell recruitment 
into the BAL in FasL ∆Intra mice. The diagram displays the total number of cells per 
milliliter BAL. right: Significantly lower numbers of B, T and NK cells in the BAL of FasL 
∆Intra mice. Differential cell count was performed by flow cytometry. (B) Enhanced 
activation of CD8
+ T cells in BAL of FasL ∆Intra mice. CD4
+ or CD8
+ T cells (living 
CD45
+CD3
+ cells) present in BAL were quantified (left most column in each diagram). 
Expression of activation markers in the respective CD4
+ or CD8
+ subpopulation was 
measured by FACS analysis by staining for Ly6c, CD25 or CD62L. CD62L expression 
negatively correlates with cell activation.  Results 
 
 
- 90 - 
3.4.6 FasL reverse signaling modulates the germinal center reaction  
Searching for an in vivo correlate for the enhanced B cell proliferation in the abence of 
the FasL ICD, a potential participation of FasL reverse signaling in thymus-dependent 
(TD) immune responses was investigated. Immunization with the hapten antigen   
4-hydroxy-3-nitrophenyl acetate coupled to the carrier protein chicken gamma globuline 
(NP-CGG) results in the formation of germinal centers in the spleen. B cells recruited 
into germinal centers undergo somatic hypermutation and immunglobulin isotype class 
switch, resulting in plasma cells that produce high affinity antibodies predominantly of 
the IgG isotype. With help from Ursula Zimber-Strobel’s group (Department of Gene 
Vectors, Helmholtz Zentrum München, Munich), germinal center reactions in FasL 
∆Intra and wildtype mice were analyzed 14 days post-immunization. Flow cytometric 
analyses of splenocytes revealed significantly higher levels of germinal center B cells 
(GCs; B220
+CD95
+PNA
+) and of plasma cells (PCs; Syndecan
+B220
low lymphocytes) in 
FasL  ∆Intra mice following antigen exposure, providing an in vivo correlate for the 
enhanced B cell proliferation observed in these mice ex vivo (Fig. 3.23 A). At the same 
time, similar levels of marginal zone B cells (MzB) and of follicular B cells (FoB), i.e. of 
resting cells normally present in the spleen, were detected (Fig. 3.23 B).  
 
Furthermore, immunization did not alter the overall amount of B and T cells in the 
spleen or the general activation status of B cells (Table 3.3 and compare Table 3.1). 
This indicates that immunization did not lead to an unspecific, aberrant expansion of 
immune cells.  
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Figure 3.23 FasL reverse signaling modulates the germinal center reaction.  
Mice were immunized by i.p. injection with 100 µg NP-CGG/alum and sacrificed after  
14 days. Single cell suspensions of splenocytes were used for FACS analysis. (A) The 
amount of Syndecan
+ B220
low plasma cells (left) and CD95
+ PNA
+ germinal center B 
cells (right) was signifcantly higher in FasL ∆Intra mice. (B) Levels of marginal zone B 
cells (IgM
high IgD
low) and follicular B cells (IgM
+ IgD
+) are comparable in wildtype and 
FasL ∆Intra mice. Columns represent mean values and bars represent the SEM from 
two independent experiments with five mice per group each.  
 
 
Table 3.3 Overall B cell and T cell levels in the spleen of immunized wildtype and 
FasL ∆Intra mice. Five mice per group were immunized by i.p. injection of 100 µg NP-
CGG/alum. Fourteen days post-immunization, single cell suspensions of splenocytes 
were stained for the presence of B cells (B220
+) and T cells (CD3
+) and analyzed by 
flow cytometry. The activation status of B cells was determined by co-staining for CD80 
and CD86. 
 
  Marker profile  wildtype  FasL ∆Intra 
T cells  CD3
+  26.47 ± 1.14  27.88 ± 1.63 
B cells  B220
+  62.66 ± 1.63  61.86 ± 1.44 
Activated B cells  B220
+CD80
+CD86
+    2.40 ± 0.13    2.29 ± 0.10 
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According to the enhanced germinal center reaction and the elevated number of PCs, 
serum titers of antigen-specific IgM and IgG antibodies should be increased in FasL 
∆Intra mice. Following immunization with NP, antigen-specific antibodies are produced 
which can bind to the NP multimer NP17. Therefore, the levels of NP17-binding IgM 
and IgG1 antibodies in the serum of immunized mice were quantified by ELISA. Indeed, 
titers of both, IgM and IgG1 antibodies, were significantly higher in FasL ∆Intra than in 
wildtype mice after immunization (Fig. 3.24). Thus, the increased serum titers of NP-
specific IgM and IgG1 antibodies correlated with the elevated number of PCs in FasL 
∆Intra mice and support the notion that signaling via the FasL ICD apparently 
participates in the regulation of TD immune responses by dampening B cell activation 
and expansion in germinal centers. 
 
 
 
Figure 3.24 Significantly elevated titers of NP-specific IgM and IgG1 after 
immunization in FasL ∆Intra mice. Mice were immunized by i.p. injection with 100 µg 
NP-CGG/alum and sacrificed after 14 days. Serum was prepared from whole blood. 
The serum titers of NP17-specific IgM (left panel) and IgG1 (right panel) antibodies 
were quantified by ELISA. Each symbol represents one mouse, and the vertical bar 
indicates the mean value of five (wildtype) or four (FasL  ∆Intra) animals per group. 
Immunglobulin titers in the serum of wildtype mice are represented by filled hash keys 
and titers in FasL ∆Intra mice by open rectangles.  
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3.4.7 Thioglycollate-induced peritonitis as a model for neutrophil migration 
Recently, FasL expression on myeloid cells was reported to be important for 
recruitment of these cells to the site of infection. Notably, it was shown that both, 
induction of FasL cell surface expression and its cross-linking by Fas, were a 
prerequisit for migration (Letellier et al., 2010). However, myeloid cells can express 
FasL as well as Fas, and it has not been determined which signal, the FasL forward or 
the reverse signal, is the important one involved in this process. 
We used thioglycollate-induced peritonitis to test an involvement of FasL reverse 
signaling in the recruitment of neutrophils. In mimickry of a systemic bacterial infection, 
thioglycollate injection into the peritoneal cavity induces peritonitis with the activation of 
innate immune responses and an increase of local neutrophils within the first hours. 
Following two challenges with thioglycollate, neutrophils (Ly6G
+) in the peritoneal 
lavage were quantified by flow cytometry three hours after the last challenge. While the 
induction of peritonitis resulted in a significant neutrophil recruitment (challenged vs. 
untreated) as expected, no differences between FasL ∆Intra and wildtype mice could be 
detected (Fig. 3.25). Thus, peritonitis-induced neutrophil recruitment is apparently not 
guided by a signal transduced via the FasL ICD.  
 
Figure 3.25 Neutrophil recruitment during thioglycollate-induced peritonitis.  
Four mice per group were injected i.p. (+) with 1 ml [3%] thioglycollate broth in the 
evening of day one and were treated a second time in the morning of the following day. 
Control groups were left untreated (-). Neutrophil recruitment into the peritoneal lavage 
was determined by FACS analysis as the percentage of Ly6G (Gr-1)-expressing cells. 
Columns represent mean values and bars represent the SEM of data obtained from 
four mice each. Discussion 
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4 Discussion 
 
Reverse signaling via the FasL ICD has been associated with the regulation of 
lymphocyte activation and proliferation (Lettau et al., 2009), but conflicting data about 
the consequences exist, and neither the precise molecular mechanism, nor its 
physiological relevance have been addressed at the endogenous protein level in vivo. 
In the present study, a ‘knockout/knockin’ mouse model, in which wildtype FasL was 
replaced with a deletion mutant lacking the intracellular portion (FasL  ∆Intra), was 
phenotypically characterized and was employed to investigate the physiological 
consequences of FasL reverse signaling at the molecular and cellular level. 
 
4.1 FasL ∆Intra mice represent a suitable model for FasL reverse signaling  
     deficiency and do not display an abnormal phenotype 
To ensure that FasL ∆Intra mice represent a suitable model to study the consequences 
of FasL reverse signaling, FasL expression and functionality were analyzed. Proper 
execution of FasL/Fas-mediated apoptosis is an important issue as naturally occuring 
mutant mice, in which Fas-apoptosis is almost completely abrogated due to inactivating 
mutations in the FasL (FasL
gld/gld) and Fas (Fas
lpr/lpr) gene, respectively, develop a 
severe lymphoaccumulative syndrom with the occurrence of an aberrant 
CD3
+B220
+CD4
-CD8
- T cell population, splenomegaly and auto-antibodies (Adachi et 
al., 1993; Takahashi et al., 1994a). A similar phenotype in FasL ∆Intra mice could mask 
the consequences of defective reverse signaling and, thus, render the mice inapt as an 
experimental model. 
Comparable FasL expression on lymphocytes of homozygous FasL ∆Intra and wildtype 
mice was verified by RT-PCR and flow cytometric staining (Fig. 3.3). Co-culture assays 
demonstrate that the truncated FasL is still capable to induce apoptosis in Fas-bearing 
cells, although this is less efficient than with the full length protein (Fig. 3.4). This 
decrease in cytotoxicity is in agreement with a study showing that FasL raft partitioning 
is essential for maximum contact with the Fas receptor and its ability to induce Fas-
mediated apoptosis. Raft localization of FasL is depending on the intracellular domain 
which is lacking in the FasL ∆Intra protein (Cahuzac et al., 2006). However, the killing 
capacity of FasL ∆Intra effectors is significantly higher than that of cells derived from 
homozygous and heterozygous FasL
gld  mice, of which only homozygous FasL
gld/gld Discussion 
 
 
- 95 - 
animals develop the lymphoaccumulative diesase, while heterozygous FasL
wt/gld mice 
are rescued by the presence of the single wildtype allele (Nagata et al., 1995).  
Additionally, phenotypic screening of FasL ∆Intra mice does not reveal any phenotypic 
anomalies. Normal T and B cell populations develop, and even old mice do not present 
with any signs of the FasL
gld/gld associated pathology (Tables 3.1, 3.2 and data not 
shown). Notably, while FasL
gld/gld cells express elevated levels of Fas at the surface 
(Stuart et al., 2005), normal Fas levels are found on cells isolated from FasL ∆Intra 
mice (Fig. 3.7 B). Although Fas expression is increased, FasL
gld/gld T cell blasts fail to 
be eliminated by FasL-dependent AICD upon re-stimulation (Tanaka et al., 1995; O' 
Reilly et al., 2009). Thus, the comparable extent of cell death in lymphocytes from FasL 
∆Intra and wildtype mice underlines the notion that FasL ∆Intra mice do not resemble 
FasL-defective FasL
gld/gld or FasL
-/- animals (Fig. 3.6).  
 
The localization of FasL is thought to differ between hematopoietic and non-
hematopoietic cells. In hematopoietic cells, FasL is stored intracellularly in 
multivesicular bodies and becomes externalized upon cell activation only, while non-
hematopoietic cells constitutively express FasL at the cell surface (French et al., 1996a; 
Kavurma et al., 2003). It has been suggested that nascent FasL is sorted to secretory 
lysosomes (Bossi et al., 1999) and that this critically depends on the FasL PRD, since 
deletion of the cytoplasmic tail leads to the constitutive expression of FasL on the cell 
surface of hematopoietic cells (Blott et al., 2001). Probably, FasL sorting and targeted 
discharge at the immunological synapse is mediated and regulated by post-translational 
modifications and by the binding of cytosolic SH3 domain-containing proteins, such as 
Nck, to the PRD (Lettau et al., 2006; Qian et al., 2006; Zuccato et al., 2007). However, 
the non-pathologic phenotype of FasL ∆Intra mice does not support this hypothesis. 
Default FasL expression at the cell surface of lymphocytes, due to deletion of the ICD, 
should lead to the massive and systemic induction of apoptosis and severe disease. In 
contrast, expression levels and killing capacity of truncated and full length FasL are 
similar (Fig. 3.3, 3.4). It is not likely that this reflects a compensatory increased 
shedding of FasL from the surface of FasL ∆Intra cells, as membrane-bound FasL is 
the primary functional form of FasL in mice (O' Reilly et al., 2009). Furthermore, 
preliminary data indicate that the amount of FasL-containing microvesicles secreted by 
activated T cells into the culture medium is comparable in FasL ∆Intra and wildtype 
mice (data not shown). This agrees with results from Jurkat cells transfected with either Discussion 
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wildtype or mutant (truncated ICD) FasL that secrete comparable amounts of vesicular 
FasL (Richard Siegel, personal communication). Providing possible explanations for 
this discrepancy, more recent studies claim that FasL is stored in compartments distinct 
from secretory lysosomes and suggest alternative pathways involving direct transport of 
FasL to the cell surface, not depending on the PRD (but rather on the total amount of 
FasL protein) (Xiao et al., 2004; He et al., 2007; Thornhill et al., 2007; Kassahn et al., 
2009; Schmidt et al., 2009). 
 
In summary, the FasL  ∆Intra mouse line represents a suitable model to study the 
consequences of reverse signaling via the FasL ICD at the endogenous protein level in 
vivo, due to the proper expression of functional FasL protein (in terms of its apoptosis-
inducing function). 
 
 
4.2 Signaling via the FasL ICD impairs activation-induced lymphocyte  
      proliferation by a mechanism involving PLCγ2, PKCα and ERK1/2 
FasL reverse signaling has first been described by two studies that demonstrated either 
co-stimulation of murine CD8
+ T cell lines by FasL cross-linking or inhibition of 
activation-induced proliferation, IL-2 production and cell cycle progression of murine 
CD4
+ T cells. In both cases, co-stimulation or inhibition of TCR-initiated signals critically 
depended on the presence of signaling-competent FasL, as the capacity of FasL
gld/gld T 
cells to expand in response to mitogenic stimulation differed from that of wildtype and 
Fas
lpr/lpr cells (Desbarats et al., 1998; Suzuki et al., 1998). Based on these observations, 
the proliferative capacity of lymphocytes lacking the FasL ICD was investigated to 
decide which of these apparently contradictory findings, co-stimulation or inhibition, 
reflects the physiological role of FasL reverse signaling. It could be demonstrated that 
activation-induced proliferation of CD4
+ T cells, CD8
+ T cells and of B cells is enhanced 
in the absence of the FasL ICD (Fig. 3.5). Interestingly, this effect is most pronounced 
in B cells and could only be detected in CD4
+ T cells after depletion of CD4
+CD25
+ 
regulatory T cells. To our knowledge the findings presented here describe FasL reverse 
signaling in B cells for the first time.  
These  ex vivo data support a negative regulatory role for FasL in mitogen-induced 
expansion of lymphocytes. Consistently, the proliferative capacity of cells completely 
lacking FasL (FasL
-/-) is even higher than that of cells devoid of the FasL ICD only, a Discussion 
 
 
- 97 - 
result that is also in agreement with current literature describing a proliferative 
advantage of FasL
-/- cells over wildtype cells (Mabrouk et al., 2008).  
 
In order to shed light on the molecules involved in transmission of the reverse FasL 
signal, the activation of several pathways that are known to play important roles in 
signaling from the antigen receptor was assessed. Providing a molecular correlate for 
the observed enhanced proliferation, ERK1/2 phosphorylation is significantly increased 
in B cells isolated from FasL  ∆Intra mice upon BCR triggering (Fig. 3.8). Further 
characterization of the upstream pathway revealed an involvement of PLCγ2 and PKCα 
signals in the FasL-dependent ERK1/2 regulation: Absence of the FasL ICD augments 
the activating phosphorylation of PLCγ2 and PKCα, and pharmacologic inhibition of 
PKCα results in diminished ERK1/2 activation and attenuated proliferation, underlining 
an important role for PKCα in FasL reverse signaling (Fig. 3.11). Activation of PLCγ2 in 
B cells and of PLCγ1 in T cells by protein tyrosine kinases like Syk and Bruton’s 
tyrosine kinase (Btk; B cells) or Fyn and Lymphocyte-specific protein tyrosine kinase 
(Lck; T cells) is a major downstream event of antigen receptor triggering (Kurosaki et 
al., 2000; Marshall et al., 2000). PLCγ then converts phosphatidylinositol 4,5-
bisphosphate into the second messengers inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). While IP3 promotes calcium release and NFAT activation, DAG is 
responsible for activation of PKC which in turn triggers the MAPK pathway.  
Although PKCα has been reported to directly target c-Raf-1 and MEK1/2 (Kolch et al., 
1993; Schonwasser et al., 1998), MAP-kinases upstream of ERK1/2 (Raf-1 and 
MEK1/2) seem not to be responsible for the differential regulation of ERK1/2 in our 
FasL mutant mice (Fig. 3.9). MEK1/2 inhibition impairs, but does not completely abolish 
B cell proliferation in response to BCR cross-linking, suggesting the involvement of an 
alternative, MAPK-cascade independent pathway in FasL ICD signaling. In agreement 
with this, PKC-dependent proliferation, specifically stimulated by PMA/ionomycine, is 
not affected by the presence of MEK inhibitors (Fig. 3.10). 
The notion of PLCγ, PKCα and ERK1/2 as mediators of FasL reverse signaling is 
consistent with published data, demonstrating that concomitant engagement of FasL 
and the antigen receptor initiates reverse signaling via TCR-proximal molecules, such 
as ZAP-70, LAT, PLCγ, PKC and ERK1/2, and that cross-talk of the two signaling 
entities occurs at a very early step, probably at the level of receptor internalization (Sun 
et al., 2006; Paulsen et al., 2009). However, engagement of FasL enhances activating Discussion 
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TCR signals according to Sun et al. (2006), while it is inhibitory in primary human 
peripheral blood T cells analyzed by Paulsen and co-workers (2009). 
 
How can the conflicting data regarding the consequences of FasL reverse signaling be 
explained? As detailed above, initial studies described either co-stimulatory or inhibitory 
functions in different murine CD4
+ or CD8
+ T cells. Follow-up studies by the group of 
Pamela Fink collected data supporting FasL-mediated co-stimulation and claimed that 
AICD masks the co-stimulatory signal in CD4
+ T cells in later phases of the immune 
response, thereby contradicting Desbarats et al. (1998) (Suzuki et al., 2000b; 
Boursalian et al., 2003; Sun et al., 2006; Sun et al., 2007b). A recent study on FasL 
reverse signaling challenges these reports and proposes an inhibitory FasL ICD/TCR 
cross-talk in human PBMCs (Paulsen et al., 2009).  
The discrepancies probably reflect the use of distinct and artificial experimental 
systems. In the ex vivo and in vivo experiments conducted with FasL ∆Intra mice during 
this project, FasL reverse signaling is initiated and regulated by its natural inducers, 
resulting in inhibitory signals. Other studies employed agonistic anti-FasL antibodies or 
Fas-Fc fusion proteins to cross-link FasL, possibly generating unphysiologically strong 
or weak signals. However, these reagents were used in both publications reporting co-
stimulation and those describing inhibition mediated by FasL reverse signaling. 
Furthermore, Pamela Fink and co-workers used an artificial mouse FasL fusion 
construct which was overexpressed in murine CD8
+ T cell lines or human Jurkat cells 
(Sun et al., 2006; Sun et al., 2007b). This construct consists of the FasL ICD, 
dimerization domains that allow mimicry of ligand cross-linking, and a myristoylation 
motif for tethering the construct to the inner plasma membrane. A variant of this 
construct was engineered to harbor the transmembrane and extracellular domain of 
Ly49a, for cross-linking with an anti-Ly49a antibody, fused to the FasL ICD. Also in this 
model, the strength of FasL cross-linking and the extent of FasL triggering might be 
unphysiologically high. 
 
It is important to note that effects observed in FasL ∆Intra mice indeed reflect FasL 
reverse signaling. First, the amount of cell death in stimulated and re-stimulated 
lymphocytes of FasL  ∆Intra mice is comparable to that of wildtype mice (Fig. 3.6), 
showing that the differential proliferative response does not reflect diminished cell 
death. In addition, non-apoptotic/pro-survival signaling through the Fas receptor, which Discussion 
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might account for the increased proliferation in cells devoid of the FasL ICD, could be 
excluded. Even in a Fas-defective setting (FasL
wt/wt/Fas
lpr/lpr  vs. FasL
∆/∆/Fas
lpr/lpr), the 
enhanced proliferative capacity of FasL ∆Intra lymphocytes is maintained (Fig. 3.7). 
Nevertheless, data from experiments employing Fas
lpr/lpr or FasL
gld/gld mice have to be 
interpreted with care, as neither mutation completely abrogates FasL/Fas signaling 
(Adachi et al., 1993; Karray et al., 2004; Mabrouk et al., 2008).  
Furthermore, non-apoptotic Fas signals have been associated with co-stimulatory 
functions, so that the increased expansion of FasL ∆Intra cells, correlating with the 
absence of FasL reverse signaling, would have to be explained with increased pro-
proliferative Fas engagement. There is no evidence supporting this hypothesis, as Fas 
cell surface expression levels are comparable in wildtype and FasL ∆Intra lymphocytes, 
and the latter exhibit a rather reduced killing capacity in co-culture assays (Fig. 3.4). 
 
 
4.3 Reverse FasL signals regulate target gene transcription: differential  
      expression of pro-proliferative and Lef-1-dependent genes in FasL ∆Intra mice 
Previous studies in our group revealed a Notch-like proteolytic processing of FasL at 
the cell surface, resulting in the liberation of the FasL ICD after two consecutive 
cleavage steps. The liberated ICD was shown to translocate to the nucleus and 
regulate reporter gene expression (Kirkin et al., 2007). Furthermore, using different in 
vitro protein binding assays, an interaction of the FasL ICD with the transciption factor 
Lef-1 could be demonstrated that leads to inhibition of Lef-1-dependent Luciferase 
activity (Lückerath et al., manuscript submitted). Additionally, data presented in this 
study show a FasL ICD-mediated differential activation of ERK1/2, and ERK1/2 itself is 
involved in the transcriptional regulation of various target genes.  
Based on these findings, expression profiling of activated lymphocytes was performed 
to identify bona fide FasL reverse signaling target genes. The enhanced proliferation in 
the absence of the FasL ICD correlates with and can be explained by the upregulation 
of several genes associated with lymphocyte proliferation and activation in homozygous 
FasL ∆Intra mice relative to wildtype mice, for example of NFAT, NF-κb and Irf4 (Fig. 
3.13).  
Interestingly, an extensive regulation of genes related to Wnt/β-Catenin- and/or Lef-1-
signaling, such as Cyclin D1, EDA, FGF4 and IL-4, was found as well (Fig. 3.13, 3.14). 
Consistent with the repression of IL-4 transcription by direct binding of Lef-1 to the IL-4 Discussion 
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promoter (Hebenstreit et al., 2008), IL-4 mRNA levels are significantly decreased in 
FasL  ∆Intra B cells, where Lef-1 activity is enhanced due to the absence of the 
inhibiting FasL ICD. FasL expression in mature B cells has been confirmed in several 
studies (Hahne et al., 1996; Lundy et al., 2002; Lundy, 2009; Lundy et al., 2009), but 
different publications suggest that Lef-1 expression becomes downregulated during B 
cell development (Reya et al., 2000; Jin et al., 2002). Contrary to these reports, Lef-1 
mRNA and protein can be detected in splenic B cells isolated from FasL ∆Intra and 
wildtype mice (Fig. 3.15). Co-expression of both, FasL and Lef-1, allows FasL ICD-
mediated inhibition of Lef-1-dependent gene expression in mature lymphocytes, 
initiated by Notch-like processing of FasL.  
However, direct interaction of the FasL ICD with Lef-1 has only been shown in vitro, and 
Wnt/Lef-1 signaling could not be detected in vivo in splenic B cells from 
FasL
wt/wt/TopGal and FasL
∆/∆/TopGal mice (data not shown). TopGal mice, similar to 
BatGal mice, express the LacZ gene under control of a Lef-1-dependent promoter. 
These mouse lines do not allow sensitive detection of Wnt signaling, and the absence 
of a positive signal does not exclude Wnt/Lef-1 activity (Barolo, 2006). Thus, from our 
experiments it cannot be concluded if the failure to detect Luciferase signals in the 
reporter mice is due to the insensitivity of the experimental model or to the lack of Lef-1 
activity.  
 
 
4.4 Molecular model for FasL reverse signaling 
Based on the data presented here, a model is proposed in which reverse signals 
transmitted by the FasL ICD proceed through at least two different pathways to regulate 
early events of antigen receptor signaling, resulting in transcriptional regulation of target 
genes and, finally, in attenuation of lymphocyte proliferation (Fig. 4.1). 
 
(i) We previously reported a ternary complex consisting of full length FasL, the SH3 
domain-containing adaptor PSTPIP and the phosphatase PTP-PEST, whose formation 
is promoted by FasL cross-linking (Baum et al., 2005). This complex is an attractive 
candidate for the initiation of FasL reverse signaling. Upon concomitant antigen 
receptor and FasL engagement, PSTPIP binds to the FasL PRD and recruits PTP-
PEST, resulting in enhanced phosphatase acitivty. PTP-PEST, associated with 
PSTPIP, has been described as a negative regulator of lymphocyte activation Discussion 
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(Davidson et al., 2001; Veillette et al., 2002; Yang et al., 2006; Arimura et al., 2008). As 
such, overexpression of the human analog of PSTPIP, CD2BP1, in the B cell lymphoma 
cell line A20 selectively diminished the phosphorylation of PLCγ, ERK1/2 and p38 upon 
antigen receptor cross-linking in a PTP-PEST-dependent manner (Yang et al., 2006). 
Furthermore, several PTP-PEST substrates have been identified, including Lck, Shc, 
Cytoplasmic tyrosine kinase (Csk), Grb2, Breast cancer antiestrogen resistance 1 
(BCAR1; Cas), Focal adhesion kinase (FAK), and Proline-rich tyrosine kinase 2 (Pyk 2), 
that are involved in antigen receptor proximal signaling events and might directly or 
indirectly regulate PLCγ activation (Davidson et al., 2001; Faisal et al., 2002; 
Yamamoto et al., 2003; Arimura et al., 2008; Veillette et al., 2009). Thus, FasL reverse 
signals could be transmitted through a FasL/PSTPIP/PTP-PEST complex that forms 
upon FasL triggering and in which PTP-PEST activity is increased. This allows cross-
talk with antigen receptor-initiated pathways at an early step, resulting in diminished 
PLCγ, PKC and ERK1/2 activation and finally attenuating the transcription of pro-
proliferative genes and the expansion of lymphocytes. Interestingly, PTP-PEST has 
recently been described to sensitize cells to death receptor-mediated apoptosis. While 
PTP-PEST enhances caspase activity during apoptosis initiation, it subsequently 
becomes cleaved by Caspase-3 itself. This cleavage regulates the catalytic activity, 
interactions and adaptor functions of PTP-PEST to ultimately facilitate the characteristic 
rounding up of dying cells (Halle et al., 2007). The anti-proliferative and pro-apoptotic 
effects of FasL/PSTPIP/PTP-PEST might possibly work hand in hand in the termination 
of immune responses by simultaneously preventing ongoing clonal expansion and 
promoting AICD of lymphocytes. 
 
However, other scenarios how reverse signaling via full length FasL can regulate 
lymphocyte proliferation can be envisioned as well. PSTPIP/PTP-PEST have been 
implicated in the regulation of T cell activation through cytoskeletal rearrangements. By 
binding of PSTPIP/PTP-PEST to the cytoplasmic tail of CD2, molecules involved in the 
re-organization of the Actin cytoskeleton are recruited to enable formation of the 
immunological synapse and, hence, optimal T cell activation (Li et al., 1998; Bai et al., 
2001; Badour et al., 2003). A similar mechanism could be possible for the interaction of 
FasL, PSTPIP and PTP-PEST. Furthermore, it cannot be excluded that FasL reverse 
signaling regulates PLCγ2 activity by a completely different mechanism, for example 
through the adaptor proteins Grb2 or Gab1, both of which have been identified as FasL Discussion 
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PRD interaction partners that play important roles in BCR-induced PLCγ activation 
(Marshall et al., 2000; Pao et al., 2007; Voss et al., 2009). Likewise, a proteomic screen 
identified the IL-2-inducible T cell kinase (Itk) as a potential interaction partner of the 
FasL PRD (Voss et al., 2009). Analysis of Itk
-/- mice indicates an important role of Itk in 
TCR-induced PLCγ phosphorylation and in the promotion of T cell proliferation (Berg et 
al., 2005). To elucidate how FasL reverse signaling modulates PLCγ activity, 
knockdown experiments could be performed in lymphocytes isolated from wildtype and 
mutant mice in which the expression of PTP-PEST or an alternative protein is silenced, 
for example, by virally-transduced shRNAs.  
 
 
(ii) An alternative pathway for FasL reverse signaling is initiated via Notch-like 
processing of cell surface FasL by the proteases ADAM10 and SPPL2a, which leads to 
liberation of the FasL ICD into the cytoplasm and its translocation into the nucleus 
(Kirkin et al., 2007). In the nucleus, the FasL ICD can bind to Lef-1 to negatively 
regulate Lef-1-dependent transcription, predominantely of pro-proliferative target genes. 
Although a direct FasL ICD/Lef-1 interaction has been shown in vitro, the exact 
molecular mechanism how the FasL ICD inhibits Lef-1 transcriptional activity remains 
unclear. Lef-1 binding seems to require the first 39 aa in the FasL ICD and, consistent 
with the lack of a SH3 domain in Lef-1, appears independent of the FasL PRD. 
Regarding the binding of FasL to Lef-1, a direct competition of the FasL ICD with the 
Lef-1 activating β-Catenin is unlikely, as the predicted binding site for FasL does not 
overlap with the N-terminal β-Catenin binding site in Lef-1 (Lückerath et al., manuscript 
submitted and unpublished data).  
 
In light of the important role of Lef-1 in B cell development, it could be assumed that the 
FasL ICD/Lef-1 interaction does not exclusively occur in mature lymphocytes, but also 
in B cell progenitors to prime B cells. In agreement with this, direct binding of a Lef-1-
containing complex to the Recombination-activating gene-2 ( Rag-2) promoter in 
immature B cells influences V(D)J gene recombination, resulting in differential 
immunglobulin expression in mature B cells (Jin et al., 2002). To test this possibility, 
Rag-2 expression levels could be quantified and patterns of V(D)J gene recombination 
could be analyzed in B cell progenitors isolated from FasL ∆Intra and wildtype mice. Discussion 
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There might also be an additional or alternative route for the regulation of Lef-1 by FasL 
reverse signaling, not involving direct interaction of the two proteins. The FasL ICD-
dependent PLCγ and PKC regulation could lead to modulation of Glycogen synthase 
kinase-3 beta (GSK-3β) activity by PKC, resulting in the accumulation of β-Catenin and 
the activation of Lef-1 (Christian et al., 2002). 
 
 
 
Figure 4.1 Molecular model for FasL reverse signaling. 
FasL reverse signaling negatively regulates lymphocyte proliferation by at least two 
different pathways: FasL cross-linking promotes the formation of a ternary complex 
consisting of FasL, PSTPIP and PTP-PEST that enhances the phosphatase activity of 
PTP-PEST. As a consequence, PLCγ, PKC and ERK1/2 activation is inhibited, resulting 
in diminished transcription of pro-proliferative genes. Alternatively (and not necessarily 
exclusively), proteolysis of FasL liberates the ICD that might translocate to the nucelus 
to bind Lef-1 and, thus, to inhibit Lef-1-dependent transcription of pro-proliferative and 
Wnt signaling-related genes. 
 
 
 
 Discussion 
 
 
- 104 - 
It would be interesting to identify the factors that determine which of these two 
pathways is triggered. A possibility would be the differential post-translational 
modification of the FasL ICD, such as phosphorylation of the tyrosine residue at 
position seven vs. serine phosphorylation within the CK-I site or vs. C82 palmitoylation 
which has already been identified as a pre-requisite for FasL raft localization and 
proteolysis by ADAM10 (Guardiola et al., manuscript in preparation). Likewise, it is 
intriguing to speculate about a potential interplay between the proposed 
PLCγ/PKC/ERK1/2- and the FasL ICD/Lef-1-dependent pathways: Lef-1 activity could 
be affected by PKC-mediated inhibition of GSK-3β; Wnt/Lef-1 signaling can regulate 
and/or feedback on PLCγ and PKC via the Wnt-Ca
2+-pathway, in which Wnt agonists 
trigger the Ca
2+-dependent activation of PLCγ and PKC (Staal et al., 2008). 
 
 
4.5 Analysis of FasL reverse signaling in vivo 
A potential participation of the FasL ICD in the regulation of immune responses to 
various challenges was analyzed in vivo, to elucidate the function of FasL reverse 
signaling in the context of the whole organism. Immune responses are characterized by 
the activation, recruitment and clonal expansion of immune effector cells. Thus, 
modulation of the proliferative capacity of lymphocytes, as observed ex vivo, should 
impact their course in vivo. 
 
4.5.1 Signaling via the FasL ICD is apparently not important for thymocyte  
         development 
FasL reverse signaling has been reported to aid in the positive selection of thymocytes 
in OT-1 TCR transgenic mice (Boursalian et al., 2003). To investigate whether T cell 
proliferation and maturation in the thymus of FasL  ∆Intra mice is disturbed in the 
absence of the FasL ICD, BrdU incorporation into newly synthesized DNA was 
quantified (Fig. 3.16). In contrast to the results from Boursalian and co-workers, the 
findings presented here do not support a role for FasL signaling in T cell development, 
since neither thymic nor peripheral T cell subsets of FasL ∆Intra mice deviated from 
wildtype cells. Most likely, this discrepancy reflects the use of different experimental 
systems. In the study by Boursalian et al. (2003), FasL
wt/wt and FasL
gld/gld mice 
expressing either a diverse, polyclonal TCR repertoir (C57Bl/6N) or a transgenic TCR 
specific for an OVA-derived epitope (OT-1/C57Bl/6N) were compared. Strikingly, not Discussion 
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only OT-1/FasL
gld/gld but also OT-1/FasL
wt/wt mice displayed a lower thymic cellularity, an 
abnormal distribution of thymocyte subsets and an increased expression of FasL when 
compared to standard C57Bl/6N mice. Furthermore, while substantial differences in the 
relative abundance of thymic T cell populations of OT-1/FasL
gld/gld  and OT-1/FasL
wt/wt 
were found, BrdU incorporation was not affected by the FasL
gld/gld   mutation. Thus, FasL 
reverse signaling might aid positive selection under very specific circumstances only 
and, in agreement with the findings in FasL ∆Intra mice, does not seem to play a major 
role during thymocyte selection. 
However, the data presented in this study should be interpreted with caution: double 
positive (DP) T cells represent the most abundant thymic T cell population (Oehme et 
al., 2005), but appear as the least abundant subset here. 
 
 
4.5.2 FasL reverse signaling modulates the germinal center reaction 
Encounter of forgein antigens leads to the clonal expansion and differentiation of non-
circulating marginal zone B cells (MzBs) and circulating follicular B cells (FoBs) in the 
periphery. FoBs form germinal centers in which they undergo class switch 
recombination of immunglobulins, affinity maturation and further proliferation to give rise 
to short lived, antibody secreting plasma cells (PCs). Differentiation into PCs is guided 
by the transcription factors B lymphocyte-induced maturation protein 1 (Blimp-1), X box-
binding protein-1 (Xbp-1) and IRF-4 (McHeyzer-Williams et al., 2005; Tarlinton et al., 
2008). In agreement with the observed hyperactivation of lymphocytes in the absence 
of the ICD ex vivo, in vivo immunization with a TD-antigen revealed elevated numbers 
of PCs and a significantly increased generation of germinal center B cells (GCs) in 
response to the immunization in homozygous FasL ∆Intra mice (Fig. 3.23), leading to 
increased titers of NP-binding, antigen-specific IgM and IgG1 antibodies in the serum 
(Fig. 3.24). Possibly, the upregulation of Irf4 mRNA levels in activated B cells of FasL 
∆Intra mice (Fig. 3.13) might contribute to the higher percentages of PCs in the spleen. 
At the same time, numbers of MzBs and FoBs, of overall T and B cell subsets and of 
activated B cells are comparable before and after immunization (Fig. 3.23 and Tables 
3.1, 3.3), indicating a specific response. These in vivo data match the previous ex vivo 
findings, and suggest that FasL reverse signaling exerts immunmodulatory functions.  
Interestingly, β-Catenin knockout mice present with a similar phenotype. While T and B 
cell populations are normal, in vitro immunization experiments reveal a defect in the Discussion 
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generation of PCs that correlates with decreased IRF-4 levels and a slight 
enhancement of class switch recombination to IgG3 and IgG1 (Yu et al., 2008b). Thus, 
FasL ICD signaling through Lef-1, possibly involving the modulation of GSK-3β activity 
and hence, of β-Catenin levels, might contribute to the germinal center reaction in FasL 
∆Intra mice. An involvement of Lef-1 is supported by increased Irf-4 expression in the 
absence of the FasL ICD (Fig. 3.13), as Lef-1 may regulate Irf-4 by direct binding to a 
consensus binding site within the Irf-4 regulatory region (Yu et al., 2008b).  
 
 
4.5.3 Signals transmitted through the FasL ICD participate in Ovalbumin-induced  
         allergic airway disease 
Supporting an immunmodulatory function of FasL reverse signaling, a participation of 
FasL in the course of Ovalbumin-induced allergic airway inflammation (AAD) was 
detected. Upon re-challenge of sensitized animals with OVA, significantly less cells are 
recruited into the BAL of FasL ∆Intra mice. Differential cell counts within the BAL reveal 
that absolute cell numbers of all cell types analyzed (eosinophils, macrophages, 
neutrophils, T cells, B cells, NK cells) are slightly decreased, with T, B and NK cells 
being significantly underrepresented in FasL  ∆Intra mice, although their relative 
abundance is maintained (Fig. 3.22 and data not shown). At the same time, activation 
of CD8
+ T cells (CD62L
-) is enhanced in the absence of the FasL ICD as measured by 
CD62L staining. This is largely consistent with a study in which enhanced activation of 
antigen-specific CD8
+ T cells negatively correlates with disease severity, i.e. cell 
recruitment into the BAL, eosinophilia and serum IgE levels (Aguilar-Pimentel et al., 
2010), and with the hyperactivation of FasL ∆Intra lymphocytes observed ex vivo and in 
vivo. Surprisingly, the percentage and activation status of antigen-specific CD8
+ T cells 
is similar in wildtype and FasL ∆Intra mice (data not shown) and, hence, the beneficial 
effect during the course of AAD would need to be explained by enhanced activation of 
unspecific CD8
+ T cells. Several possible explanations for this discrepancy have been 
suggested: (i) The OVA-challenge might have been not strong enough to reveal 
relevant differences in antigen-specific effector cells; (ii) The propensity to undergo 
AICD might be altered; (iii) Homing defects might lead to the sequestration of antigen-
specific lymphocytes in other organs, e.g. in peripheral lymph nodes or the liver 
(Aguilar-Pimentel et al., 2010); Marcus Ollert, personal communication). However, the 
analysis of AICD in FasL ∆Intra and wildtype T and B cells ex vivo does not provide Discussion 
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evidence for a differential sensitivity to cell death (Fig. 3.6). It is clear, that the analysis 
performed with this OVA peptide-induced model of AAD does not allow elucidation of 
the underlying mechanism, and further experiments are needed to solve the 
contradictory findings. 
From the presented findings, it can already be deduced that FasL reverse signaling 
participates in the course of OVA-induced AAD, particularly in the recruitment of 
immune effector cells into the lung. Indeed, a role for FasL signals in the migration and 
recruitment of neutrophils and macrophages to the site of inflammation has recently 
been described (Letellier et al., 2010). Furthermore, FasL
gld/gld mice were found to be 
less sensitive to chemically-induced colitis compared to wildype or Fas
lpr/lpr mice, and 
FasL/Fas signaling competence correlated with severity of inflammation (Park et al., 
2010). In contrast, in a mouse model of spontaneous coloncarcinoma (Apc
Min/+), the 
FasL
gld mutation was associated with enhanced tumor formation and reduced neutrophil 
infiltration into inflammed or cancerous tissue (Fingleton et al., 2007). In a collaboration 
with Dr. Benno Weigmann (University of Erlangen) we are currently investigating the 
susceptibiltiy of FasL  ∆Intra mice to chemically-induced colitis and colon cancer. 
Preliminary data suggest a lower tumor score in the absence of the FasL ICD. It will be 
interesting to see which cells infiltrate the inflammed and the cancerous tissue, and 
wether FasL reverse signaling contributes to cell recruitment and/or effector functions in 
this model. 
It is attractive to speculate that PTP-PEST may execute these reverse FasL signals: 
PTP-PEST has been implicated in the modulation of lymphocyte activation and of 
cytoskeletal re-organization and is an important positive regulator of cell migration in 
fibroblasts (Veillette et al., 2009). Thus, a ternary FasL/PSTPIP/PTP-PEST complex 
might have an impact on immune cell migration, infiltration and/or other processes 
involving cytoskeletal re-organization, like granule exocytosis (i.e. effector functions). 
 
 
4.5.4 Regulatory mechanism operating in vivo mask FasL reverse signaling 
Several in vivo experiments have been conducted in which no significant difference 
between FasL ∆Intra and wildtype mice became apparent. These findings might reflect 
regulatory mechanisms operating in vivo to fine-tune immune responses, such as 
control exerted by regulatory T cells. Along these lines, proliferative differences in CD4
+ 
T cells could only be detected ex vivo after depletion of CD4
+CD25
+ regulatory T cells Discussion 
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(Fig. 3.5). Support for the notion of a regulatory T cell-mediated suppression of CD4
+ T 
cell proliferation comes from studies in which no obvious difference in the expansion of 
Vβ8 TCR chain-expressing CD4
+ T cells following administration of the superantigen 
SEB was observed (Fig. 3.17). The comparable extent of SEB-induced Vβ8
+ CD8
+ T 
cell expansion in FasL ∆Intra and wildtype mice has been expected, since neither the 
FasL
gld/gld nor the Fas
lpr/lpr mutation affect the in vivo proliferation of this T cell population 
(Desbarats et al., 1998). 
Furthermore, several in vitro studies indicate that FasL reverse signal-transduction can 
only be observed under conditions of sub-optimal lymphocyte stimulation (Desbarats et 
al., 1998; Suzuki et al., 1998; Boursalian et al., 2003; Sun et al., 2007b; Paulsen et al., 
2009). If TCR signaling is induced with high (optimal) stimuli doses, FasL cross-linking 
has no detectable impact. A likely explanation for this phenomenon is the postulated 
modulating nature of the reverse FasL signal during antigen receptor-triggered 
lymphocyte activation. Strong receptor signals may override FasL signals and/or make 
them redundant, while weak signals might rely on the modulation exerted by FasL. 
Thus, the requirement for sub-optimal antigen receptor stimulation to reveal 
consequences of FasL reverse signaling offers an alternative or additional explanation 
for the comparable results obtained in experiments which analyzed either the expansion 
of antigen-specific T cells following a challenge with the superantigen SEB, with LCMV 
or with L. monocytogenes, or the recruitment of neutrophils in a thioglycollate-induced 
model of peritonitis (Fig. 3.17-21; Fig. 3.25). All of these challenging stimuli are potent 
activators of immune responses with the potential to mask inhibitory FasL reverse 
signaling (Desbarats et al., 1998; Busch et al., 2001; Huster et al., 2006; Hegazy et al., 
2010; Letellier et al., 2010). 
 
 
4.6 Conclusion 
In the study presented, FasL ∆Intra mice, which express a truncated FasL lacking the 
ICD, are characterized and analyzed as a model for FasL reverse signaling deficiency 
to elucidate the molecular mechanism and physiological importance of retrograde 
signal-transduction via the FasL ICD. While no obvious phenotypic anomalies can be 
detected in unchallenged FasL ∆Intra mice, ex vivo lymphocyte activation is augmented 
in the absence of reverse FasL signals as revealed by an enhanced activation-induced 
proliferation of B and T cells. This is mediated by amplification of antigen receptor Discussion 
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proximal events, such as increased phosphorylation of PLCγ, PKC and ERK1/2, and by 
upregulation of pro-proliferative genes. The hyperactivation of cells isolated from FasL 
∆Intra mice correlates with increased expansion and/or activation of lymphocytes in in 
vivo models of germinal center reactions and allergic airway inflammation and suggests 
an immunmodulatory function of FasL reverse signaling. However, regulatory 
mechanisms acting in vivo probably mask retrograde signals in other immune challenge 
experiments. 
In summary, the here reported ex vivo and in vivo findings based on endogenous FasL 
protein levels demonstrate that FasL ICD-mediated reverse signaling is a negative 
modulator of certain immune responses. It is tempting to speculate that FasL reverse 
signaling might be a fine-tuning mechanism to prevent autoimmune diseases, a 
possibility which will be tested in the future with suitable auto-immune mouse models. 
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6 Appendix 
 
6.1 Systematic expression analysis of T cells  
 
Molecular phenotyping of T cells using Affymetrix 21K cDNA chips: add on to 3.3.4.1 
‘Global gene expression profiling’. 
 
Table A.1 Molecular phenotyping of resting T cells. Splenic T cells were isolated 
from FasL ∆Intra or wildtype mice and used for RNA preparation. The corresponding 
cDNA was hybridized to Affymetrix 21K cDNA chips for global gene expression 
profiling. Mean log2 ratios give the fold-change [log2
n] in FasL ∆Intra cells compared to 
wildtype cells isolated from six mice per group. 
 
Mean 
log2 ratio  Array TAG ID Gene  symbol  Comment 
0,88 MG-13-25j10  Klf3  Kruppel-like factor 3 
0,71 MG-3-43i9  Cd164  CD164 antigen 
0,71 MG-15-81c5  Tardbp  TAR DNA binding protein 
0,68 MG-14-25e18  AI447904    
0,68 MG-16-190o16 Pdcd1  Programmed cell death 1 
0,67 MG-3-8a17  Tcp1  T-complex protein 1 
0,64 MG-3-16p4  Odc1  ornithine decarboxylase, structural 1 
0,62 MG-15-251k6  Tmem49  transmembrane protein 49 
0,60 MG-3-35j9  Obfc2a  oligonucleotide/oligosaccharide-
binding fold containing 2A 
0,59 MG-14-78c20  BX634656    
0,58 MG-14-5b16  Dleu2  deleted in lymphocytic leukemia, 2 
0,57 MG-14-34i8  Apg7l  Autophagy 7-like 
0,56 MG-3-264c18  D630029K19Rik    
0,55 MG-3-149l22  Crem  CAMP responsive element modulator
0,55 MG-16-49e11  CR515106    
0,52 MG-3-174k14  Efcab1  EF hand calcium binding domain 1 
0,52 MG-15-92f1  AI661017    
0,45 MG-6-42c2  CR520027      
0,44 MG-3-140g13  Polg2  Polymerase, gamma 2, accessory 
subunit 
-0,64 MG-15-119k2  Jun  Jun oncogene 
-0,72 MG-16-6f22  Ii  Ia-associated invariant chain 
-0,81 MG-14-114l18  Myd116  Myeloid differentiation primary 
response gene 116 
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Table A.2 Molecular phenotyping of activated T cells. Splenic T cells were isolated 
from FasL ∆Intra or wildtype mice, stimulated for four hours ex vivo (1 µg/ml plate-
bound anti-CD3 antibody) and used for RNA preparation. The corresponding cDNA was 
hybridized to Affymetrix 21K cDNA chips for global gene expression profiling. Mean 
log2 ratios give the fold-change [log2
n] in FasL ∆Intra cells compared to wildtype cells 
isolated from six mice per group. 
 
Mean 
log2 ratio  Array TAG ID  Gene symbol  Comment 
2,17 MG-12-205b11  1500005K14Rik    
2,04 MG-15-194f15  Slc28a2  Solute carrier family 28, 
member 2 
1,89 MG-6-64e20  2610019F03Rik    
1,83 MG-6-68f24  Camk4  Calcium/calmodulin-dependent 
protein kinase IV 
-1,20 MG-15-186e9  Pitrm1  Pitrilysin metalloprotease 1 
-1,22 MG-16-170o8  Npm1  Nucleophosmin 1 
-1,23 MG-3-96p15  Wdr36  WD repeat domain 36 
-1,23 MG-26-133l1  Eif3s9  Eukaryotic translation initiation 
factor 3, subunit 9 
-1,25 MG-8-23g17  Gcs1  Glucosidase 1 
-1,25 MG-14-102l11  Mrps18b  Mitochondrial ribosomal protein 
S18B 
-1,25 MG-16-134i15  Sfxn1  Sideroflexin 1 
-1,26 MG-3-276j1  Mpp6  Membrane protein, 
palmitoylated 6 
-1,26 MG-3-26p20  8430427H17Rik    
-1,26 MG-3-99i22  Rnu22  RNA, U22 small nucleolar 
-1,26 MG-16-5g10  BX634198    
-1,27 MG-16-159g21  Cacybp  Calcyclin binding protein 
-1,27 MG-3-277p13  Bxdc2  brix domain containing 2 
-1,28 MG-14-20i15  Gtpbp4  GTP binding protein 4 
-1,28 MG-3-24h9  1700129C05Rik    
-1,29 MG-16-9e13  Ftsj3  FtsJ homolog 3 
-1,29 MG-16-52c2  CR516105    
-1,30 MG-15-106c11  3110082I17Rik    
-1,30 MG-3-54n14  Aatf  Apoptosis antagonizing 
transcription factor 
-1,31 MG-12-248g10  D15Ertd785e  DNA segment, Chr 15, ERATO 
Doi 785, expressed 
-1,31 MG-16-10m22  6720458F09Rik    
-1,31 MG-3-21h7  A330048O09Rik   
-1,32 MG-3-62o14  Jtv1  JTV1 gene 
-1,33 MG-6-43d8  Ak2  Adenylate kinase 2 
-1,33 MG-16-6d20  Rars  Arginyl-tRNA synthetase 
-1,33 MG-12-132a20  Ddx18  DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 18 
-1,34 MG-15-52g13  Hrb2  HIV-1 Rev binding protein 2 
-1,34 MG-14-72k7  CR514785    
-1,34 MG-8-49h4  Shmt2  Serine hydroxymethyl Appendix 
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transferase 2 
-1,35 MG-4-5j23  Nfkb1 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2 
-1,35 MG-3-45l15  Sptlc1  Serine palmitoyltransferase, 
long chain base subunit 1 
-1,36 MG-26-213i9  Raver1  ribonucleoprotein, PTB-binding 
1 
-1,36 MG-8-40d18  CR517526    
-1,37 s1-B130016L12Rik  Heatr1  HEAT repeat containing 1 
-1,38 MG-15-224e21  BX635857    
-1,38 MG-14-80g20  Ddx3x  Fibroblast growth factor 
inducible 14 
-1,38 MG-6-1a17  Cycs  Cytochrome c, somatic 
-1,38 MG-3-38d12  Utp6  UTP6, small subunit 
processome component 
-1,38 MG-15-25d23  Xpot  Exportin, tRNA 
-1,39 MG-3-105k23  Hspca  Heat shock protein 1, alpha 
-1,39 MG-6-54e3  Acsl5  Acyl-CoA synthetase long-
chain family member 5 
-1,41 MG-8-26m3  BX636174    
-1,41 MG-3-23e8  D130017N08Rik   
-1,42 MG-3-73i12  2610528E23Rik    
-1,42 MG-16-3e3  2410015N17Rik    
-1,43 MG-26-111f17  Shmt2  Serine hydroxymethyl 
transferase 2  
-1,43 MG-6-40l14  Gart  Phosphoribosylglycinamide 
formyltransferase 
-1,44 MG-14-117n21  D8Ertd319e  DNA segment, Chr 8, ERATO 
Doi 319, expressed 
-1,44 MG-16-4n14  Lrmp  Lymphoid-restricted membrane 
protein 
-1,44 MG-15-232l20  BC065123    
-1,44 MG-14-107k7  Nfatc1  Nuclear factor of activated T-
cells 
-1,44 MG-6-64c5  Rnf149  Ring finger protein 149 
-1,45 MG-6-13k9  Slc6a17  Solute carrier family 6 member 
17 
-1,45 MG-6-92e18  Slc25a33  solute carrier family 25, 
member 33 
-1,45 MG-6-81e17       
-1,45 MG-6-63c21  Tars  Threonyl-tRNA synthetase 
-1,45 MG-16-152i24  5830405N20Rik    
-1,46 Nomo1  Nomo1  nodal modulator 1 
-1,47 MG-16-273g23  Kti12  KTI12 homolog, chromatin 
associated 
-1,47 MG-14-83j4  Ldha  lactate dehydrogenase A 
-1,48 MG-15-106g12  Ccdc115  coiled-coil domain containing 
115 
-1,49 MG-26-276i12  Rsl1d1  ribosomal L1 domain containing Appendix 
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1 
-1,49 MG-3-37k5  Mrpl12  Mitochondrial ribosomal protein 
L12 
-1,49 MG-6-38f21  Timm10 
Translocase of inner 
mitochondrial membrane 10 
homolog  
-1,49 MG-15-144h5  Numb  Numb gene homolog 
-1,49 MG-15-172d6  Ppat  Phosphoribosyl pyrophosphate 
amidotransferase 
-1,52 MG-3-75c15  4921511H13Rik    
-1,52 MG-3-26n8  Pomp  proteasome maturation protein 
-1,53 MG-8-60f17  Nola2  Nucleolar protein family A, 
member 2 
-1,54 MG-3-35p10  Rnu3ip2  RNA, U3 small nucleolar 
interacting protein 2 
-1,55 MG-15-1m17  Acsl5  Acyl-CoA synthetase long-
chain family member 5 
-1,55 MG-12-242l23  Pphln1  Periphilin 1 
-1,55 MG-14-81c3  AY078069    
-1,57 MG-6-39f17  Abcf1  ATP-binding cassette, sub-
family F 
-1,58 MG-6-31p20  CR521724    
-1,58 s0-Ccl4  Ccl4  chemokine (C-C motif) ligand 4 
-1,59 MG-8-57c8  2410015N17Rik    
-1,59 MG-8-118p15  D5Ertd606e  DNA segment, Chr 5, ERATO 
Doi 606, expressed 
-1,59 MG-8-98a20  Umps  Uridine monophosphate 
synthetase 
-1,59 MG-16-52e10  Sla  Src-like adaptor 
-1,60 MG-3-4n16  Bnc2  basonuclin 2 
-1,61 MG-15-255e11  Tacc2  Transforming, acidic coiled-coil 
containing protein 2 
-1,61 MG-12-133j12  Sema7a  Sema domain, immunoglobulin 
domain, 7A 
-1,61 MG-15-260i19  Txnrd1  thioredoxin reductase 1 
-1,61 MG-68-88b2  Chc1  Chromosome condensation 1 
-1,62 MG-3-57f5  Hspa9  heat shock protein 9 
-1,62 MG-6-46j8  Polr2h  Similar to polymerase (RNA) II 
polypeptide H 
-1,62 MG-15-188g13  BX633985    
-1,66 MG-15-74l4  Irf4  Interferon regulatory factor 4 
-1,67 MG-3-56e17  Pprc1  Peroxisome proliferative 
activated receptor 
-1,67 MG-3-75g7  Lyar  Ly1 antibody reactive clone 
-1,68 MG-3-106h2  Hspa9  heat shock protein 9 
-1,68 MG-3-31j8  Tmem97  transmembrane protein 97 
-1,69 MG-15-271k2  Mthfd2  Methylenetetrahydrofolate 
dehydrogenase 
-1,69 MG-26-261n18  Rrp1b  ribosomal RNA processing 1 
homolog B Appendix 
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-1,70 MG-16-40e1  Kpnb3  Karyopherin (importin) beta 3 
-1,71 MG-15-120k7  BX638845    
-1,72 MG-15-71l6  Wdr75  WD repeat domain 75 
-1,72 MG-3-38j18  Mrps6  Mitochondrial ribosomal protein 
S6 
-1,72 MG-15-3c13  Tagap1  T-cell activation GTPase 
activating protein 1 
-1,74 s1-Mrps6  Mrps6  mitochondrial ribosomal protein 
S6 
-1,74 MG-16-45k7  5830405N20Rik    
-1,75 MG-6-82j10  Smyd5  SET and MYND domain 
containing 5 
-1,75 MG-3-81o13  Mrto4  MRT4, mRNA turnover 4, 
homolog 
-1,75 MG-15-82f10  Wrd43  WD repeat domain 43 
-1,76 MG-12-244i21  Dnmt3a  DNA methyltransferase 3A 
-1,76 MG-26-78j20  Cad  Carbamoyl-phosphate 
synthetase 2 
-1,76 MG-8-20p3  Nol1  Nucleolar protein 1 
-1,77 s0-5830438K24Rik  Cd59  CD69 antigen 
-1,78 MG-16-183g4  BC018399    
-1,79 MG-13-41c7  Galk1  Galactokinase 1 
-1,79 MG-12-269j19  BX634314    
-1,79 MG-26-239b21  CR518583    
-1,80 MG-3-166n5  Mdn1  Midasin homolog  
-1,80 MG-3-123d23  Pwp2h  PWP2  homolog, yeast 
-1,81 MG-6-19l12  Eif5a  Eukaryotic translation initiation 
factor 5A 
-1,81 MG-15-146i23  Gpatch4  G patch domain containing 4 
-1,82 MG-15-260m2  Sdad1  SDA1 domain containing 1 
-1,83 MG-68-175p16  Timm13a 
Translocase of inner 
mitochondrial membrane 13 
homolog a  
-1,84 MG-3-24h16  Fbl  Fibrillarin 
-1,85 MG-3-101d3  CR515925    
-1,85 MG-6-77k11  Ctps  Cytidine 5--triphosphate 
synthase 
-1,85 MG-13-57n5  Nol5a  Nucleolar protein 5A 
-1,85 MG-16-44g1  BX637222    
-1,86 MG-13-1a19  AI429152    
-1,86 MG-15-2a10  2310056P07Rik    
-1,87 MG-3-46a10  Slamf7  SLAM family member 7 
-1,87 MG-68-170k10  Ctps  Cytidine 5--triphosphate 
synthase 
-1,89 MG-15-210g10  5830428M24Rik    
-1,89 MG-26-118g15  Nsun2  NOL1/NOP2/Sun domain family 
2 
-1,90 MG-8-19b7  Fabp5  Fatty acid binding protein 5, 
epidermal 
-1,93 MG-15-36o13  Hdac5  Histone deacetylase 5 Appendix 
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-1,95 MG-15-239g10  Bxdc1  Brix domain containing 1 
-1,97 MG-8-30k19  Mki67ip  Mki67 interacting nucleolar 
phosphoprotein 
-1,97 MG-3-12a18  Ipo4  Importin 4 
-2,05 MG-14-49d18  C1qbp  Complement component 1, q 
subcomponent binding protein 
-2,05 MG-12-1g17  Atad3a  ATPase family, AAA domain 
containing 3A 
-2,07 MG-3-40e12  C230062I16Rik    
-2,08 MG-16-134n7  Fubp1  Far upstream element binding 
protein 1 
-2,10 MG-68-113c23  Tnf  Tumor necrosis factor 
-2,13 MG-12-234j10  4933433P14Rik    
-2,15 MG-15-20g11  Slc1a5  Solute carrier family 1, member 
5 
-2,16 MG-15-164g13  BX632851    
-2,17 MG-3-88e11  C77032    
-2,17 MG-16-3j5  Timm8a 
Translocase of inner 
mitochondrial membrane 8 
homolog a 
-2,17 MG-13-133o15  BX632490    
-2,21 MG-3-256a12  Ipo4  Importin 4 
-2,22 MG-12-281j21  Ifrd2  Interferon-related 
developmental regulator 2 
-2,25 MG-3-84p19  CR519854    
-2,28 MG-6-31f19  Gramd1b  GRAM domain containing 1B 
-2,28 MG-16-41i17  Slc29a1  Solute carrier family 29 
member 1 
-2,31 MG-6-65p24  D1Ertd471e  DNA segment, Chr 1, ERATO 
Doi 471, expressed 
-2,33 MG-3-228n12  AA408556    
-2,33 s0-Cxcl10  Cxcl10  chemokine (C-X-C motif) ligand 
10 
-2,34 MG-68-147b5  Ubash3b  ubiquitin associated and SH3 
domain containing, B 
-2,37 MG-6-42b20  Ccnd2  Cyclin D2 
-2,37 MG-16-154p22  AF155546    
-2,39 MG-13-58k4  Nola1  Nucleolar protein family A, 
member 1 
-2,41 MG-68-182c20  Chi3l1  Chitinase 3-like 1 
-2,41 MG-3-8f14  Nol5  Nucleolar protein 5 
-2,41 MG-3-33g7  Slc7a1  Solute carrier family 7, member 
1 
-2,43 MG-6-41c3  Mthfd1  Methylenetetrahydrofolate 
dehydrogenase 
-2,43 MG-15-151a5  Nr4a1  Nuclear receptor subfamily 4, 
group A, member 1 
-2,45 MG-6-24n11  AI850995    
-2,53 MG-3-138c23  Gramd1b  GRAM domain containing 1B 
-2,54 MG-3-56n13  Slc7a5  Solute carrier family 7, member Appendix 
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5 
-2,55 MG-6-42c2  CR520027    
-2,57 MG-4-145m17  Srm  Spermidine synthase 
-2,57 MG-4-145h9  Serpina3g  Serine proteinase inhibitor, 
clade A, member 3G 
-2,58 MG-26-241h16  Srm  Spermidine synthase 
-2,65 MG-16-264l1  Apol7c  apolipoprotein L 7c 
-2,78 s0-Ccl3  Ccl3  chemokine (C-C motif) ligand 3 
-2,81 MG-73-18e3  Nr4a2  Nuclear receptor subfamily 4, 
group A, member 2 
-2,95 s0-Egr1  Egr1  early growth response 1 
-3,31 MG-14-5l12  Chst2  Carbohydrate sulfotransferase 
2 
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6.2 Abbreviations 
 
°C degree  Celsius 
µg microgram 
µl microliter 
µM micromolar 
µm micrometer 
aa   amino acid 
AAD  allergic airway disease 
ACAD   activated cell autonomous death 
ADAM   A disintegrin and metalloprotease 
AICD   activation-induced cell death 
ALPS   autoimmune lymphoproliferativ syndrome 
alum aluminium-potassium-dodecahydrate  (KAL(SO4)2) 
AP Alcaline  phosphatase 
AP-1   Activator protein-1 
Apaf-1   Apoptotic protease activating factor-1 
APC   antigen-presenting cell 
APS   ammoniumperoxodisulphate 
ATCC   American type culture collection 
ATP   adenosine-5´ triphosphate 
BAL bronchoalveolar  lavage 
Bcl-2   B-cell CLL/lymphoma associated-2 
BCR B  cell  receptor 
BH3-only  Bcl-2 homology domain 3-only 
BHI agar  brain heart infusion agar 
Blimp-1  B lymphocyte-induced maturation protein 1 
bp   base pair(s) 
BrdU bromo  desoxyuridine 
BSA   Bovine serum albumine 
Btk  Bruton’s tyrosine kinase 
C cystein 
C57BL/6   C57 black 6 incest mouse 
Cas  Breast cancer antiestrogen 1; BCAR 1 
Casp- Caspase 
CD   cluster of differentiation 
CD2BP1   CD2-binding protein-1 
CDK   Cyclin-dependent kinase 
cDNA   complementary DNA 
c-FLIP   Cellular FLICE-like inhibitory protein 
CFSE   Carboxyfluorescein-diacetat-succinimidylester 
CFU  colony forming units 
CIITA  MHC class II transactivator 
CK-I   Casein kinase I 
cm centimeter 
CMV cytomegalovirus 
cPLA2  Cytosolic phospholipase A2 
CRD   Cystein-rich domain  
Csk  Cytoplasmic tyrosine kinase 
Ct threshold  cycle 
CTL   cytotoxic T cell Appendix 
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CTLA-4   Cytotoxic T-lymphocyte associated protein-4 
Cyt c   Cytochrom c 
DAG   diacylglycerole 
dATP   2´-deoxy adenosine-5 triphosphate 
DC   dendritic cell 
DcR decoy  receptor 
DD   death domain 
DDM doublet  discrimination  module 
DED   death effector domain 
DISC   death-inducing signaling complex 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO   dimethyl sulphoxide 
DNA   deoxyribonucleic acid 
dNTP  desoxy nucleotide triphosphate 
DTT   dithiothreitol 
ECD extracellular  domain 
ECL   enhanced chemoluminescence light 
EDA Ectodysplasin  A 
EDTA   ethylenediaminetetraacetic acid 
e.g.  exempli gratia (for example) 
Egr Early  growth  response 
ELISA   enzyme-linked immuno absorbent assay 
ERK   Extracellular signal-regulated kinase 
EtOH   ethanol 
FACS   fluorescence-activated cell sorting 
FADD   Fas-associated protein with death domain 
FasL Fas  Ligand 
Fc   fragment crystallizable region  
FCS   fetal calve serum 
FGF Fibroblast  growth  factor 
FITC   fluoresceinisothiocyanat 
FL fluorescence  channel 
FL2-A  fluorescence channel 2-area 
FL2-W  fluorescence channel 2-width 
FoB  follicular/ transitional B cell 
FSC   forward scatter 
g   gravity 
G guanine 
Gads   Grb2-related adaptor downstream of Shc 
GAPDH Glycerinaldehyde-3-phosphate  dehydrogenase 
GC  germinal center B cell 
gDNA genomic  DNA 
gld   generalized lymphoproliferative disease 
GMC  German Mouse Clinic, Munich 
Grb-2   Growth factor binding protein 2 
h   hour(s) 
HIV   human immunodeficiency virus 
HPLC  high pressure liquid chromatography 
HPRT1  Hypoxanthine phosphoribosyltransferase 1 
HRP   Horseradish peroxidase  
i.p. intraperitoneal Appendix 
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i.v. intravenous 
IAP Inhibitor  of  apoptotsis 
ICAD  Inhibitor of caspase activated DNase 
ICD intracellular  domain 
IFN-γ Interferon-gamma 
Ig   immunglobuline 
IκB   Inhibitor of NF-κB 
IL   Interleukine 
IP3   Inositol (1,4,5)-trisphosphate 
IRF Interferon  regulatory  factor 
ITAM   immunoreceptor tyrosine activation motif 
ITIM  immunoreceptor tyrosine inhibitory motif 
Itk  IL-2-inducible T cell kinase 
JNK   c-Jun N-terminal kinase 
kb   kilobase 
kDa   kilodalton 
kHz   kilohertz 
L lysine 
l   liter 
LAT   Linker for activation of T cells 
Lck   Lymphocyte-specific protein tyrosine kinase 
LCMV  lymphocytic choriomeningitis virus 
Lef-1  Lymphoid enhancer binding factor 1 
LIGHT  lymphotoxin-like, exhibits inducible expression and competes with 
herpes simplex virus glycoprotein D for herpes virus entry mediator, a 
receptor expressed by T lymphocytes 
lpr   lymphoproliferation 
LTαβR  Lymphotoxin receptor alpha, beta  
M   molar 
MΦ  macrophage 
mA milli  Ampere 
MACS   magnetic-activated cell sorting 
MAPK   Mitogen-activated protein kinase 
MEK   Mitogen-activated ERK-activating kinase 
MFI  mean fluorescence intensity 
mg milligram 
MHC   Major histocompatibility complex 
min   minute(s) 
ml milliliter 
mM millimolar 
MOMP  mitochondrial outer membrane permeabilization 
mRNA   messenger ribonucleic acid 
MW   molecular weight 
MZB  marginal zone B cell 
NaOAc   sodium acetate 
NFAT   Nuclear factor of activated T cells 
NF-κB   Nuclear factor-κB 
NK   natural killer cells 
nm   nanometer 
nM nanomolar 
NP-40   Nonidet P-40 Appendix 
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NP-CGG  4-hydroxy-3-nitrophenyl acetate chicken gamma globuline 
o/n   overnight 
OD optical  density 
OVA Ovalbumin 
P/S   penicillin/streptomycin 
PAGE   polyacrylamide gel electrophoresis 
PARP  Poly (ADP-ribose) polymerase 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PC plasma  cell 
PCD   programmed cell death 
PCH   pombe cdc15 homology 
PCR   polymerase chain reaction 
PE   phycoerythrin 
PEI   polyethyleneimine 
PFU  plaque forming units 
pg picogram 
PH   plecstrin homology 
pH pondus  Hydrogenii 
PI   propidium iodide 
PI3K  Phosphoinositide 3 kinase 
PIP2   phosphatidyl-inositol 4,5-bisphosphat 
PKB   Proteinkinase B (Akt) 
PKC   Proteinkinase C 
PLAD preligand  assembly  domain 
PLCg   Phospholipase C gamma 
PMA   phorbol 12-myristat-13-acetat 
PMSF   phenyl-methyl-sulfonylfluoride 
PRD   proline-rich domain 
PST-PIP  Proline, serine, threonine phosphatase interacting protein 
PTP-PEST   Protein tyrosine phosphatase-PEST, non receptor type 12 
Pyk 2  Proline-rich tyrosine kinase 2 
qRT-PCR   quantitative real-rime PCR 
RFU  relative fluorescence unit 
RICD  restimulation-induced cell death 
RIP   receptor-interacting protein 
RMPI  Rosewell park memorial 
RNA   ribonucleic acid 
RNase   Ribonuclease 
rpm   rounds per minute 
RT-PCR   reverse transcriptase-PCR 
RU relative  units 
s   second(s) 
S serine 
SEB  Staphylococcus enterotoxin B 
SEM  standard error of the mean 
SDS   sodium dodecyl sulphate 
SDS-PAGE   SDS-polyacrylamide-gel electrophoresis 
sFasL  soluble Fas Ligand 
SFK Src  family  kinases 
SH2/3   Src homology 2/3 Appendix 
 
 
- 132 - 
SHIP  SH2 domain-containing inositol polyphosphate 5’phosphatase  
SHP1/2  Protein tyrosine phosphatase 1/2 
SP-1 Stimulating  protein  1 
SPOT  signaling protein oligomerization transduction structure 
SPPL2a Signal  peptidase-like  2a 
SSC   side scatter 
T threonine 
TAE   tris-acetate-EDTA buffer 
TBE   tris-borate-EDTA buffer 
tBid   truncated Bid 
TCR   T cell receptor 
TEMED   N,N,N'N'-tetramethylethylendiamin 
TGF   Transforming growth factor 
THD   TNF-homology domain 
TM transmembrane  domain 
TNF   Tumor necrosis factor 
TNFR   TNF receptor 
TRADD  TNFR-associated protein with a death domain 
TRAF   TNFR-associated factor 
TRAIL  TNF-related apoptosis-inducing ligand 
TRANCE  TNF-related activation-induced cytokine receptor 
Tris   tris(hydroxymethyl)aminomethane 
Tween 20   polyoxyethylenesorbitan monolaurate 
U   units 
UTR untranslated  region 
UV   ultraviolett 
V   volt 
v.s. versus 
v/v   volume per volume 
w/v   weight per volume 
WASP   Wiskott-Aldrich syndrome protein 
WB   Western blot 
WT   wildtype 
WW domain   protein domain containing two conserved tryptophane residues  
X  any amino acid 
Xbp-1 X  box-binding  protein-1 
Y tyrosine 
ZAP-70   ζ-chain-associated protein kinase of 70 kDa 
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